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Abstract 
 
Cancer is one of the most common causes of the death. Currently used 
anticancer drugs have shown to be effective against various cancers. However, 
these anticancer drugs cannot differentiate between tumor cells and normal cells. 
These agents kill both types of cells resulting in severe side effects. Poor physico-
chemical properties of anticancer drugs and development of chemo-resistance in 
cancer cells aggravate the problems. Over the past one decade, nanotechnology-
based formulations have been explored to overcome the limitations of anticancer 
drugs. These nanomedicines have shown promises to deliver drugs effectively to the 
cancer cells. In this research work, efforts have been made to improve the specificity 
of the drug loaded nanocarriers towards tumor cells. Cancer cells over express some 
receptors than normal cells. Therefore, nanocarriers attached with a ligand, having 
high affinity to particular receptor, could be target to cancer cells. In this context, two 
peptides (bombesin and cyclic RGDfK) and a monoclonal antibody, trastuzumab, 
were used as targeting ligand. Polymeric nanoparticles were used as drug carriers. 
Polymers such as poly(lactic-co-glycolic acid) (PLGA), D-α-tocopheryl polyethylene 
glycol succinate (TPGS), dendrimers and poly(glutamic acid) (PGA) were used for 
the preparation of nanoparticles. The selection of the polymers depended on the 
physicochemical properties of drug, desired particle size range, target tissue and the 
functional group available on the surface for conjugation with targeting ligand.  
Bombesin conjugated PLGA nanoparticles showed the potential to improve 
the delivery of a hydrophobic anticancer drug, docetaxel, in gastrin releasing peptide 
receptors over expressing breast and prostate cancer cells. Trastuzumab conjugated 
dendrimers demonstrated high specificity towards human epidermal growth factor 2 
receptors over expressing breast cancer cells. cRGDfK conjugated TPGS 
nanomicelles showed significant cytotoxicity and anti-angiogenic activity of 
encapsulated docetaxel to integrin receptors over expressing prostate cancer cells. 
As integrin receptors have also been over expressed in other cancers such as 
ovarian, brain, lung and breast cancers, cRGDfK conjugated nanoparticles were 
investigated for the targeting of drugs to ovarian and brain cancers. cRGDfK 
conjugated PLGA nanoparticles were investigated for the delivery of hydrophilic 
gemcitabine hydrochloride to ovarian cancer. In a separate study, cRGDfK was 
conjugated to PGA nanoparticles for selective targeting of hydrophobic camptothecin 
to integrin over expressing brain tumor cells.  
In summary, this thesis presents a research done with regards to preparation 
of anticancer drugs loaded different nanoparticles, bioconjugation of targeting ligand 
on the surface of nanoparticles and evaluation of anticancer activities of these ligand 
mediated targeted drug delivery systems in cancer cells. The study revealed that the 
nanoparticle-based targeted formulations better control over the growth of cancer 
than plain drugs. 
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1.1. Overview 
The objective of this study was to develop nanocarrier based cellular targeting 
system for active targeting of anticancer drugs and to improve the therapeutic 
efficacy of chemotherapy by enhancing the bioavailability of the drug, decreasing the 
total dose requirements and dosing frequency. In this introductory chapter, the role 
of chemotherapy in cancer treatment, problems associated with current cancer 
chemotherapy and advantages of nanotechnology based targeted drug delivery 
systems in the delivery of anticancer drugs are reviewed. Typically, a targeted drug 
delivery system is composed of two basic components-first a nanocarrier and 
second a targeting ligand. The nanocarrier is required to carry the drug molecules 
while the ligand is needed for selective targeting of the drug-loaded nanocarrier to 
the cancer cells. This chapter summarizes the different nanocarrier systems with 
specific emphasis on polymeric nanoparticles, surfactant based nanomicelles and 
dendrimers which have been used in research. Similarly, various targeting ligands 
have been summarized with their potential target receptors while three ligands 
namely bombesin peptide, cRGDfK peptide and trastuzumab monoclonal antibody 
have been discussed in detail.  
1.2. Cancer and cancer treatment 
Cancer is a leading cause of death across the world. As per the GLOBOCAN 
2012 report by The International Agency for Research on Cancer (IARC) of the 
World Health Organization (WHO), about 14.1 million new cases were diagnosed 
and 8.2 million cancer-related deaths occurred in 2012. IARC also estimated an 
increase of this number to 19.3 million new cancer cases every year by 2025.  Lung 
cancer is the most commonly diagnosed cancer with 13% of total diagnosed cases 
followed by breast cancer (11.9%) and colorectal cancer (9.7%) (IAFRO, 2013). 
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Cancer is a group of diseases characterized by uncontrolled growth and spread of 
abnormal cells. Based on origin, cancer can be categorized as: 
 Carcinoma: starts in the skin or tissues that line or cover internal organs. 
 Leukemia: in blood forming tissues. 
 Lymphoma and myeloma: cancer in the immune system 
 Sarcoma: cancer in bone, cartilage, muscles, blood vessels or other 
connective tissues.  
Commonly used cancer treatment approaches include surgery, chemotherapy 
and radiation therapy.  Surgery is the first treatment option in the case of early 
stages of cancer and when removal of the tumour from the body is possible. 
However, none of these therapies are sufficient to cure cancer. Therefore, a 
combined approach is used to provide more effective treatment than a single 
therapy. Chemotherapy helps to shrink the tumour and is followed by radiation 
therapy. High-energy radiation such as X-rays and gamma rays are used in radiation 
therapy. This therapy may work either by directly damaging the DNA of cancer cells 
making them unable to divide further or by an indirect approach by generating free 
radicals which damage DNA. (Bernier et al., 2004; Bhaskar et al., 2012)  In 
chemotherapy, anticancer agents are used to kill cancer cells. Recently, some other 
therapeutic approaches such as hormone therapy and immunotherapy have been 
designed to treat cancer (Sioka et al., 2009). 
1.3. Chemotherapy 
Chemotherapy involves the use of chemical substances to destroy cancer 
cells. As a common mechanism, chemotherapeutic agents impair mitosis and 
thereby inhibit cell division. Anticancer agents are broadly classified as (Payne and 
David, 2008):  
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a) Alkylating agents: Alkylating agents causes the cross-linking between two 
strands of DNA and thereby prevent replication of DNA. eg. Cyclophosphamide, 
mechlorethamine. 
b) Antimetabolites: These drugs have structural similarity to the biomolecules 
needed for the synthesis of RNA and DNA. Thus, these compounds act as fake 
substrate and enter in cell cycle during s-phase of cell cycle and block synthesis 
of RNA and DNA. eg. Methotrexate, 5-Fluorouracil. 
c) Natural products: These compounds are obtained from natural sources. Eg. 
Taxanes (docetaxel, paclitaxel), camptothecin, vinca alkaloids (vinblastin, 
vincristine) and podophyllotoxins (etoposide, teniposide) 
d) Antibiotics: Daunorubicin, doxorubicin, bleomycin 
e) Hormones and antagonists: Corticosteroids (prednisone, dexamethasone), 
androgen (testosterone propionate), anti-androgen (flutamide), estrogens 
(ethinyloestradiol), anti-estrogens (tamoxifen), progesterone derivative 
(megestrol acetate) and aromatase inhibitors (anastrazole). 
f) Enzymes: L-asparaginase 
g) Monoclonal antibodies: Trastuzumab, cetuximab, bevacizumab, rituximab 
1.4. Problems with current cancer chemotherapy 
 Current anticancer chemotherapy suffers with following major drawbacks: 
a) Non-specificity: Although available anticancer drugs are effective to kill cancer 
cells, they can’t differentiate between a normal cell and a cancer cell. This non-
selectivity of anticancer drugs leads to systemic toxicity and severe side effects 
(Ross et al., 2004).  
b) Tumor resistance to cancer cells: Cancer cells shows inherent and some 
acquired resistance towards anticancer drugs including altered apoptosis 
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regulation, increased DNA damage repair, alteration in metabolism, under-
expression of topoisomerase II or topoisomerase II gene mutations,decreased 
uptake of water-soluble drugs and increased energy-dependent efflux of 
hydrophobic anticancer drugs (Krishna and Mayer, 2000). Energy-dependent 
efflux of hydrophobic anticancer drugs by tumor cells is due to over expression 
of glycoproteins involved in the efflux of drugs. Due to this efflux, patients are 
needed to be exposed to high dosages of anticancer drugs.  
c) Inability to across protective lining of tissues: Anticancer drugs can’t cross the 
protective lining of some tissues. For example, the brain is well protected by the 
blood brain barrier (BBB) and anticancer drugs are unable to cross BBB to 
provide therapeutic effects in brain cancer (Elsabahy M, Wooley, 2012). 
d) Aggregation or precipitation due to poor aqueous solubility (Cho et al., 2008) 
e) In vivo degradation (Parveen et al., 2012) 
f) Short circulation half-life and  
g) Low therapeutic indices (Cho et al., 2008; Parveen et al., 2012 ) 
1.5. Targeted drug delivery systems (TDDS) 
 In the past decade, targeted drug delivery systems have shown potential to 
overcome the problems of anticancer drugs. These TDDS deliver anticancer drugs 
specifically to cancer cells with a minimum or low toxicity to normal cells. TDDS 
make use of differences in the chemical and structural biology of normal and cancer 
cells (Brannon-Peppas and Blanchette, 2012). Tumor cells demonstrate leakiness of 
blood vessels, poor lymphatic drainage in tumor tissues and enhanced vascular 
permeability. Other biochemical differences between two types of cells are lower pH 
and oxygen level (hypoxia) in cancer cells than normal cells. Most of the TDDS are 
based on the nanotechnology. Nanoparticles are small particles with a nanometre 
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size. Because of small size, nanoparticles especially particles below 200 nm can 
extravasate through the leaky vasculature of blood vessels of the tumor (~400 nm) 
and accumulate in the tumor tissues (Peer et al., 2007). This phenomenon is called 
blood circulation and extravasations (Bae and Park, 2011). Since cancer cells grow 
faster than normal cells, they require more nutrients and oxygen supply which leads 
to induction of angiogenesis. This induced angiogenesis results in increase in 
permeability of blood vessels in tumor tissue (Danhier et al., 2012).  Because of 
enhanced permeability, nanoparticles enter more into tumor tissues but are trapped 
or retained in the tumor bed due to poor lymphatic drainage. Therefore, this 
phenomenon is also called as enhanced permeability and retention (EPR) effect 
(Peer et al., 2007; Brannon-Peppas and Blanchette, 2012).  
 
Figure 1.1: Enhanced permeability and retention (EPR) effect on the transport of 
nanoparticles through a normal vasculature and leaky vasculature 
A size between 10-200 nm is the most preferable size range for nanoparticles 
to get the advantage of EPR effect for anticancer drug delivery. These nanoparticles 
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are not small enough to be excreted by the kidney (< 6 nm) or large enough to be 
rapidly recognized and trapped by the reticulo-endothelial system (RES) (>300 nm) 
(Michelle Longmire et al., 2008). Therefore, nanoparticles with this size range are 
circulated more in the blood after intravenous administration which provides more 
opportunity to accumulate in tumor tissues. However, this EPR is not effective 
enough to produce a significant improvement on the efficacy of anticancer 
formulations.  EPR shows only 20-30% specificity towards tumor cells than other 
tissues (Kobayashi et al., 2014). 
 A more effective approach which is currently being explored is active targeting 
of anticancer drugs to cancer cells (Sinha et al., 2006). The backbone of this concept 
is over expression or up regulation of some receptors on the surface of tumor cells 
than normal cells. These receptors are generally absent or present at very low 
frequency on normal cells (Shin et al., 2013). Therefore, anticancer drugs directed to 
these receptors provide a unique opportunity of selective and specific delivery of 
drugs to cancer cells (Sinha et al., 2006; Kularatne and Low, 2010). Most of the 
current TDDS are based ligand-mediated targeted delivery. In this strategy, a ligand 
is conjugated on the surface of nanoparticles which directs nanoparticles to 
particular receptors. Therefore, a TDDS is composed of two important tools-a 
nanocarrier system which carries drug molecules and a targeting ligand. 
Internalization of TDDS in cancer cells 
After binding to a target receptor, nanoparticles are taken up by cancer cells 
through receptor-mediated endocytosis. This process is also called as clathrin-
mediated endocytosis and responsible for uptake of essential nutrients such as 
cholesterol, iron. Cholesterol is taken up by cells through low density lipoprotein 
receptors while iron enters into cells via transferrin receptors.  Similarly, targeted 
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nanoparticles are engulfed through particular receptors and form early endosomes. 
Drug encapsulated in nanoparticles is released due to degradation of nanoparticles, 
triggered by pH or enzymes. Detached receptors are recycled on the surface of cells 
extracellularly.  
 
Figure 1.2: Bioconjugation and internalization of trastuzumab conjugated 
nanocarriers. Conjugated nanoparticles bind to HER2 receptors over expressed on 
the cancer cells and enter via receptor-mediated endocytosis. After internalization, 
the encapsulated molecule (imaging or drug or gene) is released by enzymatic or pH 
based activities in lysosomes. Receptors are recycled whereas encapsulated 
molecule is exposed to its target. (This figure is taken from Kulhari et al., 2014) 
 
1.6. Types of nanoparticles 
Nanoparticles enhance the aqueous solubility of hydrophobic drugs, 
controlled drug release, protect drug from degradation and improved bioavailability. 
Nanoparticles can be modified for targeted delivery of drugs and thereby reduce total 
dosage requirements and reduce side effects. Nanoparticles allow rapid-formulation 
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development and can be formulated in different ways according to route of 
administration.   
 
Figure 1.3: Different types of nanocarrier systems currently being explored as carrier 
system for anticancer drugs. This figure is taken from Bamrungsap et al., 2012. 
Based on material used for nanoparticles-matrix, NPs can be categorized as 
follows: 
a) Polymeric nanoparticles: Polymeric nanoparticles contain a polymer as matrix. 
Polymer may be a single (linear or branched) or a graft copolymer. Commonly used 
polymeric materials are D, L-lactide co-glycolide (PLGA), polylactide(PLA), 
polyethyleneimine (PEI), poly(glutamic) acid (PGA), poly(acrylic) acid, poly(ethylene 
glycol) (PEG) etc. 
b) Carbohydrate and protein based nanoparticles: Apart from synthetic polymers 
some carbohydrate based high molecular weight compounds have been investigated 
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as drug delivery carrier. These include dextran, chitosan, gelatin, bovine serum 
albumin etc. 
c) Lipid-based nanoparticles: Lipid nanoparticles are composed of a lipid, an 
emulsifier and water. These nanoparticles can be converted into different form such 
as liposomes, niosomes, solid lipid nanoparticles, lipid nanostructures, 
nanoemulsions, self-emulsifying nanoparticles etc. 
d) Inorganic nanoparticles:  The use of inorganic nanoparticles for thernostic 
applications in cancer is emerging as a new area. The unique physicochemical 
properties of inorganic nanoparticles such as extremely small size (<50 nm), high 
surface reactivity, stability in biological fluids and presence of surface plasmon 
response, make them suitable for imaging, diagnostic and drug delivery applications. 
There are types of inorganic nanoparticles: metal nanoparticles and ceramic 
nanoparticles. Metal nanoparticles are composed of a metal such as gold, silver, iron 
oxide or titanium (Song et al., 2009). Mesoporous silica nanoparticles (MSNs) are 
example of ceramic nanoparticles. MSNs are highly biocompatible and does not 
show change in porosity with pH. MSNs are highly stable and do not exhibit swelling 
in physiological conditions. 
e) Dendrimers: Dendrimers are synthetic organic compounds with nanoscale 
structural design with very low polydispersity (Mw/Mn< 1.01-1.05) and high surface 
functionality. The structure of dendrimers contains three basic components: a central 
core, branches with lots of void spaces and terminal surface group (Figure 3). The 
unique structure of dendrimers makes them ideal nanocarrier system for delivery of 
contrast agents, drugs and genes. Based on core materials dendrimers are further 
classified as poly (propylene imine) dendrimers, poly (ethylene) imine dendrimers, 
poly(amido amine) (PAMAM) dendrimers and peptide dendrimers. 
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f) Surfactant based nanomicelles: Nanomicelles synthesized using surfactants 
such as pluronics, D-α-tocopheryl polyethylene glycol succinate (TPGS) have been 
used as potential drug delivery carrier.  
In this PhD research work, three types of nanoparticles were prepared for the 
development of TDDS- a) polymeric nanoparticles using PLGA and PGA polymers, 
b) nanomicelles using TPGS and c) PAMAM dendrimers 
1.6.1. Polymeric nanoparticles 
Polymer-based nanoparticles effectively carry encapsulated drugs or proteins 
or contrast agents to target particular cells. The advantages and other common 
properties of polymeric nanoparticles are shown in figure 1.4.  
 
Figure 1.4: Characteristics of polymeric nanoparticles: (a) stealth: imparts 
biocompatibility, steric stability and protection of the encapsulated drug and reduces 
the opsonization and clearance of nanoparticles, but may also reduce the cellular 
uptake and endosomal escape capabilities, (b) charge: cationic character enhances 
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cellular uptake and endosomal escape, but subject to uncontrolled tissue distribution 
and often associated with toxicity, (c) targeting: enhances cellular uptake and 
specificity, but sometimes can accelerate the clearance and/or immunogenicity, (d) 
stimuli responsiveness: controls the dynamics of nanoparticles with possibility of 
releasing their cargoes at specific sites (selectivity). The stability and responsiveness 
of these materials under physiological and pathological conditions may vary and may 
result in premature release of the drug. (e) size: 100 nm particles is optimal for 
delivery, being large enough to avoid renal clearance and small enough to reduce 
clearance and toxicity, (f) morphology: expanded morphology results in higher drug-
loading capacity, lower clearance and cellular uptake, (g) aspect ratio: the shell vs. 
core volume and length vs. diameter can greatly affect the cellular uptake, clearance, 
drug loading and release, and toxicity, (h) assembly vs. unimolecular structures: 
unimolecular structures are more stable (no dissociation) but can be cleared rapidly 
depending on the size and usually have low drug-loading capacity, and (i) stability: 
intermediate stability to circumvent physiological barriers and at the same time be 
able to release the drug at the target sites is required and can be achieved with 
different methods, for instance, by crosslinking. This figure is taken from Elsabahy 
and Wooley, 2012. 
 
Methods of preparation of polymeric nanoparticles 
Polymers based nanoparticles can be prepared by several techniques 
including solvent displacement, double emulsification, salting out, dialysis, ionic-
gelation and super critical fluid technology. 
a) Solvent displacement method 
It is one of the oldest but highly effective methods for the preparation of 
polymeric nanoparticles. In this method, drug and polymer are dissolved in a volatile, 
water-miscible organic solvent and then transferred into aqueous phase containing 
surfactant as stabilising agent (Astete and Sabliov, 2006). For the preparation of 
surfactant-free nanoparticles, normal distilled water or phosphate buffer is used as 
aqueous phase (Tomoda et al., 2014). The dispersion may be homogenised or ultra-
sonicated followed by evaporation of solvent by either stirring on magnetic stirrer or 
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under reduced pressure. Commonly used organic solvents are ethyl acetate, 
acetone, chloroform and dichloromethane.  
b) Double emulsification method 
This method is used for the encapsulation of hydrophilic drugs. The drug is 
dissolved in water and added to the organic phase to prepare water-in-oil (w/o) 
emulsion. Thereafter, this primary emulsion is added into the large aqueous phase 
containing the surfactant solution to produce water-in-oil-in-water w/o/w type double 
emulsion. This double emulsion system is stirred to evaporate organic solvent and to 
get drug loaded nanoparticles.  
 
Figure 1.5: Emulsification process based on the modified double emulsion 
evaporation method. This figure is taken from Ahmed et al., 2012. 
c) Emulsification/ solvent diffusion  
Emulsification/ solvent diffusion is modified solvent evaporation method where 
polymer is dissolved in a partially water-soluble solvent such as propylene 
carbonate. Then, it is saturated with water until to themodynamic equilibrium of both 
the solvents. To allow the diffusion of the solvent, the dispersed phase is diluted with 
the dispersion medium. This method is generally used to prepare nanospheres or 
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nanocapsules. High drug encapsulation efficiency, batch to batch reproducibility, no 
need for homogenisation and easy scale-up are major advantages of this technique. 
However, it also suffers from disadvantages of leakage of water-soluble drugs and 
requirement of high volumes of water to be eliminated from suspension.  
d) Dialysis 
In dialysis method, the polymer and drug are dissolved in dimethyl sulfoxide 
(DMSO) or dimethyl formamide (DMF), emulsified with aqueous phase and placed in 
a dialysis tubing molecular weight cut off 12000-14000 Da (Jeon et al., 2000). Then, 
the whole assembly is placed in dialysis medium (water). As solvents DMSO/DMF 
and water, passes across the dialysis tubing, the solubility of polymer is decreased 
and it aggregates in the form of small homogenous particles.  
e) Salting out 
This method is based on the separation of water miscible solvent from 
aqueous solution using electrolytes or non-electrolytes (Konan et al., 2002). Initially, 
the polymer and drug are dissolved in a water miscible solvent like acetone and 
subsequently emulsified in aqueous solution containing a salting out agent and a 
stabilizer (Eley et al., 2004). Commonly used salting out agents includes either 
electrolytes such as calcium chloride, magnesium chloride, magnesium acetate or 
non-electrolyte like sucrose.  As the organic solvent defuses through the aqueous 
phase, nanoparticles are formed. This technique is easy to scale up and produces 
nanoparticles with high efficiency. However, it is suitable for only water-insoluble or 
lipophilic drugs (Astete and Sabliov, 2006).  
f) Ionic gelation method 
Ionic gelation method is used for the hydrophilic polymers such as poly 
glutamic acid (PGA), sodium alginate, chitosan and gelatin. In this method, the 
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polymer in study is crossed-linked with an oppositely charged polymer to 
coacervates to a particle size in the nano-range. eg. Hellmers et al., (2013) 
synthesized PGA-chitosan composite nanoparticles by ionic gelation method for the 
delivery of doxorubicin.   
g) Rapid expansion of supercritical solution 
In this technique, the polymer is dissolved in supercritical fluid to form solution 
which is rapidly expanded across an orifice or a capillary nozzle into a liquid solvent 
or ambient air to form nanoparticles.  Imran ul-haq et al., (2010) synthesized 
poly(lactic acid) nanoparticles by rapid expansion of supercritical CO2 solution. 
1.6.1.1. PLGA based nanoparticles 
PLGA is a biodegradable polymer composed of two monomer units- lactic 
acid and glycolic acid. After degradation of PLGA, both the monomer units enter into 
Kreb’s cycle and are degraded completely in the body (Avnesh et al., 2010). It 
provides excellent biodegradability and biocompatibility to PLGA and hence PLGA 
has been approved for therapeutic applications. The properties of PLGA depend 
upon the percentage of each monomer unit. PLGA containing 50:50 ratios of lactic 
and glycolic acid is degraded faster than any other compositions.  
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Figure 1.6: Biodegradation of PLGA in aqueous biological environment 
PLGA is one of the mostly explored polymers in the area of drug delivery. 
Drugs from different categories such as anticancer agents, anti-diabetic drugs, anti-
psychotic, hormones and toxoids have been delivered using PLGA-based drug 
delivery systems. Nanotechnology-based preparations have been used for the 
Chapter 1  Introduction 
 Peptide and monoclonal antibody mediated targeting of anticancer drugs 15 
 
delivery of anticancer agents to explore the inherent advantages of nanocarrier 
systems such as EPR, bypass multi drug resistance etc. Docetaxel, paclitaxel, 5-
fluorouracil, etoposide, camptothecin, cisplatin, xanthone, triptorelin, and doxorubicin 
have been successfully encapsulated in PLGA nanoparticles.  
1.6.1.2. Poly(glutamic) acid (PGA) 
PGA is a water soluble poly amino acid comprising monomer units of D- and 
L-glutamic acid. These units are linked together via amine bonding between γ-
carboxylic acid and α-amino acid groups. PGA can be synthesized either chemically 
or microbiologically. Chemical synthesis method produces α-PGA while γ-PGA is 
obtained by certain strains of Bacillus. PGA is a non-toxic, non-immunogenic, 
biodegradable and biocompatible polymer. PGA nanoparticles are prepared by either 
dialysis or ionic gelation method as described earlier.  
 PGA has been used as drug delivery carrier for the delivery of anticancer 
drugs. Anticancer drugs are either conjugated with a polymer or encapsulated in a 
polymer matrix.  Anticancer drugs delivered by using PGA as the polymeric 
backbone include paclitaxel (Markovsky et al., 2014), docetaxel (Lollo et al., 2014), 
doxorubicin (Cao et al., 2011; Markovsky et al., 2014), idarubicin (Wadhwa and 
Mumper, 2012), cisplatin (Xiong et al., 2012) and plitidepsin (Gonzalo et al., 2013).  
1.6.2. Surfactant-based nanomicelles 
 Amphiphilic molecules, with a hydrophilic and a hydrophobic part, have 
unique properties of getting self-assembled when exposed to a solvent. Above a 
particular concentration i.e. critical micellar concentration (CMC), these molecules 
form aggregates or cluster called micelles (Trivedi and Compella, 2010). These 
micelles have several properties such as small size (10-100 nm), increased drug 
solubility, enhanced tissue penetration and longer circulation time which are suitable 
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for their applications as drug delivery carrier system (Li et al., 2013; Torchilin, 2007; 
Nishiyama and Kataoka, 2006). Pluronic F127, F68 and P123 are commonly 
explored surfactants or copolymers for the delivery of anticancer drugs (Kabanov et 
al., 2002; Batrakova and Kabanov AV, 2008; Hu et al., 2012). Recently, D-α-
tocopheryl polyethylene glycol succinate (TPGS) have also identified as 
pharmaceutically safe surfactant which could be used as nanocarrier system.  
1.6.2.1. D-α-tocopheryl polyethylene glycol succinate (TPGS) 
TPGS is a PEG derivative of natural vitamin E. It is synthesized by 
esterification of Vit E succinate with PEG. The molecular weight of TPGS depends 
upon the length of PEG chain. Generally, the molecular weight of TPGS containing 
PEG1000 is 1513. A hydrophobic part (Vit E) and a hydrophilic part (PEG) provide 
an amphiphilic nature to TPGS with a hydrophilic-lipophilic balance 13.2 and a 
critical micellar concentration 0.02% w/w. Above CMC value, TPGS forms micelles 
with nano-size range (< 50 nm) and with very low polydispersity. TPGS is highly 
stable in wide range of pH. TPGS has been used as solubilizer, non-ionic surfactant, 
emulsifier, absorption and permeability enhancer and nutritional supplement. The 
oral lethal dose 50 for TPGS is >7g/kg for adult rates and therefore, TPGS has been 
approved by FDA as a pharmaceutically safe adjuvant. In addition, TPGS is also an 
inhibitor of P-gp, a protein strongly involved in multi-drug resistance.  
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Figure 1.7: Chemical structure of D-α-tocopheryl polyethylene glycol 1000 
succinate 
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These unique properties of TPGS make it an important tool for the delivery of 
lipophilic drugs by improving their absorption and bioavailability. TPGS has been 
used in the delivery of various anticancer drugs as solubilizer (Pooja et al., 2014), 
nanocarrier system (Mu et al., 2005; Mi et al., 2011), stabilizer in polymer or lipid-
based nanoparticles formulation (Mu and Feng, 2002; Feng et al., 2007; Zhai et al., 
2008; Katragadda et al., 2011; Muthu et al., 2004, 2011). TPGS has also been 
conjugated directly with anticancer drugs to synthesized prodrugs (Cao and Feng., 
2008; Lee and Feng; 2005).  
Methods of preparation of Nanomicelles 
 There are two methods for the preparation of TPGS nanomicelles- 
a) Solubilisation above CMC value 
Self-assembled TPGS nanomicelles could be prepared by solubilizing TPGS 
in water above its CMC value.  
b) Solvent-casting method 
 This method is generally used to increase the drug loading if hydrophobic 
drugs. In this method, TPGS and drug are solubilized in organic solvent and then 
extracted with water under stirring or reduced pressure to form drug loaded 
nanomicelles. 
1.6.3. Dendrimers 
 Dendrimers are unique architecture polymers and have been used as 
potential drug delivery carrier system. Dendrimers are three-dimensional, highly 
branched monodisperse macromolecules with defined size, mass, topology and 
surface chemistry. Dendrimers are composed of a unique tree- like branched 
structure originating from a central core with branching out with the increase in 
generation number (Svenson and Tomalia, 2005; Mignani et al., 2013).  
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Therefore, a typical dendrimer structure contains four components: 
(i) A central core  
(ii) Branch units attached to the core and called as generation.  
(iii) Terminal surface functional groups attached to the outmost generation 
(iv) Void spaces 
 
Figure 8: Schematic diagram of a typical dendrimer molecule. This figure is taken 
from Tolia and Hannah, 2008. 
Advantages of dendrimers as drug delivery system: 
 Dendrimers are highly monodisperse system (Mw/Mn< 1.01-1.05) and can be 
synthesized with high purity. 
 Dendrimers not only carry a drug but can also enhance the solubility of lipophilic 
drugs. 
 Improve the oral bioavailability of both hydrophilic and lipophilic drugs. 
 Free terminal surface groups provide an opportunity of easy surface modification 
to develop a targeted drug delivery system. 
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 These surface groups can also be modified as stimuli responsive to release drugs 
(Ramireddy et al., 2012). 
 Because small size, dendrimers avoid the RES uptake and enhance the resident 
time of drug in the blood circulation (Mignani et al., 2013) 
 Dendrimers have also shown enhanced permeability and retention effect for the 
passive targeting of anticancer drugs. 
 Biocompatibility and opportunity to deliver multiple drugs at a time. 
 outstanding capability to be used with different routes of administration (Gupta et 
al., 2006) 
Methods of preparation of dendrimers-based formulations  
 Dendrimer based nanomedicines can be prepared by two methods: 
a) Encapsulation in interiors cavities:  
  Drug molecules can be encapsulated into empty internal cavities or void 
spaces present between branching units. The hydrophobic nature of these cavities 
makes them suitable for the encapsulation of lipophilic drugs (Svenson, 2009). In 
these cavities, drug may be present as an entrapped molecule or may be bound 
through electrostatic interactions. Although, electrostatic interactions are mostly 
observed between drug-molecules present on the surface of dendrimers. High 
density of functional groups on the surface of dendrimers has been explored to 
enhance the solubility of hydrophobic drugs using electrostatic interactions. 
For the preparation of drug loaded dendrimers formulations, an excess 
amount of drug is added to the dendrimer solution and kept shaking overnight using 
an orbital shaker. Thereafter, the formulation is allowed to stand for 24 h to 
equilibrate the dendrimers-drug complex followed by filtration through a suitable 
filter, usually 0.22 or 0.45 µm (Chauhan et al., . 2004) 
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b) Covalent conjugation 
  This technique is used for the site-specific and controlled release of the drug. 
Drug molecule is covalently conjugated to the free surface groups of the dendrimers. 
The drug is released by chemical or enzymatic cleavage of chemical bonds between 
drug and dendrimers (Ramireddy et al., 2012). Cancer cells have lower pH and 
higher glutathione reductase level than normal cells. Therefore, in case of anticancer 
drugs, covalent conjugation technique is used to make pH-sensitive or glutathione 
reductase triggered release of drug from the dendrimers-drug complexes.  
Dendrimers in the delivery of anticancer drugs 
 For the delivery of anticancer drugs, dendrimers have been used as both 
solubility enhancer and carrier system. Kojima et al., (2000) used PEG conjugated 
PAMAM dendrimers for the encapsulation of adriamycin and methotrexate. Similarly, 
Bhadra et al., (2003) used PEGylated PAMAM dendrimers for encapsulation of 5-
fluorouracil. Camptothecin has been encapsulated using polyester dendrimers 
(Morgan et al., 2006), 1,3,5 triazine based dendrimers (Steffensen et al., 2006) and 
poly (etherhydroxylamine) PEHAM dendrimers (Tomalia et al., 2006). Various 
research groups have encapsulated cisplatin using G3.5 PAMAM dendrimers (Malik 
et al., 1999; Kulhari et al., 2013). Other anticancer drugs, encapsulated using 
dendrimers, include doxorubicin (Gillies and Frechet, 2005), etoposide (Sideratou et 
al., 2010) and taxanes (Pooja et al., 2014). 
Apart from physical encapsulation, anticancer drugs have also been 
conjugated on the surface to form dendrimer-drug conjugate. Doxorubicin was 
covalently conjugated to polyester dendrimers through an acid-labile hydrazone 
bond (Padilla De Jesús et al., 2002). Dendrimers, based on amino apidic acid and β-
glutamic acids, have been coupled with epirubicin to improve solubility and stability 
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of the drug (Pasut et al., 2005). Paclitaxel was conjugated to PAMAM dendrimers to 
improve its cytotoxicity (Majorosetal., 2006; Khandare et al., 2006). Recently, Zhang 
et al., (2014) conjugated peptide dendrimers to doxorubicin via an enzyme-sensitive 
linker to target ovarian cancer. 
1.7. Physicochemical characterization of TDDS 
 Nanoparticles based formulations are characterized by several instrumental 
techniques: 
a) Dynamic light scattering: Nanoparticle size, polydispersity and zeta potential 
are measured by dynamic light scattering techniques. This technique is also known 
as photon correlation spectroscopy. Nanoparticles are dispersed in buffer or distilled 
water and measured for above parameters using a Zeta sizer Nano ZS.  
b) Surface morphology: Shape and surface morphology of nanoparticles are 
determined by scanning electron microscopy (SEM), transmission electron 
microscopy (TEM), atomic force microscopy (AFM) and small angle neutron 
scattering (SANS) analysis 
c) Fourier transform infrared (FTIR) analysis: Chemical interactions between 
drug molecules, excipients and matrix of nanoparticles are determined by FTIR 
analysis. FTIR is also used for confirmation of binding of a targeting ligand on the 
surface of nanoparticles.  
d) Differential scanning calorimetry (DSC): DSC is a thermo-analytical technique 
and used for the determination of physical state of drug inside the nanoparticles. It is 
also used for the thermal stability of nanoparticles. 
e) X-ray diffraction analysis (XRD): XRD is used to study the crystalline 
materials. Most of the anticancer drugs are crystalline in nature. However, after 
encapsulation in nanocarrier matrix, physical state is transformed to amorphous or 
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disordered crystalline or solid solution. Therefore, XRD is used to determine the 
physical sate of drug in nanoparticles.  
f) High performance liquid chromatography (HPLC): HPLC is used for both 
characterization and determination of drug content in nanoparticles. Therefore, 
HPLC is an analytical tool for the estimation of drug encapsulation efficiency and 
drug loading. Release of encapsulated drug from nanoparticles at different time 
period is also studied using a HPLC system. 
1.8. Targeting ligand 
A targeting ligand is a molecule which has high affinity towards receptors 
overexpressing on the surface of cancer cells. Therefore, nanoparticles could be 
directed specifically to the cancer cells by decorating their surface with a targeting 
ligand. A targeting ligand can be conjugated to the nanoparticles either directly or 
through a spacer between nanoparticles and a targeting ligand. A variety of 
molecules have been explored as potential targeting ligand. These include: 
 Low molecular weight compounds eg. Folic acid, β-hydroxy butyric acid 
 Peptides and proteins: Lectins, transferrin, RGD peptides, bombesin, 
somatostatin 
 Antibodies: EGFR targeting antibodies, monoclonal antibodies such as 
trastuzumab, cetuximab etc 
 Nucleic acids: Aptamers 
 Monosaccharide sugars: Mannose, lactose, galactose, glucose 
 Polysaccharides: Hyaluronic acid 
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Figure 1.9: Nanomaterial strategies from the point-of-view of the cell. This figure 
summarizes unique targeting, diagnostic and therapeutic mechanisms related to the 
cancer cell. This figure is taken from Schroeder et al., 2011. 
 
1.8.1. Peptides  
A peptide is a chain of amino acids. Initially, peptides were recognised as 
hormones or vaccines which act through g-protein coupled receptors. However, with 
the increasing knowledge of peptide chemistry and functionality, peptides have been 
used as drug carrier, targeting ligand and proteases substrate. Cell penetrating 
peptides found their application as drug delivery carrier to overcome the problem of 
passage through the cellular plasma membrane barrier. As targeting ligand peptides 
have several advantages of high specificity, small size and possibility of large scale 
synthesis by chemical methods. Peptides like bombesin, Tat, PIVO-8, PIVO-24, LyP-
1 and RGD-based peptides have been successfully used as targeting ligand for 
cancer imaging and therapy (Chang et al., 2009; Luo et al., 2010; Danhier et al., 
2012; Karmali et al., 2009; Zhang et al., 2012; Stott Reynolds et al., 2015; Cheng et 
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al., 2014; Li et al., 2014; Zhan et al., 2010). In this PhD research work, two peptides-
bombesin and cyclo (-Arg-Gly-Asp-D-Phe-Lys) have been used as targeting ligands. 
1.8.1.1. Bombesin  
Bombesin receptors are a type of G-protein coupled receptors and have 4 
subtypes- BB1, BB2, BB3 and BB4. BB1 is known as the neuromedin B (NMB) 
receptor because of its affinity towards mammalian ligand NMB. BB2 receptor with 
high affinity to mammalian gastrin releasing peptide (GRP) is called as GRP receptor 
(Jenson et al., 2008). Among bombesin receptors, in particular BB2 have been found 
to be over expressed in several cancers (Table 1.1).  
Table 1.1: Different types of bombesin receptors, their agonist, physiological role and 
over expression in cancer 
Bombesin 
Receptor 
Agonist Physiological role Over expression 
in cancer  
References 
BB1 
(NMB) 
Neuromedin  
B 
Urogenital and 
gastrointestinal smooth 
muscles contraction 
Small cell lung 
cancer cells, non-
small cell lung 
cancer, Colon 
cancer 
Reubi et al., 
2002; Moody 
et al., 1995; 
Matusiak et 
al., 2005 
BB2 
(GRP) 
Bombesin Stimulation of acid 
secretion, pancreatic 
exocrine and enteric 
peptide hormones, gut 
motility, Stimulation of 
immune response 
Breast, prostate, 
lung, colon, 
glioblastoma, 
neuroblastoma, 
head and neck 
squamous cell 
cancers  
Gugger and 
Reubi, 1999; 
Markwalder 
and Reubi, 
1999; Reubi 
et al., 2004; 
Fleischmann 
el., 2005; 
Jensen et al., 
2008;  
BB3 MK-50946 
and Bantag-
1 
Regulation of blood 
glucose level, energy 
balance and weight 
control 
Testis, lung and 
ovarian cancer 
Moreno et al, 
2013 
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Role of bombesin peptide (BBN) in cancer  
Bombesin (BBN) is a 14-amino acid peptide and has structural similarity with 
GRP naturally present in human.  BBN was originally isolated from a frog Bombina 
bombina by Antansi et al., in 1971. Gargosky et al., then found that the C-terminal 
peptide ligand containing 7 to 9 amino acids sequence is sufficient to achieve 
receptors-mediated response of bombesin. Since then several analogues of BBN 
have been synthesized to target GRP receptors for the imaging, diagnosis and for 
the treatment of cancer.  
BBN in imaging and diagnosis 
Bombesin analogues have been conjugated with radionuclide and fluorescent 
substances for the imaging and diagnostic of cancers. Wagh et al. (2012), 
synthesized 111In-labelled BBN conjugates, comprising 2-nitroimidazole as 
pharmacophore, for the imaging of PC3 human prostate cancer cells. Abiraj et al. 
(2011), constructed and evaluated BBN antagonist (PEG4-D- Phe-Gln-Trp-Ala-Val-
Gly-His-Sta-Leu-NH2) based radioligands for single, photon emission computed 
tomography (SPECT) and positron emission tomography (PET) nuclear imaging in 
PC3 tumour bearing nude mice. Chanda et al., (2010) used radiolabelled gold 
nanoparticles-BBN conjugate for the imaging of prostate cancer cells and to study 
the BBN-mediated biodistribution of nanocarrier. Mendoza-Sanchez et al., (2010) 
used 99m Tc-labelled gold nanoparticles and then conjugated with Lys3-bombesin 
for the imaging of GRP-receptors in vivo in athymic mice with PC3 induced tumours.  
BBN in targeting of cancer 
Yang et al., (2013) synthesized chimeric peptide by conjugating BBN with a 
mitochondrial-disrupting peptide B28 to enhance the selectivity and toxicity of B28 
against bombesin receptor over expressing prostate cancer cells. BBN conjugated 
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B28 peptide was found to be 10 time more cytotoxic with specifically accumulation in 
mitochondria than unconjugated B28. In an interesting study, Cascato et al., (2008) 
evaluated in vitro and in vivo targeting potential of two GRP receptors antagonists 
(Demobesin 1 and Demobesin 4) in comparison to an agonist.  The results 
demonstrated that GRP receptor antagonists could be a better targeting agent than 
GRP receptors agonist. Accardo et al (2012) synthesized doxorubicin loaded 
liposomes for the targeting of GRP receptors over expressing prostate cancer cells.  
1.8.1.2. Arg-Gly-Asp (RGD) based peptides 
Integrin receptors have been recognised as potential targets for delivery of 
anticancer drugs. Integrins are cell adhesion receptors for extracellular matrix 
proteins, enzymes like proteases, immunoglobulins and cytokines (Wang et al., 
2013). Integrins are heterodimeric trans-membrane glycoproteins composed of two 
subunits α and β. There are 18 α-subunits and 8 β-subunits which form 24 different 
types of functional integrins (Desgrosellier and Cheresh, 2010). Integrins are 
overexpressed in different cancer and therefore consider potential target for drug 
delivery applications. Among all integrins, αvβ3 is specifically involved in metastasis, 
tumour proliferation and angiogenesis (Danhier et al., 2012).  
Peptides containing an RGD moiety preferentially bind to the αvβ3 receptor 
and have been used as targeting ligand for therapeutic application in cancer. 
Anticancer drugs such as doxorubicin (Murphy et al., 2008; Zhou et al., 2012), 
paclitaxel (Danhier et al., 2009, 2012; Zhan et al., 2010), docetaxel (Ray et al., 
2012), gemcitabine (Xu et al., 2012), cisplatin (Graf et al., 2012) and geldanamycin 
(Borgman et al., 2009) have been targeted to αvβ3 receptor over expressing cancer 
cells.  Apart from drug delivery, RGD-based peptides have also been explored for 
imaging of integrin receptors over expressing cancer cells in vitro and in vivo. 
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(Schmieder et al., 2008; Pike et al., 2010; Nasonkla et al., 2006; Tsiapa et al., 2013; 
Shen et al., 2013; Yang et al., 2011). cRGDfK is a cyclic peptide with a sequence 
cyclo (-Arg-Gly-Asp-D-Phe-Lys) and molecular weight 603.7 Da. more stable than 
linear peptide. The lysine residue with free amine group provides an opportunity for 
chemical coupling with nanoparticles.  
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Figure 1.10: Chemical structure of cRGDfK, a RGD-based cyclic peptide that binds to 
αvβ3 receptor over expressing cancer cells 
 
1.8.2. Monoclonal antibody: Trastuzumab 
 Trastuzumab (TZ) is a recombinant humanized monoclonal antibody that 
binds with extracellular domain IV of human epidermal growth factor receptor HER2 
(Valabrega et al., 2007). HER2 receptors have been found to over express in 15-
20% of breast cancer and TZ is one of the first line treatment drugs for HER2 
positive breast cancer (Colozza et al., 2006). TZ is also the standard care of 
treatment for metastatic gastric cancer (Boku et al., 2014). Although TZ was 
developed as a drug, it is being tested as targeting ligand for the delivery of various 
anticancer drugs and nucleic materials (Yousefpour et al., 2011; Shukla et al., 2008; 
Steinhauser et al., 2008). I have published a review article describing the role of TZ 
as anticancer drug and as targeting ligand. Please refer appendices. 
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1.9. Anticancer drugs used in the research work 
1.9.1. Docetaxel (DTX) 
IUPAC name: 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-
acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-
phenylpropanoate} 
Chemical formula: C43H53NO14 
Molecular mass: 807.87 g/mol;    
Meting point: 176-178 °C 
Category: Semisynthetic, taxane derivative.  
Physical state: White crystalline powder                  
Solubility: insoluble in water, freely soluble in ethanol, sparingly soluble in 
acetonitrile, soluble in acetone, methanol and ethyl acetate. 
Clinical applications: DTX has been approved by the FDA for treatment of locally 
advanced or metastatic breast cancer, gastric cancer, head and neck cancer, 
hormone-refractory prostate cancer and non-small-cell lung cancer.  
Mechanism: DTX disrupt the microtubule assembly and inhibits the cell division 
leading to apoptosis and cell death (Musumeci et al., 2006; Oliveira et al., 2013).  
Plasma half-life: 86 h 
Protein binding: >98% 
Metabolism: Hepatic 
Excretion: Biliary 
Side effects: Taxotere is the marketed formulation of DTX which is formulated with a 
high concentration of Tween® 80 (40 g/L) which causes severe side effects like 
hypersensitivity reactions, cumulative fluid retention, nausea, fatigue, hair loss, 
peripheral neuropathy, and anaemia (Gelderblom et al., 2001; Lee et al., 2011) 
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1.9.2. Gemcitabine hydrochloride (GEM) 
IUPAC name: 4-amino-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin-
2(1H)-on 
Chemical formula: C9H11F2N3O4. HCl 
Molecular mass: 299.66 g/mol;   Meting point:  
Category: Nucleoside analogue 
Physical state: White to off-white solid, crystalline.  
Solubility: Soluble in water, slightly soluble in methanol, and practically insoluble in 
ethanol and polar organic solvents. 
Clinical applications: GEM has been approved by Food and Drug Administration 
(FDA) for the treatment of breast cancer (with paclitaxel), non-small cell lung cancer 
(with cisplatin), ovarian cancer and pancreatic cancer.  
Mechanism: GEM is a prodrug and phosphorylated by deoxycytidine kinase to 
gemcitabine monophosphate followed by gemcitabine di- and triphosphates.  
Gemcitabine triphosphate is incorporated into DNA chain by DNA polymerase that 
results to termination of chain elongation. GEM also inhibits DNA polymerase. By 
another mechanism, diphosphate analogue of GEM binds with ribonucleotide 
reductase and inactivates the enzyme irreversibly. Ribonucleotde reductase is an 
essential enzyme for DNA replication and repair (Mini et al., 2006).   
GEM half-life: 8-17 min (Joshi et al., 2014) 
Protein binding: <10% 
Side effects: GEM is reported to cause leukopenia, thrombocytopenia and anemia by 
suppressing bone marrow function. GEM also causes pulmonary, renal (haemolytic 
uremic syndrome) and hepatotoxicity. Being embryotoxic, GEM can cause fetal 
malformations (cleft palate, incomplete ossification) when given to pregnant woman.   
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1.9.3. Camptothecin (CPT) 
Camptothecin (CPT) is a plant quinolone alkaloid obtained from bark and stem of 
Camptotheca acuminata, a Chinese tree (Amna et al., 2013).  
IUPAC name: (S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-
3,14-(4H,12H)-dione 
Mol. Wt.: 348.35 g/mol 
Chemical formula: C20H16N2O4 
Solubility: Poorly soluble in water (logP=1.74) 
Melting point: 275-277 °C 
Physical state: CPT is found as yellowish, solid powder. CPT is present in two inter-
convertible forms; lactone (active form) and carboxylate (inactive form) (Zou et al., 
2013). 
Mechanism of action: CPT binds to the topoisomerase I and DNA complex, stabilizes 
it and prevents DNA re-ligation and therefore resulting in DNA damage followed by 
apoptosis (Amna et al., 2013). 
Pharmacokinetics:  
Protein binding: high plasma protein binding. Lactone form and carboxylate form 
bind about 81% and 98% to human serum albumin, respectively (Schluep et al., 
2006). 
Toxicity: Acute oral toxicity (LD50 in miceis 50.1 mg/kg 
Clinical applications:  
CPT has shown a broad spectrum of anticancer activity against different cancers in 
human including breast, lung, prostate, colon, stomach, ovarian carcinomas and 
melanoma (Venditto and Simanek, 2010).  
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1.10. Focus area of this research work 
Ligand mediated nanoparticles is attractive research area for the targeted 
delivery of anticancer drugs to tumor cells. Bombesin has been reported to bind with 
the GRP receptors. Human breast cancer cells such MDA-MB-231 over express the 
GRP receptors. The initial objective of the study was to develop BBN-conjugated 
PLGA nanoparticles for the delivery of DTX. During the formulation optimization, I 
observed, surprisingly, that BBN-conjugated PLGA nanoparticles were more stable 
than unconjugated nanoparticles. Therefore, the major focus of Chapter 2 was to find 
out the possible mechanisms behind the higher stability of BBN-conjugated PLGA 
over unconjugated nanoparticles. In chapter 3, BBN-conjugated PLGA nanoparticles 
were explored for the delivery of DTX to GRP-over expressing breast cancer cells. 
As prostate cancer cells also over express the GRP receptors, in a separate study 
(chapter 4), the anticancer activity of these nanoparticles was studied against two 
human prostate cancer cells DU145 and PC3 cells along with biodistribution studies 
in male Balb/c mice. 
In chapter 5, TZ was conjugated to dendrimers for the delivery of DTX to 
HER2-postive cancer cells. Although antibody conjugated nanoparticles have been 
reported for the delivery of anticancer drugs, the major focus was to study the 
pharmacokinetic profile of DTX loaded in TZ-conjugated dendrimers. In chapter 6-8, I 
explored the potential of integrin receptor-binding peptide, cRGDfK as targeting 
ligand. As integrin receptors have been found to be over-expressed in more than one 
cancer, the efficacy of cRGDfK-conjugated nanoparticles (as targeted delivery 
system) was studied against prostate cancer (chapter 6), ovarian cancer (chapter 7) 
and brain cancer (Chapter 8).  
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2.1. Background 
Nanoparticles are promising carriers for several biomedical applications such 
as imaging, diagnostics and drug delivery (Davis et al., 2008; Arruebo et al., 2009; 
Koi et al., 2012. In drug delivery, their applications are mostly explored in 
development of targeted drug delivery systems especially for anticancer drugs. 
Because of small size, nanoparticles can easily enter into the cancer cells through 
the leaky vasculature (passive targeting). In addition, the surface of nanoparticles 
can be easily manipulated to give receptor-specific targeted system (Ruoslahti et al., 
2010).  
The efficacy of the nanoparticulate systems is very much dependant on three 
basic surface properties such as size, surface charge and hydrophobicity (Muller, 
1997; Jiang et al., 2009). These parameters affect stability as well as in vivo 
performance like translocation to target site, binding and cellular uptake (Petros and 
DeSimone; 2010). Nanoparticles are colloidal systems that range in size range 10-
1000 nm and their stability is mainly determined by the surface chemistry. The 
physical stability of colloidal systems is explained by their aggregation and 
coagulation behavior.  
According to DLVO theory, the stability of nanoparticles depends on the 
balance between attractive Van der Waals and repulsive electrostatic forces due to 
double layer of counter ions (Derjaguin and Landau, 1941; Verwey et al., 1948). 
Among three different types of Van der Waals forces (Keesom, Debije and London), 
London forces i.e. induced dipole – induced dipole, are mainly responsible for 
attraction and aggregation of nanoparticles. The strength of electrostatic repulsion 
forces depends on the distance from the nanoparticle surface. Electrostatic forces 
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are expressed in terms of Nernst potential and Zeta potential (ζ). The Nernst 
potential is the potential difference between the actual nanoparticle surface and 
electroneutral region. The zeta potential or electrokinetic potential is the potential 
difference between shear plane and electroneutral region. Nernst potential has little 
effect in colloidal stabilization and is not practically assessable. Thus zeta potential is 
an important parameter of electrostatic repulsion. When the electrostatic repulsive 
forces dominate the attractive Van der Waal forces, the system remains stable and 
in dispersed state. Thus high zeta potential value (more negative or positive) 
indicates more the colloidal stability of nanoparticles. But, practically attractive forces 
are found to be stronger compared to repulsive forces and nanoparticles tend to form 
aggregates within seconds.  
Surface hydrophobicity is another major cause of the instability of 
nanoparticles. It also affects the behavior of nanoparticles in aqueous environment 
and decides the fate and transport of nanoparticles (Muller, 1997). The 
hydrophobicity plays an important role in the interaction of nanoparticles with the bio-
membranes (Li et al., 2008; Kim et al., 2013; Xiao and Wiesner, 2012). 
Several approaches can be used to increase the stability of nanoparticles 
(Chen et al.,2010). First, by forming an electric double layer around nanoparticles i.e. 
charge or electrostatic stabilization. Second, by adsorption or chemically attachment 
of polymeric molecule on the nanoparticle surface (steric stabilizer) i.e. steric 
stabilization (Luckham, 1996). Third, combination of both electrostatic and steric 
stabilization i.e. electrosteric stabilization. Generally, steric stabilization or 
electrosteric stabilization approaches are used in nanoparticle stabilization because 
of its several advantages- electrolyte insensitivity, redispersibility of nanoparticles, 
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can accommodate high concentration and suitability to multiphase systems (Ortega-
Vinuesa et al., 1996; Russel et al., 1992; Birdi, 2008). 
The primary objective of this investigation was to develop a sterically 
stabilized bombesin (BBN) peptide conjugated biodegradable polymeric 
nanoparticles based system for cancer targeting. Several targeting ligands have 
been conjugated to nanoparticles for the delivery of anticancer drugs (Liang et al., 
2011; Zheng et al, 2010; Dhar et al., 2008). However, surface conjugation changes 
the dimension and other physicochemical parameters such as surface charge, which 
are directly related to the stability of nanoparticle. Hence, the colloidal stability of 
unconjugated polymeric nanoparticles (PNP) and BBN conjugated nanoparticles 
(BPNP) was studied in the presence of electrolytes and physiological conditions. The 
nanoparticle stabilization and aggregation mechanisms were investigated in detail. 
This study also provides insight about the selection of method for the determination 
of stability factor. 
2.2. Experimentation 
2.2.1. Materials 
Poly (D,L-lactic-co-glycolic acid) (PLGA) containing a free carboxyl end group 
(uncapped) with L/G molar ratio of 50:50, Bombesin, Sodium cholate, 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC), N-Hydroxysuccinimide (NHS), 2-(n-
morpholino) ethanesulfonic acid (MES)  and N-[tris(hydroxymethyl)methyl]-2-
aminoethane sulfonic acid (TES) were purchased from Sigma-Aldrich (Mumbai, 
India). Bradford reagent was purchased from Biomatik (Hyderabad, India). Rose 
Bengal dye and other chemicals were of analytical grade and were purchased from 
s. d.  fine-chem Ltd. (Hyderabad, India).  
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2.2.2.  Preparation of PLGA nanoparticles 
PLGA nanoparticles (PNP) were prepared by a modified solvent evaporation 
(nano-precipitation) method. PLGA (20 mg) was dissolved in 2 mL acetone and then 
quickly poured in 20 mL of deionised water containing different concentrations 
(0.1%, 0.25% and 0.5% w/v) of surfactants (polyvinyl alcohol, Tween® 20 and sodium 
cholate). The dispersion was sonicated for 2 minutes in an ice bath. The organic 
phase was evaporated off by magnetic stirring at 1000 rpm for 3 h. Finally, the 
dispersion was centrifuged at 15000 rpm for 20 minutes at 4 °C. Nanoparticles were 
washed thrice with deionised water, lyophilized and stored at 2-8 °C.   
 
2.2.3. Bioconjugation of BBN to PLGA nanoparticle  
Ten milligrams of PNP were dispersed in 5 ml of MES buffer (0.1 M) and 
incubated with 497.95 µM of EDC and NHS each. The dispersion was kept on gentle 
stirring for one hour at room temperature. To this, 100, 250 and 500 µl of BBN 
solution (1 mg/ml) was added, mixed well and kept for further stirring of 6 h. BBN 
conjugated nanoparticles (BPNP) were collected after centrifugation at 10000 rpm 
for 10 min and washed thrice with distilled water. The conjugation efficiency was 
determined by measuring BBN in supernatant by Bradford protein assay. The 
absorbance was measured at 595 nm using microplate reader (Synergy 4, Biotek). 
 
2.2.4.  Effect of pH and buffer on conjugation efficiency 
The effect of pH and buffer medium on the peptide conjugation efficiency was 
studied using 0.1 M MES buffer pH 6.2, phosphate buffer saline pH 7.4 (PBS) and 
0.1 M TES buffer pH 8.2.  
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2.2.5. Nanoparticle characterization 
Nanoparticles were characterized for particle size, zeta potential, surface 
morphology and chemical interactions between the molecules. Mean particle 
diameter (PD), polydispersity index (PDI) and zeta potential of both PNP and BPNP 
were measured by proton correlation spectroscopy using Zetasizer Nano-ZS 
(Malvern instrument Ltd., Malvern, UK). Samples were diluted 10 times with distilled 
water and analyzed at 25 °C with a backscattering angle of 173°.  
Surface morphology of nanoparticles was determined by scanning electron 
microscopy (SEM) analysis. The samples were sputtered on thin film of gold and 
scanned using SEM machine (SEM-LEOS 1430VP, LEO Electron Microscopy Ltd, 
U.K) equipped with tungsten filament. The chemical interaction between amine 
group of BBN and carboxylic group of PNP was studied by Fourier transform infrared 
(FTIR) analysis. FTIR analysis was carried out by potassium bromide (KBr) pellet 
technology. An amount (3 mg) of nanoparticles was mixed with the 100 mg of KBr 
using a mortar and pestle. The mixture was filled in the die and pressed using 15 ton 
laboratory Hydraulic Pellet Press. The formed pellet was placed in the pellet holder 
and scanned using FTIR (Perkin Elmer, Spectrum one) spectrophotometer in the 
range of wave number 450 to 4000 cm-1. 
2.2.6. Colloidal and serum stability studies 
2.2.6.1. Stability of nanoparticles in serum and physiological conditions 
Stability of PNP and BPNP with time was tested in bovine serum (1% v/v), 
PBS and physiological saline (NS) as per earlier reports (Lazzari et al., 2012; 
Chaudhari et al., 2012). A stock solution (1 mg/ml) of nanoparticles was prepared in 
distilled water. Aliquot (0.5 ml) of the stock solution was taken and diluted with 4.5 
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mL of study medium. The samples were stored at room temperature and particle 
size, polydispersity and zeta potential were determined. 
2.2.6.2. Salt induced aggregation of nanoparticles 
 Salt induced aggregation of nanoparticles was studied by the method reported 
previously (Chaudhari et al., 2012). Both nanoparticles were dispersed in 0.1 to 1 M 
sodium sulphate solutions and the optical density of the dispersions was measured 
at 595 nm by UV/VIS spectrophotometer (Perkin Elmer, Lambda 25, UK). 
2.2.6.3. Determination of Fuchs or stability factor 
 Stability or Fuchs factor was determined by two different methods. a) On the 
basis of optical density: The optical density of nanoparticle suspension was 
determined at 595 nm using UV/VIS spectrometer. The total aggregation 
measurement time was 200 s.  b) On the basis of average hydrodynamic diameter: 
The nanoparticles were dispersed in varying concentration of salts solutions (NaCl 
and CaCl2). The hydrodynamic diameter of nanoparticles and aggregates was 
determined as a function of time by dynamic light scattering method. 
The Fuchs factor (W) for every electrolyte concentration was calculated using 
following equation:  
             Kf            (dAbs/dt)f 
 W =             =                                                               ………….. (Equation 1) 
            Ks             (dAbs/dt)s 
 
Where, Kf is the fastest aggregation-kinetic constant and Ks is slower aggregation-
kinetic constant.  
These rate constants can be calculated from following equation: 
   dAbs               (0.5C2 – C1) N20 l 
                  =                                  k                               ………….. (Equation 2) 
    dt                            2.3 
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Where; C1 and C2 are scattering cross-sections of a monomer and a diamer, 
respectively, N0 is the initial particle concentration, and l is the optical path length. 
Similarly, the W was calculated for particle diameter studies by replacing the 
absorbance with particle diameter in equation 1. 
2.2.7. Surface hydrophobicity of nanoparticles 
 Surface hydrophobicities of PNP and BPNP were determined by Rose Bengal 
dye adsorption test as reported earlier (Jung et al., 2002). The nanoparticles were 
dispersed in different concentration of dye solutions (5- 40 µg/ml) and incubated at 
25 ºC for 3 h. Nanoparticle dispersion was centrifuged at 15000 rpm for 1 h and 
amount of dye adsorbed on the nanoparticle surface was determined indirectly by 
measuring unbound dye in supernatant at 542 nm using UV-VIS spectrophotometer.  
The binding constant (K) of Rose Bengal for PNP and BPBP was determined 
by Scatchard transformation:  
r/a = KN-Kr                                                                    ………….. (Equation 3) 
 Where; r = where r is the amount of Rose Bengal adsorbed per mg nanoparticles 
(mg/mg); a is equilibrium concentration of Rose Bengal (mg/ml); K is the binding 
constant (ml /mg); and N is the maximum amount bound (mg/mg).  
2.2.8. Peptide desorption studies 
The integrity of the chemical bond between nanoparticle and BBN was tested 
by measuring the release of BBN from the nanoparticles surface. Ten milligram of 
BPNP were dispersed in 5 mL of PBS, mixed well and kept on mechanical shaker. At 
scheduled time intervals, the nanoparticles were centrifuged at 10000 rpm for 5 
minutes and supernatant was estimated for BBN content. 
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2.3. Results and discussion 
2.3.1. Optimization of PLGA nanoparticles using different surfactants 
PLGA nanoparticles were prepared by solvent evaporation method. PLGA 
was dissolved in acetone and transferred to aqueous surfactant solution to get o/w 
emulsion.  The formed emulsion was stirred to evaporate the organic phase and 
form drug encapsulated nanosized particles. PLGA nanoparticles preparations have 
been reported with or without surfactant solutions (Dailey et al., 2003; Wang et al., 
2009). However, nanoparticles prepared without surfactant were found to be less 
stable compared to with surfactant nanoparticles. In this study, PLGA nanoparticles 
were prepared using three different surfactants: PVA, Tween 20 and sodium cholate, 
at three different concentrations (0.1%, 0.25% and 0.5% w/v). The observed mean 
particle size and zeta potential of the different formulations are shown in Table 1. 
Nanoparticles prepared with sodium cholate were of smaller size (< 100 nm) 
compared to PVA (102.65-119.82 nm) and Tween 20 (109.33-149.92 nm). Among 
the various formulations prepared with sodium cholate (F3, F6 and F9), F6 
formulation showed the smallest size (86.15 ± 2.47 nm). Both increase and decrease 
in surfactant concentration produced larger nanoparticles. It can be attributed to 
adsorption of surfactant molecules on nanoparticle surface at higher concentration. 
On the other side, low surfactant concentration may be insufficient to keep particle 
separate leading to agglomeration of small particles. 
The zeta potential observed for various formulations ranged from -23.3 to- 
24.2 mV for PVA, -21.8 to -34.7 mV for Tween 20 and -27.6 to -36.5 mV for sodium 
cholate. So formulation F6 was considered as optimized formulation because of the 
smallest size and good zeta potential value (Figure 2.1).  
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Table 2.1: Optimization of PLGA nanoparticle prepared with different surfactants 
(Mean ± SD, n=3) 
Formulation Surfactant Size (nm) PDI 
Zeta 
Potential 
(mV) 
F1 0.5% PVA 110.64 ± 1.28 0.12 ± 0.05 -24.2 ± 2.6 
F2 0.5% Tween 20 115.90 ± 2.42 0.07 ± 0.01 -21.8 ± 3.1 
F3 0.5% Sod. cholate 91.12 ± 1.53 0.18 ± 0.02 -36.5 ± 3.7 
     
F4 0.25% PVA 119.82 ± 3.46 0.11 ± 0.02 -23.3 ± 1.2 
F5 0.25% Tween 20 109.33 ± 1.54 0.07 ± 0.02 -24.5 ± 2.8 
F6 0.25% Sod. cholate 86.15 ± 2.47 0.11 ± 0.03 -34.2 ± 2.3 
     
F7 0.1% PVA 102.65 ± 4.07 0.13 ± 0.04 -23.7 ± 2.3 
F8 0.1% Tween 20 149.92 ± 3.28 0.33 ± 0.05 -34.7 ± 3.5 
F9 0.1% Sod. cholate 98.42 ± 1.89 0.20 ± 0.04 -27.6 ± 4.1 
 
 
 
a) 
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b) 
Figure 2.1: a) Particle diameter and b) zeta potential of bombesin conjugated PLGA 
nanoparticles (BPNP) measured by Dynamic light scattering method 
2.3.2. Conjugation of BBN to PNP surface 
Bombesin was conjugated to the PNP surface by well known EDC/NHS 
reaction. The free carboxylic group on nanoparticle surface was activated by 
EDC/NHS and allowed to react with free amine group present on BBN. The 
conjugation was carried out in three different peptide/polymer ratios (Table 2.2). As 
the peptide concentration was increased, the size of the particles was also 
increased. But, the zeta potential was changed from -34.2 mV to -9.1 mV. The 
surface charge of PLGA nanoparticle is due to presence of negatively charged 
carboxylic group on the surface. During conjugation, this carboxylic group interacts 
with positive amine group of BBN and overall surface charge moves towards 
neutrality.  
The conjugation efficiency was decreased with the increase in peptide 
concentration in reaction mixture. This can be explained by the steric hindrance on 
the nanoparticle surface at higher peptide concentration. However, the peptide 
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conjugation to per mg of nanoparticle was increased. The BBN conjugated to per mg 
of nanoparticles was 4.75 µg, 9.06 µg, and 19.13 µg for BPNP1, BPNP2 and 
BPNP3; respectively. The slight variation in pH and buffer medium did not show 
significant difference in conjugation efficiency and other physicochemical 
parameters. Hence, it is suggested that BBN conjugation to nanoparticles can be 
carried out in the pH range 6.2-8.2.  
Table 2.2: Characterization of Bombesin conjugated PLGA Nanoparticles (Mean ± SD, 
n=3) 
Formulation Particle 
diameter (nm) 
Polydispersity 
index 
Zeta potential 
(mV) 
Conjugation 
efficiency (%) 
PNP 86.15 ± 2.47 0.11 ± 0.04 -34.2 ± 2.9 - 
BPNP 1 101.32 ± 3.96 0.22 ± 0.02 -15.7 ± 1.8 94.47 ± 0.62 
BPNP 2 112.59 ± 2.15 0.19 ± 0.04 -11.3 ± 1.5 90.59 ± 2.11 
BPNP 3 129.72 ± 4.06 0.31 ± 0.03 -9.1 ± 2.6 76.52 ± 1.84 
 
2.3.3. SEM analysis   
The surface morphology was studied using scanning electron microscope 
(Figure 2.2). Nanoparticles were spherical in shape and well dispersed in the 
dispersion medium. The average particle size was in the range of 100-150 nm. 
2.3.4. FTIR analysis 
Binding of BBN to the nanoparticle surface was confirmed by the FTIR 
analysis. FTIR spectra of pure BBN showed characteristic peaks at 3299, 1647 and 
1533 cm-1 corresponding to -NH stretching, C=O stretching (amide I) and -CN 
stretching (amide II), respectively (Figure 2.3). The characteristic carboxylic group 
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500 
 
peak of PNP was appeared at 1760 cm-1. The other peaks of PNP were observed at 
3392 (-OH stretching), 2938 (-CH stretching) and at 1082 cm-1 (-C-O stretching). In 
BPNP FTIR spectra, the carboxylic group peak was disappeared and amide bond 
peak was appeared at 1650 cm-1 which confirmed the formation of amide bond 
between carboxylic group of PNP and amine group of BBN. 
 
 
 
 
 
 
 
Figure 2.2: Scanning electron microscopy (SEM) of bombesin conjugated PLGA 
nanoparticles (BPNP). Size-scale is represented in nm. 
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Figure 2.3: FTIR spectra of a) Bombesin, b) PLGA nanoparticle and c) Bombesin 
conjugated PLGA nanoparticles 
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2.3.5. Colloidal stability of nanoparticles in serum and physiological 
conditions 
 Colloidal stability of nanoparticles was determined in distilled water, NS, and 
PBS and was expressed as change in particle size (Figure 2.4) and PDI (Figure 2.5) 
with time. After intravenous administration, the size and charge of nanoparticles are 
mainly determined by the adsorbed serum components (Lourenco et al., 1996). 
Hence, a similar study was also carried out in 1% bovine serum. Both PNP and 
BPNP were to be found stable in all four medium up to 24 h. The observed particle 
size of PNP was 221.3, 217.6, 131.5 and 130.9 nm in DW, NS, PBS and serum, 
respectively. In case of BPNP, the particle size was 258.8, 277, 171.3 and 158.2 nm 
in DW, NS, PBS and serum, respectively. Although, an increase in particle size was 
observed with nanoparticles dispersed in DW and NS, no agglomeration was 
observed. Nanoparticles were dispersible and stable in the medium. Similar effect 
was observed on PDI after dispersion in to different medium. After 24 h, the PDI for 
both PNP and BPNP was below 0.3 in serum and PBS. In NS and distilled water, the 
PDI was more than 0.5 for PNP and BPNP.  
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Figure 2.4: Change in particle size of a) polymeric nanoparticle (PNP) and b) 
Bombesin conjugated PLGA nanoparticles (BPNP) with time in different medium (n=3) 
a) PNP
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 4 8 12 16 20 24
Time  (h)
Po
ly
di
sp
er
si
ty
 in
de
x
Serum
NS
PBS
DW
 
b) BPNP
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 4 8 12 16 20 24
Time  (h)
Po
ly
di
sp
er
si
ty
 in
de
x 
Serum
NS
PBS
DW
 
Figure 2.5: Change in polydispersity of a) polymeric nanoparticle (PNP) and b) 
Bombesin conjugated PLGA nanoparticles (BPNP) with time in different medium (n=3) 
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2.3.6. Salt induced aggregation of nanoparticles 
 Nanoparticles were incubated in increased concentration of sodium sulphate 
to evaluate their aggregation resistance property (Figure 2.6). The critical flocculation 
concentration (CFC) of PNP and BPNP in Na2SO4 was 0.4M and 0.7M. The results 
showed that nanoparticles were stable through electrostatic forces and addition of 
Na2SO4 solution resulted in destruction of electrostatic double layer. The increase in 
CFC of BPNP may be to steric stabilization of nanoparticles by the BBN.  
 
 
Figure 2.6: Change in optical density of PNP and BPNP dispersion with sodium 
sulphate concentration (n=3) 
 
2.3.7. Determination of stability or Fuchs factor (W) 
 Aggregation-kinetics studies were performed to determine the stability or 
Fuchs factor. According to DLVO theory, the aggregation of a lyophobic colloidal 
system increases with increase in electrolyte concentration. Generally the optical 
density increases with the increase in aggregation. Hence the measurement of 
optical density of the colloidal system provides insight about the stability of 
nanoparticles. The change in the optical densities of PNP and BPNP with the time 
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were measured (Figure 2.7). The curves were found steeper in CaCl2 than in NaCl 
and the steepness was increased with the concentration.  
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d)  
Figure 2.7: Change in optical density with time: a) PNP in NaCl; b) PNP in CaCl2; c) 
BPNP in NaCl; and d) BPNP in CaCl2 
But, these curve provide only a general picture of stability and difficult to differentiate 
the effect of little variation in electrolyte concentration. Therefore, the data were 
treated to calculate the Fuchs factor for individual electrolyte concentration (Equation 
1 and 2).   
Fuchs factor is related to the number of collisions that must occur between 
two colliding particles before they stuck completely. The value W =1 indicates the 
complete instability of colloidal system while W= ∞ means the total stability (Fuchs, 
1934). Further, for the determination of exact CFC, the Fuchs factor was plotted 
against the electrolyte concentration (Figure 2.8). For PNP, the CFC was observed 
1.5M for NaCl and 30 mM for CaCl2. For BPNP, the optical density values were 
negative at lower concentration of both NaCl and CaCl2. At higher concentration (> 
1M), the CFC was not observed up to 2.5 M concentration of both NaCl and CaCl2. 
However, the minimum observed W value was 4.2 and 1.8 in NaCl and CaCl2. All 
above data indicated that both PNP and BPNP showed faster aggregation in CaCl2 
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than NaCl. It is because of the faster neutralization of negative surface charge of 
nanoparticles by the divalent Ca+2 ions than monovalent Na+1. The BPNP showed 
more stability than PNP. It may be due to presence of bombesin peptide on the 
surface which may affect the surface properties on nanoparticles in two ways. First, 
BBN is hydrophilic in nature and may reduce the surface hydrophobicity of 
nanoparticle. Second, the nanoparticle stabilization mechanism might have switched 
to steric from electrostatic. 
 
Figure 2.8: Stability or Fuchs factor (W,) determined by optical density method, as a 
function of electrolyte concentration  
 
To confirm the stabilization mechanism, nanoparticles were incubated with 
low and high electrolyte concentrations. At low ionic strength, electrostatic 
stabilization is sufficient to stabilize the particles. The thickness of electric double 
layer is about 5-10 nm and elecreostatic repulsion forces are able to counteract the 
attractive Van der Waals forces. But as the ionic strength is increased (> 0.1M), the 
thickness of double layer is reduced (< 1 nm) and Van der Waals forces dominates 
over electrostatic forces and particles tends to form agglomerates (Napper, 1983).  
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But, as mentioned earlier, the optical density values were found to be 
negative at lower concentrations. Hence a different method (based on particle 
diameter) was used to determine the stability factor. The concept was that the 
negative values may be because of very dilute solution used in optical density 
method. But the diameter of a particle is independent on its concentration. The 
change in particle diameters of PNP and BPNP with time are shown as Figure 2.9.  
 
 
a) 
 
 
 
b) 
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c) 
 
 
 
d) 
Figure 2.9: Change in particle diameter with time: a) PNP in NaCl; b) PNP in CaCl2; c) 
BPNP in NaCl; and d) BPNP in CaCl2 
The stability factor was calculated and plotted against electrolytes 
concentration (Figure 2.10). The CFC values observed for different solutions were as 
follows: 1.5M for PNP in NaCl, 0.08M for PNP in CaCl2, 0.1M for BPNP in CaCl2. 
CFC was not observed for BPNP in NaCl. The results indicated that CFC value 
observed in particle diameter method was similar (1.5M) for PNP in NaCl and slightly 
higher (0.08M v/s 0.03M) for PNP in CaCl2. Again, CFC was not observed for BPNP 
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in NaCl. It confirmed that BPNP were stabilized by both electrostatic and steric 
stabilization. The massive difference in particle size measured in NaCl and CaCl2 
solution could be explained by rapid and more neutralization of negative charge of 
nanoparticles by Ca+2 ions than monovalent Na+ ion. 
 
Figure 2.10: Stability or Fuchs factor (W), determined by particle diameter method, as 
a function of electrolyte concentration 
Although the methods used in the assessment of stability of the formulations 
are different in nature, the optical density value is concentration dependent whereas 
particle size of nanoparticle is independent of concentration of the sample. In our 
study, the results were found to be independent of method used which indicates that 
both the methods can be used as complementary. When the sample quantity is less 
or for costly formulation, particle diameter measurement could be a better approach 
than optical density measurement. For less expensive or concentrated samples, 
optical density measurement is more suitable. 
A separate study was carried out to determine the nanoparticle-aggregation 
mechanism. The PNP and BPNP dispersed in 0.08M CaCl2 were diluted four times 
with distilled water and vortexed for 5 min. The size of PNP was not changed 
significantly but in case of BPNP, it was reduced to half (similar to 0.03M). It suggest 
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that PNP were aggregated by coagulation (irreversible) while BPBP formed floccules 
which were reversible at some extant.  
2.3.8. Surface hydrophobicity of nanoparticles 
 Hydrophobicity of nanoparticle plays an important role in fate and transport in 
biological system. Adsorption of organic dye such as rose bengal on nanoparticle 
surface is good indicator of hydrophobicity of nanoparticles (Jung et al., 2002; Thiele 
et al., 2003). The binding constant (K) of rose bengal was 0.018 for PNP and 0.011 
for BPBP which indicated that BPNP were more hydrophilic than PNP. The results 
were in good agreement with change in surface potential.  
2.3.9. Bombesin desorption studies  
Bombesin release from the nanoparticle surface was determined to check the 
stability of the conjugate (Figure 2.11). About 12.76% of BBN was released after 24 
h indicating the stability of the bonding between peptide and nanoparticles. However, 
9.35% of BBN was released in very first hour of the study. It may be due to release 
of BBN present on nanoparticle surface not conjugated covalently but was only 
adsorbed or entangled with conjugated BBN. 
 
   
 
 
 
 
 
 
 
Figure 2.11: Percent release of BBN from nanoparticle surface with time (n=3) 
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2.4. Conclusion 
The assessment of colloidal stability is an important tool in the development of 
effective and efficient drug delivery system. In the present research work, bombesin 
conjugated biodegradable polymeric nanoparticles (BPNP) were prepared, 
characterized and their stability was determined in various physiological conditions. 
The change in optical density and particle diameter were used as stability indicators 
and were compared. Both the methods showed similar results. However, for dilute 
and costly formulations particle diameter determination was found better than 
optical density measurement. The formulations were further investigated for 
stabilization and aggregation mechanisms. Unconjugated and peptide conjugated 
nanoparticles were stabilized by two different mechanisms-electrostatic and electro-
steric stabilization, respectively. Similarly, particle aggregation mechanisms for PNP 
and BPNP were also different. PNP were aggregated by coagulation process 
whereas BPNP formed floccules. All the above results were well supported by 
surface hydrophobicity studies and peptide desorption studies. Thus bombesin, 
which was grafted on nanoparticles as targeting ligand, also improved the stability 
of nanoparticles. 
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3.1. Background 
 Nanoparticle mediated targeted drug delivery has attracted lot of attention in 
last one decade especially for anticancer drug delivery. Conventional use of 
anticancer drugs is often hampered by non-specific toxicity and side effects in non-
targeted tissues. Nanoparticle mediated intracellular delivery of anticancer drugs 
provides the advantages of increased local drug delivery due to EPR effect, 
specificity, controlled drug release and avoidance of systemic drug toxicity. Apart 
from passive targeting, nanoparticles also offer an opportunity of active targeting 
through surface modification (Byrne et al., 2008; Danhier et al., 2010). 
Currently various small chemicals such as folic acid (Oliveira et al., 2013), 
beta hydroxybutyric acid (Venishetty et al., 2013) and biomolecules like mannose-6-
phosphate (Prakash et al.,2010), galactose (Pimm et al., 1993; David et al., 2004), 
peptides (Kim et al., 2012), glycoproteins (Mo and Lim, 2005), aptamers (Yu et al., 
2011) and  monoclonal antibodies (Xu et al., 2012) are being used for active 
targeting of anticancer drugs (Byrne et al., 2008; Oliveira et al., 2013; Xu et al., 
2012). However, physiologically occurring or regulatory peptides have several 
unique advantages that make them attractive as targeting ligand. For e.g. peptides 
are small molecules with high permeability and biocompatibility. The small size of a 
peptide minimizes the overall size of nanoconjuagte while still maintaining high 
surface density (number of peptides per nanoparticle). Further, peptides are usually 
hydrophilic in nature and can’t cross (less than 0.1% of total injected peptide) the 
blood brain barrier. This property of peptide gives an extra benefit when peripheral 
tumors are the desired targets (Reubi, 2003; Wang and Thanou, 2010; Yu et al., 
2010). Various peptides such as K237, RGD, LyP-1, I4R have been conjugated to 
nanocarriers to target tumor neovasculature, endothelium, lymphatic metastatic 
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tumors and other tumor tissues [8,16-18]. (Kim et al., 2012; Yu et al., 2010; Danhier 
et al., 2009; Luo et al., 2010). 
 The primary objective of this study was to develop BBN-conjugated 
biodegradable polymeric drug delivery system for anticancer drug. BBN, a 
tetradecapeptide, was first isolated from the skin of the frog Bombina bombina 
(Anatasi et al, 1971). BBN contains a mammalian counterpart called gastrin 
releasing peptide (GRP). BBN and GRP show structural and functional similarities 
especially on C-terminus residue. Because of this, BBN and its analogues may be 
used to target BBN receptor subtype 2 i.e. GRP receptors. GRP receptors have 
been found over expressed on lung, breast, ovarian and prostate cancer cells 
(Sancho et al., 2011). 
DTX is a semi-synthetic, taxane derived, highly potent anticancer drug. It has 
shown broad spectrum anti-tumor activity against prostate, breast, pancreatic, lung, 
gastric and hepatic carcinomas (Hwang, 2012; Zhao and astruc, 2012; Xu et al., 
2009). DTX binds irreversibly to the β-actin and stabilizes the microtubule assembly 
which is responsible for inhibition of cell division and finally cell death (Musumeci et 
al., 2006).   
In this study, BBN was conjugated to PLGA nanoparticles for targeted delivery 
of DTX in GRP receptor over-expressing breast cancer cells. PLGA has been 
approved by US FDA and European Medicine Agency (EMA) for use in various 
therapeutic applications in human. Chemically, it is a cyclic dimer of two monomers 
namely lactic acid and glycolic acid. Both monomers are endogenous and by-
products of normal metabolic pathways in the body. This provides excellent 
biocompatibility and biodegradability to PLGA and makes the polymer of choice for 
drug delivery system development (Danhier et al., 2012). PLGA nanoparticles 
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provide the advantages of high structural stability, availability of free surface groups 
for bioconjugation and require less number of excipients than lipid based 
nanoparticulate systems. On the other hand, they also avoid the problem of rapid 
agglomeration and surface drug loading of inorganic nanocarriers (Soppimath et al., 
2001; Jong et al., 2008). BBN was covalently coupled to the PLGA nanoparticle 
surface using EDC/NHS chemistry. The nanoconjugate was physico-chemically 
characterized and studied for in vitro cytotoxicity studies.  
3.2. Experimentation 
3.2.1. Materials  
Docetaxel was obtained as gift sample from TherDose pharma pvt ltd 
(Hyderabad, India). Poly (D, L-lactic-co-glycolic acid, 50:50 Molecular weight ~ 
30000-60000) (PLGA) and Bombesin were purchased from Sigma Aldrich (St. Louis, 
MO, USA). HPLC grade solvents were purchased from Merck specialties (Mumbai, 
India). MDAMB-231 (breast cancer) cell line was obtained from American Type 
Culture Collection (ATCC, Manassas, USA). Dulbecco’s modified eagle’s medium 
(DMEM), 3-(4, 5- dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT), 
Trypsin, EDTA were purchased from Sigma Chemicals Co (St. Louis, MO, USA). 
Fetal bovine serum (FBS) was purchased from Gibco, USA. 96 well flat bottom 
tissue culture plates were purchased from Tarson Ltd (Mumbai, India).  
3.2.2. Preparation of DTX loaded nanoparticles 
PLGA nanoparticles were prepared by a modified solvent evaporation 
(nanoprecipitation) method (Kulhari et al., 2014). Five milligrams of DTX was 
dissolved in 5 ml of PLGA solution (10 mg/ml in acetone) and then quickly poured in 
50 mL distilled water with 0.25% w/v sodium cholate. The dispersion was briefly 
sonicated for 2 minutes in an ice bath and kept on stirring. After 3 h, the dispersion 
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was centrifuged (15000 rpm) for 30 minutes to separate DTX loaded nanoparticles 
(DNP) from free DTX. Nanoparticles were washed thrice with distilled water, 
lyophilized and stored at 2-8 °C. Blank nanoparticles (BNP) were prepared using 
same procedure but without DTX. 
3.2.3. Bioconjugation of BBN to DTX loaded nanoparticles 
 Twenty milligrams of DNP were dispersed in 5 ml 0.1M MES buffer (pH 6.2) 
and incubated with 14.62 mg NHS and 191.22 mg EDC. The dispersion was kept on 
gentle stirring for 1 h at room temperature. To this, 0.5 mg of BBN was added, mixed 
well and kept for further stirring overnight. BBN-conjugated DTX loaded 
nanoparticles (BDNP) were collected after centrifugation at 10000 rpm for 10 min 
and washed thrice with distilled water. Conjugation efficiency was determined by 
estimating free or unconjugated BBN content in the supernatant.  
BBN was quantified using standard Bradford protein assay. A calibration 
curve of standard range of 0.5 -10 µg/ml was prepared using standard BSA stock 
solution (2 mg/ml). The supernatant was diluted and absorbance was measured at 
595 nm using microplate reader (Synergy 4, Biotek, USA). 
3.2.4. Nanoparticle characterization  
Mean particle size and zeta potential of BNP and DNP were measured by 
proton correlation spectroscopy using Malvern Zetasizer Nano-ZS (Malvern 
instrument Ltd., Malvern, UK). Samples were diluted 1: 9 with distilled water and 
analyzed at 25 °C with a backscattering angle of 173°. Surface morphology of 
nanoparticles was examined by atomic force microscopy (AFM) using Digital 
Nanoscope IV (Veeco Instruments, Santa Barbara, CA). A drop of sample was 
placed on metal substrate, air dried for 24 h and scanned for analysis.  
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DSC scans were carried out on DSC-Q100 (TA Instruments, USA). The 
samples were scanned from 30 °C to 200 °C at a speed of 10 °C/min, under nitrogen 
environment. The thermal properties of DTX, BNP, DNP and BDNP were 
investigated by TGA analyzer (TGA/SDTA 851e Mettler Toledo, Switzerland). A 
weighed amount of the compound was placed in a crucible and heated from 25 °C to 
650 °C with a heating rate 10 °C/min in nitrogen environment. The change in weight 
was plotted as a function of temperature. 
X-ray diffractograms of DTX, DNP and BDNP were obtained using X-ray 
diffractometer (D8 Advance, Bruker, Germany) equipped with Cu-Kα X-ray radiation 
source, at 40 KV and 30 mA. The diffraction angle (2θ) was measured at 2 to 50° at 
a scanning speed of 2°/min and step time 13.6 s.  
3.2.5.  Analytical method 
  DTX content was measured using high performance liquid chromatography 
(HPLC) with photodiode array detector (Waters, USA). An octadecylsilane column 
(Shodex, 250 x 4.6 mm, 5 µm) was used for analysis and column temperature was 
maintained at 25 °C ± 5 °C. The mobile phase, acetonitrile (60%) and water (40%), 
was pumped at a flow rate of 1.0 ml/min and monitored at a wavelength of 229 nm. 
The calibration graph was rectilinear in the concentration range of 0.5-10 μg/ml with 
a correlation coefficient of 0.999. The inter-intraday accuracy and precision was 
within a relative standard deviation (RSD) of ≤ 5%. 
3.2.6. Drug loading and encapsulation efficiency 
 Lyophilized DNP (10 mg) were completely dissolved in 2 mL acetonitrile, 
centrifuged and supernatant was analyzed for DTX content using HPLC. Drug 
loading and encapsulation efficiency were determined as follows: 
% Drug loading = (WD in NP/WNP) × 100 
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% Encapsulation efficiency = (WD in NP/WI) × 100 
Whereas WNP: weight of nanoparticles; WD: weight of DTX; WI: Initial weight of DTX 
3.2.7.  In vitro drug release 
 To study the DTX release profile, pure DTX, Taxotere, DNP and BDNP 
(containing 1 mg of DTX) were suspended in 1 mL distilled water and placed in a 
dialysis tubing (12,000-14000 molecular weight cutoff, Sigma Aldrich, USA). The 
tubing were placed individually into 75 mL release media at 37 °C and kept for 
stirring at 100 rpm. The phosphate buffer saline (PBS, pH 7.4) and sodium acetate 
buffer (SAB, pH 5.0) containing 0.5% Tween® 80 were used as release media. An 
aliquot of one ml was withdrawn from the release medium at different time intervals 
and was replaced with same volume of fresh medium. The total release medium was 
replaced every 3rd hour with fresh medium. The samples were appropriately diluted, 
filtered through 0.22 µm nylon filter and analyzed for DTX content by HPLC as 
described above. 
3.2.8.  Cell culture 
MDA-MB-231 human breast cancer cell line was grown as adherent in DMEM 
medium supplemented with 10% fetal bovine serum, 100 µg/ml penicillin, 200 µg/ml 
streptomycin and 2 mM L-glutamine. The culture was maintained in a humidified 
atmosphere with 5% CO2. Dilutions were made with sterile PBS to get required 
concentration. Formulations were filtered with 0.22 µm sterile filter before adding to 
the wells containing cells. 
3.2.9. In-vitro cytotoxicity studies 
Cytotoxicity of formulations was determined by MTT assay based on 
mitochondrial reduction of yellow MTT tetrazolium dye to a highly colored blue 
formazan product. 1x104 Cells (counted by Trypan blue exclusion dye method) in 96 
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well plates were incubated with formulations and standard Erlotinib with series of 
concentrations for 48 h at 37 °C in DMEM with 10% FBS medium. Then the above 
media was replaced with 90 µl of fresh serum free media and 10 µl of MTT reagent 
(5 mg/ml) and plates were incubated at 37 °C for 4 h. After removing the media, 200 
µl of DMSO was added and incubated at 37 °C for further 10 min. The absorbance at 
570 nm was measured using spectrophotometer (Spectramax Plus, Molecular 
Devices, USA). The mean % of cell viability relative to that of untreated cells was 
estimated from data of three individual experiments. The half maximal inhibitory 
concentration (IC50) of each compound was calculated by curve fitting method.  
3.2.10. Statistical analysis 
 All the studies were performed in triplicate and results are expressed as Mean 
± SD (standard deviation). Statistical significance was analyzed using student t-test 
for two groups and one way ANOVA for multiple groups. The p value less than 0.05 
were considered as significant.  
 
3.3. Result and discussion 
3.3.1. Preparation of blank and DTX loaded PLGA nanoparticles  
BNP and DNP were prepared using sodium cholate, an anionic surfactant.  
Nano-precipitation or solvent displacement method was used for nanoparticle 
preparation because of its simplicity and high drug loading efficiency. The prepared 
nanoparticles showed very narrow size distribution and low polydispersity. The size 
of BNP was 92.71 ± 1.46 nm with 0.083 PDI while the DNP showed particle diameter 
111.35 ± 2.19 nm with 0.152 PDI (Table 1).  
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Table 3.1: Physicochemical characterization of nanoparticles: particle size, size 
distribution, zeta-potential and drug encapsulation efficiency. Data represent Mean ± 
SD, n=6. 
Formulation Particle 
Diameter 
(nm) 
Polydispersity 
Index (PDI) 
Zeta 
Potential 
(mV) 
Drug 
Loading 
(%) 
Encapsulation 
Efficiency (%) 
BNP 92.71 ± 1.46 0.08 ± 0.02 -28.7  ± 2.76 - - 
DNP 111.35 ± 2.19 0.15 ± 0.04 -26.9 ± 2.55 8.03 ± 1.4 81.38 ± 2.45  
BDNP 136 ± 3.95 0.24 ± 0.05 -11.5 ± 1.34 7.52 ± 0.63 83.27 ± 1.74 
 
3.3.2. Drug loading and encapsulation efficiency 
  DTX loading and encapsulation efficiency of PLGA nanoparticles were 
determined at two drug/polymer (D/P) ratios- 5 %w/w and 10 %w/w (Table 3.1). 
Initially, 5 %w/w DTX was added to polymer solution and observed DTX loading and 
encapsulation efficiency were 4.58% and 96.12%. Because of high drug 
encapsulation efficiency, drug to polymer ratio was increased to 10 %w/w. At this 
level, drug loading was found to be 8.03% whereas encapsulation efficiency was 
81.38%. Thus 10 %w/w D/P ratio was considered as optimum level for DTX loading 
in PLGA nanoparticles.  
3.3.3.  Bioconjugation of BBN to DNP 
  Bombesin was conjugated on DNP surface by an EDC/NHS reaction.  About 
18.2 µg of BBN was conjugated to per mg of nanoparticles. The conjugation 
efficiency was 72.8%.  
3.3.4.   Physicochemical characterization of nanoparticles 
 Bombesin surface conjugation was characterized in terms of mean particle 
diameter, polydispersity index and zeta potential. After BBN conjugation, the size of 
nanoparticles was increased to 136 ± 3.95 nm (Figure 3.1a) with 0.247 polydispersity 
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index while the zeta potential was decreased to -11.5 mV (Table 3.1). The change in 
surface potential confirmed the conjugation between BBN and PLGA nanoparticles. 
AFM analysis showed that BDNP were spherical in shape (Figure 3.1b). The 
average particle size observed with AFM analysis was 142.35 ± 8.91 nm (n=5). 
 
a) 
 
 
b) 
Figure 3.1a-b: Particle size and surface morphology of BBN conjugated nanoparticles 
(BDNP) determined by a) Dynamic light scattering and b) Atomic force microscopy 
analysis. 
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 FTIR analysis was carried out to confirm the surface group interaction 
between -NH2 group of BBN and –COOH group of DNP (Figure 3.2). FTIR spectra of 
pure BBN showed two characteristic peaks at 3299 cm-1 (free amine group) and 
1647 cm-1 (carbonyl group of peptide bond). DNP showed characteristic carbonyl 
peak of carboxylic group at 1761 cm-1. BDNP showed amide bond peaks at 1646 
cm-1 and 1566 cm-1 indicating the conjugation between BBN and DNP. As BBN also 
shows the amide bond peaks, absence of carboxylic group peak of PLGA 
nanoparticles in BDNP confirmed the conjugation of BBN to the DNP.  
 
 
Figure 3.2: FTIR spectra of a) Docetaxel, b) Bombesin, c) Docetaxel loaded PLGA 
nanoparticle (DNP) and d) Bombesin conjugated DNP nanoparticles (BDNP) 
  The physical state of DTX as pure compound and inside the nanoparticles 
was determined by DSC analysis (Figure 3.3). The melting endothermic peak of pure 
DTX was appeared at 178.7 °C. However this peak was not observed in nanoparticle 
formulation. DNP formulation showed only glass transition temperature (Tg) peak of 
PLGA at 50.4 °C. It suggested two important things: first, the pure DTX was present 
as crystalline form but in nanoparticles it was transformed to amorphous or 
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disordered crystalline or to the solid solution state. Second, the nanoparticle 
preparation method used in this study, does not affects the properties of the PLGA. 
 
Figure 3.3: Differential scanning calorimetry (DSC) spectra of a) Docetaxel b) PLGA 
and c) DTX loaded PLGA nanoparticles 
` The thermal behaviour of DTX, PLGA, DNP and BDNP was studied using 
thermo gravimetric analyzer. Figure 3.4 shows the thermal degradation behaviour of 
DTX, BNP, DNP and BDNP. The weight loss in pure DTX was started about 200 °C 
while in case of BNP and DNP it occurred after 300 °C. BDNP formulation showed 
an early degradation at 220 °C.  
 
Figure 3.4: Thermo gravimetric analysis (TGA) of pure DTX, blank nanoparticles 
(BNP), DTX loaded nanoparticles (DNP) and bombesin conjugated DNP (BDNP) 
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 XRD spectra of pure DTX showed characteristic sharp peaks between 2 to 
20°, confirming the crystalline state of DTX (Figure 3.5). In DTX loaded nanoparticle 
spectra, the sharp peaks of DTX were disappeared and a hump was observed from 
10 to 22° which indicated that in nanoparticle formulation DTX was present in its 
amorphous form rather than crystalline.  In BDNP spectra, the some sharp peaks 
were appeared which may be because of BBN present on nanoparticle surface. 
  
 
 
 
 
 
 
 
Figure 3.5: Powder X-ray diffraction (PXRD) analysis of pure DTX, DNP and BDNP 
3.3.5.  In vitro drug release 
  In vitro release of DTX from pure drug suspension, Taxotere and 
nanoparticles was performed in PBS (Figure 3.6a) and SAB (Figure 3.6b). From pure 
drug suspension and Taxotere, DTX was released completely within 10 h in both 
PBS and SAB. The nanoparticle formulations showed biphasic pattern of DTX 
release. About 21% of drug was released in first 24 h but after that only 11% and 
15.3% DTX was released in next 96 h from DNP and BDNP formulations, 
respectively. The initial faster drug release may be due to the release of drug present 
on the surface or near to the periphery of the nanoparticles (Fredenberg et al., 
2011). The drug release was slightly higher in BDNP than from DNP which may be 
because of hydrophilic nature of BBN present on the surface. A similar kind of 
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pattern was observed in SAB. But the overall release of DTX from nanoparticles was 
more in SAB (36.2%) compared to PBS (31.57%). It can be explained by the faster 
degradation of PLGA at acidic pH (Yoo et al., 2005). This faster degradation of 
nanoparticles and hence increased DTX release in acidic pH than PBS would 
provide the advantage of maximum drug release in cancer cells.  
 
a) 
 
b) 
Figure 3.6a-b: In vitro drug release studies of different DTX formulations in a) PBS and 
b) SAB (Mean ± SD; n=3) 
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3.3.6.  Cytotoxicity studies 
 The anticancer activity of DTX, Taxotere, DNP and BDNP was studied by 
MTT assay against MDA-MB-231 human breast cancer cells (Figure 3.7 and 3.8).  
MDA-MB-231 cells were selected for in vitro cytotoxicity study for three reasons. 
First, these cells are reported to over express GRP receptors (Chao et al., 2009). 
Second, MDA-MB-231 cells are triple negative cells- estrogen receptor negative, 
progesterone receptor negative and human epidermal growth factor 2 (HER 2) 
receptor negative. So the hormonal and trastuzumab therapy may not be useful for 
the treatment of these cells. Third, MDA-MB-231 cells show intermediate response 
to the chemotherapy (Holliday and Speirs, 2011). So the effect of peptide conjugated 
formulation can be clearly observed from the effect of unconjugated formulation. The 
IC50 value for both free DTX and Taxotere was more than the highest tested 
concentration (375 ng/ml). Both DNP and BDNP showed more cellular toxicity than 
free DTX and Taxotere. The IC50 value for DNP and BDNP was 142.23 ± 18.95 and 
35.53 ± 5.91.  
 
Figure 3.7: Cell viability studies of DTX, Taxotere, DTX loaded nanoparticles (DNP) 
and BBN conjugated-DTX loaded nanoparticles (BDNP) (Mean ± SD; n=3) 
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At low concentration of 3.125 ng/ml, both DNP and BDNP showed significant 
cytotoxicity compared to either pure DTX or Taxotere. However, the difference of 
cytotoxic potential of DTX was insignificant between DNP and BDNP. Significant 
improvement in cytotoxicity was observed with BDNP compared to DNP in a dose-
dependent manner from 6.25 to 100 ng/ml. At higher concentration (200 ng/ml), 
BDNP could not enhance the cytotoxicity over DNP. The significant increase in 
toxicity of DNP compared to free DTX or Taxotere can be attributed to passive 
targeting of nanoparticles. Several anticancer drugs including dexamethasone, 
paclitaxel, vincristine, curcumin, etoposide, campatothecin, 5-fluorouracil, 
doxorubicin and cisplatin have been successfully delivered and passively targeted by 
encapsulation in PLGA nanoparticles (Acharya and Sahoo, 2011). BDNP were 4 
times more toxic (p < 0.001) than DNP which may be due to receptor-mediated 
endocytosis of nanoparticles. The enhanced cellular internalization of actively 
targeted BDNP resulted in enhanced cytotoxicity of DTX.  
 
Figure 3.8: Phase contrast images of MDA-MB-231 cells treated with control, free DTX, 
Taxotere, DNP and BDNP after 48 h 
 
 
Chapter 3  Bombesin-PLGA-DTX for breast cancer 
 Peptide and monoclonal antibody mediated targeting of anticancer drugs  85 
 
3.4. Conclusion  
 Targeted drug delivery systems have shown a great advance in delivery of 
anticancer drugs exclusively to cancer cells. In this study, Bombesin peptide was first 
time conjugated with biodegradable polymeric nanoparticles for the delivery of an 
anti-cancer drug, DTX, to breast cancer cells. The breast cancer cell lines used in 
this study were low to intermediate chemotherapy responsive. The peptide 
conjugated nanoparticles showed significantly higher in vitro cytotoxicity to the 
targeted cells than free DTX. As per the generalized and well accepted concept, 
nanoparticles of less than 200 nm size with hydrophilic surface exhibits improved 
EPR effect due to longer retention of nanocarriers in the blood stream. Because of 
small size, sustained drug release and enhanced and targeted delivery, the 
developed drug delivery system has great potential to deliver anticancer drugs to 
GRP receptor over-expressing and to low chemotherapy-responsive cells.  
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4.1. Background 
Prostate cancer is one of the leading causes of cancer related death in men. 
Surgery, radiation and chemotherapy are approaches available for the treatment of 
prostate cancer (Fong et al., 2012; Guan and Chen, 2006). Generally prostate 
cancer is treated with surgery or radiation therapy. Chemotherapy is the treatment of 
choice when cancer recurs or when a patient's tumor can be controlled at an earlier 
stage by manipulating its growth signals (Salvador-Morales et al., 2009). 
Chemotherapy for prostate cancer treatment includes hormone therapy, vaccines 
and chemical agents. Hormone therapy is used in androgen-dependent prostate 
cancer (Namiki et al., 2012). Provenge®, the only cancer therapeutic vaccine, is 
approved by the FDA for use in men with metastatic prostate cancer that does not 
respond to hormone therapy (Cheever and Higano, 2011). Of the anticancer drug 
docetaxel (DTX), in combination with prednisolone, is approved for the treatment of 
metastatic hormone-refractory or castration-resistant prostate cancer (Aragon-Ching 
and Dahut, 2007). This androgen-independent or androgen-insensitive cancer 
spreads throughout the body, beyond the prostate alone, and continues to grow, 
even when testosterone is inhibited (Kwon et al., 2012).  
DTX is a semi-synthetic analogue of paclitaxel and is used to treat various 
cancers, including prostate cancer. It binds with β-tubulin and inhibits mitotic 
progression and cell proliferation leading to cell death (Hwang, 2012). In refractory, 
advanced disease with poor prognosis, prostate cancer cells exhibits high levels of 
Bcl-2 expression. DTX inactivates this pro-survival protein and promotes apoptosis 
(Bray et al., 2009; Kraus et al., 2003). But, water insolubility, toxicity to normal cells 
and drug resistance are three major constraints in the therapeutic applications of 
DTX (Hwang, 2012; Tannock et al., 2004). DTX is soluble in water at only microgram 
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levels. Therefore, the use of the non-ionic surfactant polysorbate 80, which can 
cause severe anaphylactic hypersensitivity reactions, is required (Loos et al., 2003).  
Nanoparticle-mediated targeted DTX delivery may help to overcome all these 
inherent problems (Salvador-Morales et al., 2009; Sanna and Sechi, 2012). 
Nanoparticle formulations, irrespective of the method of preparation, enhance the 
solubility of poorly-water soluble agents by converting drug micro-particles to 
nanoparticles and thus increasing the overall effective surface area (Yarnell, 2012; 
Merisko-Liversidge and Liversidge, 2008). Site-specific delivery using specific 
targeting ligands further decreases total dose requirements. In addition, ligand-based 
targeting of drug encapsulated nanoparticles reduces non-specific uptake into 
normal cells. Nanoparticles enter tumor cells via endocytotic processes, increasing 
intracellular drug concentrations and overcoming efflux-pump mediated drug 
resistance (Dong and Mumper, 2010).  
In this study, DTX was encapsulated in biodegradable and well characterised 
poly (lactic-co-glycolic acid) (PLGA) nanoparticles. Bombesin was ligated to the 
nanoparticle surface for site-specific delivery of drug to prostate cancer cells. 
Bombesin is a tetradeca peptide that has high binding-affinity for gastrin-releasing 
peptide (GRP) receptors (Cornelio et al., 2007; Jensen et al., 2008). Human prostate 
cancer cell lines such as PC3 and DU145 have been reported to over-express GRP 
receptors (Accardo et al., 2012; De vesser et al., 2007; Reile et al., 1994). Therefore, 
site-specific delivery of DTX may improve the therapeutic potential of DTX. In a 
previous study, BBN conjugated PLGA nanoparticles demonstrated a significant 
improvement in the cytotoxic efficacy of DTX against GRP over-expressing breast 
cancer cells (Kulhari et al., 2014). Here, the anticancer activity of these formulations 
were evaluated against prostate cancer cells which also over-express GRP 
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receptors. Also, the pharmacokinetic and tissue distribution profiles of BBN 
conjugated, DTX loaded PLGA nanoparticles were studied and compared to those of 
Taxotere®, a marketed formulation of DTX. 
4.2. Experimentation  
 
4.2.1. Preparation and characterization of bombesin conjugated PLGA 
nanoparticles 
DTX loaded PLGA nanoparticles (DNP) and bombesin-conjugated DNP 
(BDNP) were prepared as per previously optimized method (Kulhari et al., 2014). 
Mean particle diameter and zeta potential of DNP and bombesin conjugated DNP 
(BDNP) were measured by the dynamic light scattering method using a particle-size 
analyser Zetasizer Nano-ZS (Malvern Instrument Ltd., UK). Nanoparticle surface 
morphology was examined using transmission electron microscopy (FEI Tecnai, 
G112, Philips, USA).  
4.2.2. Cell culture 
DU145 human prostate cancer cells were grown in DMEM medium 
supplemented with 10% FBS, 0.3% sodium bicarbonate, 10 mL/L 
antibiotic/antimycotic solution (10,000 U/mL penicillin, 10 mg/mL streptomycin and 
25 μg/mL amphotericin B), 1 mL of 2 mM L-glutamine and 1 mL of 100 mM sodium 
pyruvate.  
PC3 human prostate cancer cell line was grown in RPMI-1640 medium 
supplemented with 10% FBS, 2 mM glutamine, penicillin (100 U/mL), and 
streptomycin (0.1 mg/mL). Cells were cultured in a CO2 incubator at 37 ºC with a 
90% humidified and 5% CO2 atmosphere. 
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4.2.3. In vitro cytotoxicity studies 
The cytotoxicity of DTX, DNP and BDNP against DU145 and PC3 human 
prostate cancer cells was evaluated using a tetrazolium-based calorimetric MTT 
assay. Cells were seeded into 96 well plates at a density of 5×103 cells per well. 
After overnight incubation, cells were treated with DTX, DNP and BDNP at 
concentrations ranging from 1-10000 ng/mL.  After 48 h, the media was replaced 
with 90 µL fresh serum free media and 10 µL MTT (5 mg/mL in PBS). Plates were 
incubated at 37 ºC for another 4 h. Thereafter, media was discarded and 150 µL of 
DMSO was added in each well to dissolve purple formazan crystals. The absorbance 
of samples was measured at 570 nm using a SpectraMax plus 384 UV-Visible plate 
reader (Molecular Devices, Sunnyvale, CA, USA). Half maximal inhibitory 
concentration (IC50) values were determined by the Probit analysis software package 
of MicroSoft-excel. 
4.2.4. Cellular uptake studies 
Coumarin-loaded PLGA nanoparticles (CPN) were prepared and conjugated 
with BBN (BCPN) for comparative cellular uptake studies. Coumarin-6 is a 
hydrophobic florescent dye and therefore, has been used as model compound to 
study the uptake of hydrophobic drugs. In this study, we encapsulated coumarin-6 
into PLGA nanoparticles in place of DTX and then conjugated BBN to the 
nanoparticles to study role of BBN in the uptake of nanoparticles.  For quantitative 
studies, 1×105 cells per well were seeded in 12 well plates and allowed to adhere for 
24 h. Cells were incubated with coumarin-6, CPN, and BCPN formulations for time 
intervals of 0.5, 1, 3 and 6 h. After removal of culture media, cells were washed twice 
with cold PBS and observed under a fluorescence microscope (Olympus Corp., U-
LH100HG, Japan). 
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4.2.5. Apoptosis assay by acridine orange and ethidium bromide double 
staining 
PC3 Cells (1×105 cells/well) were grown in 12 well plates and incubated 
overnight. Next day, cells were treated with DTX, DNP or BDNP, equivalent to 100 
ng/mL DTX. After 24 h, cells were washed with PBS and fixed with 4% of 
paraformaldehyde. Cells were washed twice with PBS and stained with a solution of 
AO and EB (5 µg/mL of each). After 30 min of incubation, cells were again washed 
with PBS and observed under a fluorescence microscope (Nikon, Japan). 
4.2.6. Wound healing scratch assay 
PC3 cells (5×105 cells/mL) were seeded in petri-dishes and allowed to grow to 
80% confluence. Wounds were created with sterile 250 µL pipette tips. Cells were 
incubated with DTX, DNP or BDNP, equivalent to 100 ng/mL DTX. The zone of 
wound healing was observed at 0, 12 and 24 h using a bright field microscope.  The 
percentage of wound closure was determined by measuring the wound area using 
Image J analysis software.  
4.2.7. Clonogenic assay 
For colony formation assays, PC3 cells were seeded at a density of 500 cells 
per well in a 6 well plate. From days 3 to 8, cells were incubated with DTX, DNP or 
BDNP. Then, media was removed and cells incubated in fresh media without drug. 
On day 14, cells were washed with PBS, fixed with 4% formaldehyde and stained 
with 0.5% w/v methylene blue. Cells were washed and photographs captured using a 
digital camera.  
4.2.8. Animal study protocols 
 The animal experimental protocol for this study was approved by the 
Institutional Animal Ethics Committee (IAEC) of the CSIR-Indian Institute of 
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Chemical Technology, Hyderabad and all the studies performed on the animals were 
in accordance with the guidelines of the Committee for the Purpose of Control and 
Supervision of Experiments on Animals (CPCSEA). Male BALB/c mice weighing 
between 20-25 g were used for the pharmacokinetic and tissue distribution studies. 
Animals were kept in polypropylene cages under standard laboratory conditions 
(12:12 h light/ dark cycle) at 24 °C.   
4.2.9. Bio-analytical method  
For the determination of DTX content in plasma and tissue samples, an 
analytical method was validated using a HPLC system (Waters, USA) equipped with 
a C18 column (Grace, 250 x 4.6 mm, 5 µm) and a photodiode array detector. The 
mobile phase consisted of acetonitrile (48%) and 0.1% orthophosphoric acid (52%). 
A volume of 5 µL paclitaxel (PTX) solution (1 mg/ml) was used as an internal 
standard. The flow rate was maintained at 1 mL/min. Peaks were monitored at 230 
nm λmax. Retention times were 9.1 and 11.2 min for DTX and PTX, respectively.  
4.2.10. Pharmacokinetic and tissue distribution studies 
 Ninety six animals were randomly divided to three treatment groups (n=32). 
Four animals were used separately as normal controls. The treatment groups 
received Taxotere®, DNP and BDNP, respectively. Taxotere®, DNP and BDNP were 
administered intravenously (tail vein) at a dose of 10 mg/Kg body weight of the 
loaded drug. Blood samples were collected by retro-orbital venous plexus puncture 
with the aid of glass heparinized capillary tubes at different time intervals. Blood 
samples were centrifuged at 4,000 rpm for 10 min to separate plasma from cell 
mass. The supernatant (plasma) was separated and analyzed for DTX content. After 
blood collection, animals were euthanized by cervical dislocation, and tissues (heart, 
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liver, spleen, lung, brain and kidney) were harvested, rinsed in buffer, weighed and 
frozen at −80 °C until analysis.  
4.2.11. Plasma and tissue sample processing 
Plasma and tissue samples were processed and analyzed for DTX content as 
reported previously by Wang et al (2012). After the addition of 1 ml of normal saline, 
the tissue samples were homogenized using a tissue homogenizer. A volume of 200 
µL of plasma or tissue sample was extracted with 250 µL of methanol and 250 µL of 
acetonitrile, vortexed for one minute and finally centrifuged at 15,000 rpm for 15 min. 
The supernatant was separated, filtered through a 0.22 µm filter and analyzed by 
HPLC as described above. 
4.2.12. Determination of pharmacokinetic parameters & statistical analysis 
Non-compartmental analysis with WinNolin software was used to estimate 
pharmacokinetic parameters of different DTX formulations. The peak plasma 
concentration (Cmax) and time to reach Cmax (tmax) were determined directly from the 
observed concentration versus time profiles. Area under curve (AUC) and area 
under first moment curve (AUMC) were calculated using the linear trapezoidal rule. 
Mean residence time (MRT) was calculated by dividing AUMC by AUC.  
Results are expressed as the mean ± SD (standard deviation) of at least four 
experiments (n=4). Statistical significance was assessed using the Student’s t-test or 
Dunnett’s test for multiple comparisons with p < 0.05 as the minimal level of 
significance. 
4.3. Results and discussion 
4.3.1. Characterization of nanoparticles 
Mean particle diameter and zeta potential of DTX loaded PLGA nanoparticles 
(DNP) were 98.52 ± 2.31 nm and −29.06 ± 1.57 mV, respectively. DTX 
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encapsulation efficiency was 79.52 ± 2.08%. Bombesin was grafted onto 
nanoparticle surfaces by carbodiimide chemistry with a conjugation efficiency of 
77.39%. After conjugation of BBN, nanoparticle size was increased to 115.74 ± 1.86 
nm while potential was decreased to −12.6 ± 0.95 mV; thus confirming grafting of 
BBN. TEM analysis of BDNP showed that nanoparticles were spherical in shape and 
uniform in size (Figure 4.1).  
 
Figure 4.1: Transmission electron microscopy of bombesin grafted docetaxel loaded 
PLGA nanoparticles (BDNP) 
4.3.2. In vitro cytotoxicity studies 
Prostate cancer is basically of two types: localized and advanced 
metastasized. Localised prostate cancer can be treated by either radical 
prostatectomy or radiation therapy. Advanced and metastasized is usually treated by 
androgen deprivation therapy. However, long-term deprivation of androgen results in 
the development of resistance in the cancer cells i.e. androgen-independent cancer. 
This androgen-independent prostate cancer has increased proliferation and invasion 
capacity and spreads beyond prostate (Carrión-Salip et al., 2012; Saraon et al., 
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2011). Chemotherapy like taxanes has shown significant potential in controlling the 
androgen-independent prostate cancer (Schrijvers, 2007).  However, to avoid the 
non-specific toxicity, in this study we developed targeted nanocarrier system for the 
delivery of DTX and evaluated their potential against androgen-independent human 
prostate cancer cells DU145 and PC3.  In this study, The cell viability of human 
prostate cancer cells (DU145 and PC3) exposed to different DTX formulations was 
investigated and results are presented in Figure 4.2. All three formulations showed 
concentration-dependent toxicities to both cell lines. At very low concentration (1 
ng/mL), there was no significant difference in viability of cells when treated with DTX, 
DNP or BDNP. However, as the drug concentration level was increased, the 
viabilities of the cells treated with nanoparticle formulations were decreased rapidly 
in comparison to native DTX. Between nanoparticle formulations, bombesin grafted 
nanoparticles exhibited higher toxicity than unconjugated nanoparticles.  
After 48 h incubation, the IC50 values against DU145 cells for DTX, DNP and 
BDNP were 241.89, 126.04 and 77.41 ng/mL, respectively (Table 4.1). 
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b) 
Figure 4.2 a-b: Growth inhibition of human prostate cancer cells, DU145 (A) and PC3 
(B) after 48 h exposure of docetaxel (DTX), DTX loaded nanoparticles (DNP) and 
bombesin conjugated DNP (BDNP) (mean ± SD, n=4) 
 
For PC3 cells, IC50 values were 122.95, 74.44 and 45.02 ng/mL for DTX, DNP 
and BDNP, respectively. The enhanced cytotoxicity of BDNP in comparison to DNP 
can be attributed to increased cellular uptake of BDNP through receptor-mediated 
endocytosis. Human prostate cancer cells have been reported to over-express GRP 
receptors compared to normal cells (Markwalder and Reubi, 1999). Both PC3 and 
DU145 cells express high levels of GRP receptors (Accardo et al., 2012; De Visser 
et al., 2007; Reile et al., 1994; Yang et al., 2013). Therefore BBN grafted 
nanoparticles would be expected to be taken up more by the cancer cells, leading to 
increased intracellular DTX delivery.  
To confirm this, a separate study was performed using coumarin loaded 
nanoparticles. PC3 cells were used for further experiments as they are more 
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sensitive to the formulations than DU145 cells. It would be worth mentioning that 
both PC3 and DU145 cells are androgen-independent and show no expression of 
androgen receptors or prostate specific antigens which are characteristics to 
prostate cancer (Sancho et al., 2011). Therefore, GRP-mediated targeting and 
enhanced cytotoxicity of DTX using BDNP could be very promising in the treatment 
of androgen-independent prostate cancer. Figure 3 shows the change in the 
morphology of PC3 cells treated with DTX, DNP and BDNP. Control cells were 
observed as polygonal to spindle in shape, whilst treated cells were mostly rounded.  
 
Table 4.1: IC50 values of different DTX formulations against DU145 and PC3 human 
prostate cancer cells after 48 h incubation. (Mean ± SD; n=4). 
Formulation 
IC50 value (ng/mL) 
DU145 PC3 
DTX 241.89 ± 1.3 122.95 ± 2.7 
DNP 126.04 ± 2.1 74.44 ± 1.9 
BDNP 77.41  ± 1.7 45.01 ± 1.6 
 
DTX: Docetaxel; DNP: Docetaxel loaded PLGA nanoparticles; BDNP: Bombesin grafted 
DNP 
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Figure 4.3: Phase contrast images of PC3 human prostate cancer cells after treatment 
with docetaxel (DTX), DTX loaded nanoparticles (DNP) and bombesin-conjugated DNP 
(BDNP). Untreated cells are shown as control. Cells treated with DTX formulations 
showed a significant change in morphology 
 
4.3.3. Cellular uptake studies 
Florescence microscopy provided preliminary evidence of cellular 
internalization of nanoparticles. Coumarin-6 loaded PLGA nanoparticles (CPN) and 
BBN grafted CPN (BCPN) were separately formulated for cellular uptake studies. 
CPN were prepared by the same method reported in section 2.2, except that 3 mg of 
coumarin-6 was used instead of DTX. Figure 4.4 shows the fluorescent microscopic 
images of PC3 cells following incubation with coumarin-6, CPN or BCPN. A time-
dependent cellular uptake of the different formulations was observed (Figure 3). 
Non-encapsulated coumarin-6 was barely taken up by cells even after 3 h. Cells 
incubated with BCPN showed higher fluorescence at all the time points than 
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unconjugated nanoparticles (CPN). The higher cellular uptake of BCPN than CPN 
may be attributed to increased interaction of BCPN to the cell surface through GRP 
receptors (Yang et al., 2013).  
 
Figure 4.4: In vitro cellular uptake of coumarin-6, coumarin-6 loaded PLGA 
nanoparticles (CPN) and bombesin-conjugated CPN (BCPN) by PC3 prostate cancer 
cells after incubation for different times (0.5, 1, 3 and 6 h). 
 
4.3.4. AO/EB assay 
Induction of apoptosis by DTX formulations was studied using the AO/EB 
assay. This double staining method visualizes the nuclear changes and apoptotic 
body formation that are characteristic of apoptosis (Paul et al., 2013). Intact live cell 
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membranes are permeable to AO, producing green fluorescence after excitation.  In 
contrast, EB can only enter cells through damaged cell membranes and produces 
orange fluorescence. Therefore, live cells can be discriminated from dead cells by 
AO/EB staining on the basis of membrane integrity (Huang et al., 2011). Figure 4.5 
shows the fluorescent microscopic images of untreated cells and cells treated with 
DTX, DNP or BDNP. Untreated cells appeared green in colour while treated cells 
were dark orange-red colour. BDNP treated cells showed higher apoptosis and 
decreased cell numbers compared to DNP and DTX, suggesting superior apoptosis-
induction capability of BDNP. This could also be explained by the enhanced 
intracellular delivery of DTX by BDNP than other formulations.  
 
 
 
Figure 4.5: Induction of apoptosis studies using acridine orange and ethidium 
bromide double staining of PC3 human prostate cancer cells after treatment with 
docetaxel (DTX), DTX loaded nanoparticles (DNP) or bombesin conjugated DNP 
(BDNP). Untreated cells are shown as control 
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4.3.5. Wound healing scratch assay 
Angiogenesis is an important step for the growth of cancer cells especially 
when tumor size reaches about 2 mm3. Angiogenesis involves the formation of new 
blood vessels from existing blood vessels. Therefore, the inhibition of angiogenesis 
is complementary to anti-proliferation activity of anticancer drugs (Danhier et al., 
2012). The effect of different DTX formulations on the migration of PC3 cells was 
determined by the wound healing scratch assay. In control experiments, the wound 
zone was completely filled with cells after 24 h; while a clear wound zone was 
observed in cells incubated with DTX, DNP and BDNP formulations (Figure 4.6a). 
However, among these DTX formulations, inhibition of cell migration was greatest 
with BDNP. The percentage of wound closure was found 93.6, 45.2, 29.4 and 11.3% 
for untreated (control), DTX-, DNP- and BDNP-treated cells, respectively (Figure 
4.6b). The enhanced anti-angiogenic activity of BDNP may be attributed to higher 
cellular uptake and therefore increased intracellular delivery of DTX.  
 
a) 
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b) 
 
Figure 4.6 a-b: Wound healing scratch assay. (a) Bright field images of PC3 human 
prostate cancer cells. Untreated cells migrated promptly towards the wound area. 
Migration was inhibited in cells treated with DTX, DNP and BDNP. The wound area 
remained practically unchanged, even after 24 h, in cells treated with BDNP, reflecting 
anti-angiogenic activity. (b) Quantitative determination of % wound area closure. 
 
 
4.3.6. Clonogenic assay 
The potential long-term anti-cancer effects of the DTX formulations under 
study were examined by a colony formation assay. The three formulations showed a 
significant reduction in colony number compared to control or untreated cells (Figure 
4.7). The nanoparticle-based formulations, DNP and BDNP, showed superior colony 
formation inhibition activities against PC3 cells over DTX alone. These results can be 
explained by sustained release of DTX from DNP and BDNP as observed in our 
previous study.  
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Figure 4.7: Clonogenic assay. DTX formulations showed a significant control over the 
colony formation inhibition activity of PC3 human prostate cancer cells 
 
4.3.7. Pharmacokinetic studies 
In drug delivery, the understanding of pharmacokinetic and biodistribution of 
formulations helps to predict their efficacy. In case of anticancer drugs, these studies 
are also used to determine the possible toxicities of encapsulated drugs. PK data aid 
to determine the dose and dose regimen for the encapsulated drugs to maintain the 
concentration of the drug within the therapeutic window for improved therapeutic 
effect and decreased side effects.  
For pharmacokinetic studies, Taxotere® or the nanoparticle formulations DNP 
and BDNP were administered to Balb/c mice at a dose of 10 mg/Kg body weight by 
tail vein injection. The time course of plasma drug concentrations is shown in Figure 
6a, with the corresponding pharmacokinetic parameters reported in Table 4.2. 
Compared to nanoparticle formulations, following Taxotere® injection a rapid decline 
in DTX concentration occurred and after 8 h, plasma DTX concentration was below 
the detection level (Figure 4.8). In DNP and BDNP treated mice DTX plasma half-life 
was longer than Taxotere® treated mice (Table 2). The area under the curve (AUC0-
∞) for Taxotere®, DNP and BDNP concentrations were 29.52, 108.68 and 137.21 
µg/mL/h, respectively. A significant increase in AUC for DTX nanoparticles can be 
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attributed to slow release of drug from nanoparticles. Decreased clearance of DTX 
may be another reason for the extended blood circulation time when delivered via 
DNP or BDNP.  In comparison to Taxotere®, with DNP and BDNP, clearance of DTX 
was decreased by 3.68 and 4.65 times. Increased plasma half-life and decreased 
clearance also lead to longer mean residence time of DNP (3.76 h) and BDNP (4.32 
h) (Table 4.2). Therefore, the DTX encapsulated PLGA nanoparticles showed better 
DTX pharmacokinetic (PK) profiles than Taxotere®. However, it was also noted that 
there was no significant (p > 0.05) difference between PK profiles of DNP and 
BDNP. This suggests surface functionalization with BBN does not alter the stability 
and circulation of nanoparticles in blood.  This could be due to the low density of 
BBN (0.7%, determined by XPS analysis) on the surface of nanoparticles. 
 
Figure 4.8: Pharmacokinetic profiles of Taxotere®, DNP and BDNP administered 
intravenously to Balb/c mice at a dose of 10 mg/Kg body weight by tail vein injection 
(Mean ± SD, n=4).  
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4.3.8. Tissue-distribution of different DTX formulations 
Distribution of DTX after intravenous administration of Taxotere®, DNP and 
BDNP was estimated in different body tissues including heart, brain, kidney, liver, 
lung and spleen. Tissue distribution profiles of Taxotere®, DNP and BDNP are shown 
in Figure 4.9a-c. Both DNP and BDNP showed a rapid and high drug distribution to 
spleen, lung and liver. This could be a reason why the plasma-concentration curves 
of the two nanoparticle formulations were not significantly different. From Figure 4.9a 
it is clear that the relative distribution of Taxotere® was higher in kidney (3.4 µg/g) 
than other tissues. This could explain the rapid clearance of DTX with Taxotere® 
(Table 4.2). The DNP formulation was highly distributed to spleen (4.6 µg/g) (Figure 
4.9b) while BDNP accumulated in lungs (4.8 µg/g) (Figure 4.9c).  
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b) 
 
 
c) 
Figure 4.9 a-c: Tissue distribution profiles of DTX in kidney, spleen, lung and liver 
after intravenous administration of Taxotere® (a), DNP (b) or BDNP (c) (Mean ± SD, 
n=4). 
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Table 4.2: Pharmacokinetic parameters of DTX after intravenous administration of 
Taxotere®, DNP and BDNP at a dose of 10 mg/Kg body weight in Balb/c mice. Data are 
represented as Mean ± SD; n=4. 
Pharmacokinetic 
Parameter 
Taxotere® DNP BDNP 
AUC0-∞ (µg/ml/h) 29.52±3.21 108.68±5.92** 137.21±5.37**, ### 
MRT (h) 1.39±0.16 3.76±0.28 4.32±0.198*,ns 
Cl (ml/h) 8.46±1.15 2.3±0.3* 1.82±0.21**,ns 
Terminal half life (h) 1.3±0.2 2.5±0.14 2.94±0.11 
Cmax 25.9±3.72 31±4.57 32.75±2.98 
tmax 0.25±0.04 0.5±0.08 0.25±0.05 
 
Statistical analysis: ns Not Significant, * p<0.05, ** p<0.005, *** p<0.0005, #  p<0.05, ## p<0.005, 
### p<0.0005, 
* Indicates comparison with Taxotere®;  
# Indicates comparison with DNP  
Thus, BDNP decreased the accumulation of nanoparticles in liver, spleen and 
kindey than Taxotere®. It can be explained by the size of the BDNP (115 nm). 
Because of the small size (< 400 nm), nanoparticles escape the uptake by reticulo-
endothelial organs like liver and spleen. But, they had enough large size (> 6 nm) to 
avoid filter through kidney (Longmire et al., 2008).32   Interesting, drug was not 
detected in brain at all-time points after administration of any of the formulations. 
Therefore, the targeted drug delivery system provides the advantage of avoiding on-
specific targeting to brain with the drug being distributed only to peripheral tissues. 
Variable drug levels were observed in heart tissues making it difficult to draw a clear 
conclusion. 
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4.4. Conclusion 
In summary, bombesin-mediated cellular recognition and uptake of 
nanoparticles leads to increases in the anti-proliferative, apoptotic and migration-
inhibiting activities of DTX in PC3 androgen-independent human prostate cancer 
cells with high expression of GRP receptors. In clonogenic assays, nanoparticle 
formulations also show long-term control over growth of cancer cells. 
Pharmacokinetic data suggest longer blood circulation times and higher plasma 
concentrations of BDNP compared to Taxotere®. Therefore, BBN mediated targeted 
delivery of docetaxel could be a potential approach for the GRP over expressing 
prostate cancer.  
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5.1. Background 
According to the GLOBCON 2012 report of The International Agency for 
Research on Cancer (IARC), the specialized cancer agency of the World Health 
Organization, breast cancer is the second most common diagnosed cancer 
worldwide. In 2012, 1.7 million new cases were diagnosed, and over 5 million 
women died of breast cancer.  Since 2008, estimates of breast cancer incidence 
have increased by more than 20%, while mortality has increased by 14% (Ferlay et 
al., 2013; Bray et al., 2008). An estimated, 20% of breast cancers are HER2 positive 
(Senkusa et al., 2014). That is, they express high levels of the human epidermal 
growth factor receptor-type 2. HER2 stimulates the growth of breast cancer cells. 
HER2 positive breast cancer tends to be more aggressive and to spread more 
quickly than HER2 negative tumours. HER2 positive breast cancer can also be 
difficult to treat with hormone therapies used for other types of breast cancer. 
Younger women are more likely to present with HER2 positive breast cancer than 
older women (Senkusa et al., 2014; Figueroa-Magalhaes et al., 2014). 
Both adjuvant and neoadjuvant chemotherapies play important roles in the 
management of HER2-positive breast cancer. The latest and one of the biggest 
clinical trials conducted by Roche and the Breast International Group confirmed that 
one year of Herceptin (Trastuzumab) treatment remains the gold standard of care for 
the patients with early-stage HER2-positive breast cancer. Trastuzumab (TZ) is a 
humanized monoclonal antibody and has been approved by the Food and Drug 
Administration for the treatment of HER2-positive breast cancer. It binds with HER2 
receptors on breast cancer cells and blocks downstream signaling leading to 
antibody dependent cellular toxicity (Figueroa-Magalhaes et al., 2014; Pinto et al., 
2013; Gennari et al., 2004; Gschwind et al., 2004). 
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Clinical trials have also been carried out to optimize chemotherapeutic 
combinations and regimens. As a result, the combination of TZ with other 
chemotherapeutic agents has significantly improved disease-free survival rates and 
overall survival rates. Taxanes and anthracyclines are the most commonly used 
anticancer drugs for the treatment of breast cancer. TZ in combination with docetaxel 
(DTX) is synergistic (Moreno-Aspitia and Perez, 2009). DTX is a semi-synthetic 
analog of paclitaxel and has been used as a first-line treatment for various cancers, 
including breast, lung, ovarian, brain and prostate cancers (Zhao and Astruc, 2012; 
Kulhari et al., 2014; Feng et al., 2009; Mosallaei et al., 2013). 
Dendrimers are hyper-branched, nano-sized and multi-functionality carrier 
systems. The unique structure of dendrimers allows delivering of more than one drug 
at a time. Dendrimers contain open internal cavities and free functional groups on 
the surface (Kulhari et al., 2011, 2013, 2015; Chauhan et al., 2004). In the current 
study DTX was loaded into the internal cavities of dendrimers through non-covalent 
interactions and TZ was conjugated to free amine groups on their surface. This 
dendrimer-mediated drug delivery system was designed to use TZ as a targeting 
ligand for the site-specific delivery of DTX to HER2-positive breast cancer cells. 
Although reports are available on conjugation of TZ to a nanocarrier system, (Shukla 
et al., 2008; Yousefpour et al., 2011; Kim et al., 2012; Miyano et al., 2010; Isabel et 
al., 2006), preclinical studies have not so far been reported.  
5.2. Experimentation 
5.2.1. Materials 
G4 PAMAM dendrimers with diaminobutane core were purchased from 
NanoSynthons, Mt Pleasant, MI. Trastuzumab was purchased from Nava Sanjivani 
Drugs, Hyderabad. Maleimide-poly(ethylene) glycol-N-hydroxysuccinimide (Mal-PEG-
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NHS) was purchased from Thermo Fisher Scientific. Docetaxel was obtained as gift 
from TherDose Pharma Pvt. Ltd. (Hyderabad, India). High performance liquid 
chromatography (HPLC) grade solvents were purchased from Merck specialties 
(Mumbai, India). Nylon membrane filters of pore size 0.22 µm were obtained from 
Pall India Pvt. Ltd. (Mumbai, India). Fluorescein isothiocyanate (FITC), dialysis 
tubing (Molecular weight cut off 2000), Dulbecco’s modified eagle medium (DMEM), 
trypsin–EDTA, antibiotic/anti-mycotic solution, phosphate buffer saline (Ca2+, Mg2+ 
free), 3-(4, 5- dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT), dimethyl 
sulfoxide (DMSO), annexin V-FITC apoptosis detection kit, acridine orange and 
ethidium bromide were purchased from Sigma Aldrich (St. Louis, MO, USA). Fetal 
bovine serum (FBS) was purchased from Gibco, USA. Cell culture plastic wares 
were purchased from Tarson Ltd (Mumbai, India). 
5.2.2. Synthesis and characterization of FITC labelled TZ conjugated PAMAM 
dendrimers 
FITC labeled TZ conjugated PAMAM dendrimers were synthesized by a four 
step chemical reaction: a) synthesis of FITC conjugated dendrimers b) Conjugation 
of heterocross-linker to FITC labeled dendrimers c) Thiolation of TZ d) 
Bioconjugation of thiolated TZ to dendrimers. 
a) Synthesis of FITC conjugated dendrimers 
FITC labeled G4 PAMAM dendrimers were prepared by a previously reported 
method (Yellepeddi et al., 2008). Dendrimers (15 mg) were dissolved in phosphate 
buffer saline (PBS, pH 7.4) and mixed with 465 µL of FITC solution (5 mg/mL in 
acetone). The mixture was stirred overnight. The solution was then dialyzed against 
PBS for 24 h to remove unconjugated or untrapped FITC. The molar ratio of FITC 
conjugation to dendrimers was determined from absorbance at 495 nm using a UV-
Chapter 5 TZ-Dendrimer-DTX for HER2 positive breast cancer 
 Peptide and monoclonal antibody mediated targeting of anticancer drugs  119 
 
VIS spectrophotometer. For qualitative analysis, samples were scanned in the 
wavelength-range of 200-800 nm. The FITC labeled dendrimer solution was 
lyophilized and used for further reactions. 
b) Conjugation of NHS-PEG-MAL to FITC labeled dendrimers 
 27µL of NHS ester of PEG-MAL (100 mg/mL in DMSO) was added to FITC 
conjugated dendrimer solution in PBS, pH 8 and stirred for 30 minutes at room 
temperature. Synthesis of Dend-PEG-MAL was characterized by 1H NMR 
spectroscopy. PEGylated dendrimers were dissolved in D2O and scanned using 
Avance 500 NMR. 
c) Thiolation of TZ 
Eighty four milligrams of TZ (0.57 µM) were dissolved in PBS and reacted with 
2-iminothiolane hydrochloride (2.88µM) for 2 h. Thiolated TZ was purified by dialysis 
(MWCO 12000-14000) in PBS to remove 2-iminothiolane hydrochloride. 
d) Bio-conjugation of thiolated TZ to PEGylated dendrimers 
 Finally, thiolated TZ was coupled with heterocross-linked conjugated FITC 
labeled dendrimers to give a bio-cojugate. NHS-PEG-MAL cross-linked dendrimer 
solution was mixed with thiolated TZ solution and allowed to react at room 
temperature overnight. The dendrimer-TZ conjugate (Dend-TZ) was purified by 
passing through a Sephadex column. 
5.2.3. Characterization of Dend-TZ conjugate 
5.2.3.1. Surface charge 
Surface potential of various nanoconjugates was measured using a Malvern 
Zetasizer Nano-ZS (Malvern Instruments Ltd., UK). Samples were diluted in 
deionised water and analyzed at 25 °C. 
5.2.3.2. Polyacrylamide gel electrophoresis (PAGE) 
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TZ-Dend conjugates were also characterized by PAGE analysis. All gels were 
electrophoresed under reducing conditions using Mini-Protean II electrophoresis 
units from BioRad at a constant voltage of 200V in Tris/glycine/SDS buffer. 
5.2.4. Drug loading 
An excess (5 mg) of DTX was added to the dendrimer solution, sonicated for 
30 sec and gently stirred overnight. For preparation of DTX loaded Dend-TZ 
formulations two approaches were used. In first method, DTX loaded dendrimers 
were conjugated to TZ. Alternatively, DTX was loaded into Dend-TZ solution. 
Formulations were equilibrated for 24, and then filtered through a 0.45 µm 
membrane cellulose filter. The concentration of DTX was determined using a HPLC, 
system. 
5.2.5. In vitro drug release studies 
In vitro drug release studies were performed by a dialysis method in 
phosphate buffer saline pH 7.4 (PBS). Taxotere and dendrimer formulations, 
equivalent to 2 mg of DTX, were placed in dialysis tubing (MWCO 2000) in release 
medium (100 mL of PBS) at 37 °C stirring at 100 rpm. At different time intervals, an 
aliquot of one mL was withdrawn from the release medium and replaced with same 
volume of fresh medium. The samples were appropriately diluted, filtered through a 
0.22 µm nylon filter and analyzed for DTX content by HPLC. 
5.2.6. Cell culture 
The human breast cancer cell lines-MDA-MB-453 (HER2 positive) and MDA-
MB-231 (HER2 negative) were obtained from the American Type Culture Collection 
(ATCC) (Manassas, VA, USA).  Cells were grown in DMEM medium supplemented 
with 10% fetal bovine serum, 100 U/mL penicillin, 100 mg/mL streptomycin and 2 
mM/L L-glutamine. Cells were maintained at 37 °C in 5% CO2. 
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5.2.7. Anti-proliferation  assay 
Cells were seeded in 96-well plates at a density of 5 × 103cells per well in 
100 μL of medium and allowed to adhere overnight. Cells were then incubated with 
the DTX, Dend-DTX or TZ-Dend-DTX at equivalent drug concentrations, ranging 
from 5 to 250 ng/mL for 48 or 72 h. Media were then replaced with serum free 
DMEM containing MTT (0.5 mg/mL) and cells incubated for an additional 4 h. Media 
were removed and 150 µL of DMSO added to dissolve formazan crystals. 
Absorbance was measured at 570 nm using a microplate reader. Untreated cells 
were used as a negative control (100% viability).  IC50 was calculated by fitting the 
curve of cell viability against drug concentration.  
5.2.8. Cellular uptake studies 
For qualitative uptake studies MDA-MB-453 cells were seeded in 12-well 
plates. After 24 h cells were incubated with FITC, Dend-FITC or TZ-Dend-FITC at an 
equivalent FITC concentration (25 µg/mL). At pre-determined time intervals culture 
media was removed, cells rinsed twice with cold PBS and observed by fluorescence 
microscopopy. For quantitative studies, 0.1% Triton X-100 in 0.2 M NaOH was 
added to each well to lyse cells. Fluorescence intensities were measured using a 
microplate reader at an excitation wavelength of 495 nm and an emission 
wavelength of 520 nm.  
5.2.9. Acridine orange and Ethidium bromide (AO/EB) assays 
AO/EB assay were used to visualize changes in cell morphology such as 
chromatin condensation and apoptotic body formation that are characteristic of 
apoptosis. MDA-MB-453 cells were seeded in 6 well plates at 5 × 105 cells per well 
in 2 mL of DMEM and cultured for 24 h. Cells were incubated with various DTX 
formulations (DTX, Dend-DTX or TZ-Dend-DTX), equivalent to 56.1 ng/mL of DTX. 
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After 24 h medium was removed and cells washed in PBS twice and incubated in 
PBS containing AO and EB (5 μg/mL of each) at 37 °C for 10 min. Cell viability was 
observed with a fluorescence microscope. In live cells chromatin is stained bright 
green by acridine orange, whilst dead cells it is stained orange by ethidium bromide.  
5.2.10. Apoptosis 
Annexin V-FITC/PI assays were used as per the manufacturer's protocols to 
evaluate apoptosis and necrosis. Briefly, MDA-MB-453 cells (1 × 106 cells/well) were 
seeded in 6-well plates and maintained at 37 °C in 5% CO2 and a 95% humidified 
atmosphere. The medium was replaced with freshly prepared medium containing 
drug-loaded nanoparticles. Untreated cells were used as controls. After 24 h, cells 
were washed with PBS twice and resuspended in 500 μL of binding buffer. 5 μL of 
FITC-conjugated Annexin V and 10 μL of PI were added and cells incubated for 15 
min at room temperature in the dark. Cells were then analyzed by a Muse™ Cell 
Analyzer (Merck-Millipore, Germany). 
5.2.11. Pharmacokinetic studies 
Female Balb/c mice were purchased from National Institute of Nutrition 
(Hyderabad, India). Experimental protocols for the study were approved by the 
Institutional Animal Ethics Committee (IAEC) of the CSIR-Indian Institute of 
Chemical Technology, Hyderabad and the animal studies were performed in 
accordance with the guidelines of the Committee for the Purpose of Control and 
Supervision of Experiments on Animals (CPCSEA). Animals were kept in 
polypropylene cages under standard laboratory conditions (12 h light/12h dark 
cycle).   
Eighty four female mice (20-25 g) were randomly assigned to three groups for 
pharmacokinetics investigation. Taxotere, Dend-DTX, or TZ-Dend-DTX was injected 
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via the tail vein at an equivalent dose of 10 mg/kg DTX. At scheduled time intervals 
(0.25, 0.5, 1, 2, 4, 8, and 12 h) post-injection, 0.3 mL of blood was collected into 
heparinized polyethylene tubes from the retro-orbital plexus and centrifuged at 1500 
rpm for 5 min to obtain plasma. The samples were stored at -80 °C until analysis. 
An analytical method for the determination of the DTX content of plasma 
samples was validated using an HPLC system (Water, USA) equipped with a C18 
column (Grace, 250 × 4.6 mm, 5 µm) and a photodiode array detector. The mobile 
phase consisted of acetonitrile (48%) and 0.1% orthophosphoric acid (52%). 5 µl of 
paclitaxel solution (1 mg/mL) was used as an internal standard. The flow rate was 
maintained at 1 mL/min and column temperature set at 25±5 °C. Peaks were 
monitored at a wavelength of 230 nm. The retention times for DTX and PTX were 9.1 
min and 11.2 min, respectively.  
5.2.12. Stability studies 
For stability studies the final formulation (TZ-Dend-DTX) was stored at 2-8 °C 
for 60 days. The formulation was observed for changes in consistency and 
precipitation and analyzed for zeta potential and drug content. 
5.2.13. Statistical analysis 
Results are expressed as mean and standard deviation of three experiments 
(n=3). Pharmacokinetic and tissue distribution data are an average of four 
experiments (n=4). Statistical significance was analyzed using the student t-test for 
two groups and one-way ANOVA for multiple groups. A probability (p) of less than 
0.05 was considered as statistically significant.  
5.3. Results and discussion 
5.3.1.  Synthesis and characterization of TZ-Dend conjugate 
Trastuzumab was conjugated onto the surface of dendrimers by a four step 
chemical reaction (Scheme 5.1).  
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Scheme 5.1: Schematic diagram showing the various steps of bioconjugation of FITC 
and TZ on the surface of G4 PAMAM dendrimers 
Chapter 5 TZ-Dendrimer-DTX for HER2 positive breast cancer 
 Peptide and monoclonal antibody mediated targeting of anticancer drugs  125 
 
FITC labelled dendrimers were synthesized by reacting the primary amino 
groups of the dendrimers with the FITC isothiocyanate groups. This resulted in 
formation of a stable thiourea bond. Approximately 4.6 FITC molecules were 
attached per dendrimer molecule, as determined by UV/VIS spectrophotometric 
analysis (Figure 5.1). FITC labeled dendrimers were PEGylated with the NHS ester 
of PEG-Mal. 1H NMR analysis confirmed the synthesis of pegylated dendrimers. Two 
new peaks appeared at 3.8 and 6.2 ppm, corresponding to the protons of the PEG 
chain and Mal group methylene groups, respectively. This confirmed substantial 
conjugation between dendrimers and NHS-PEG-Mal (Figure 5.2). In a separate 
reaction, TZ was thiolated using Traut’s reagent (2-iminothiolane hydrochloride) and 
the number of thiol groups on the TZ dendrimer determined by the Ellmann’s test. 
Finally, thiolated TZ was reacted with PEGylated dendrimers and conjugation 
confirmed by PAGE analysis. (Figure 5.3) 
 
Figure 5.1: UV/VIS spectra of G4 PAMAM dendrimers (G4 Dend), FITC and FITC 
conjugated dendrimers (Dend-FITC) 
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Figure 5.2: 1H Nuclear magnetic resosnance spectra of G4 PAMAM dendrimers and 
MAL-PEG-NHS conjugated G4 PAMAM dendrimers ( Dend-PEG-MAL) 
 
Figure 5.3: Polyacrylamide gel electrophoresis studies of Dendrimers (Dend), 
Trastuzumab (TZ) and TZ conjugated dendrimers (Dend-TZ) 
Conjugation was also confirmed at various stages by the changes in surface 
charge of the dendrimers (Table 5.1). Due to presence of cationic 64 amine groups 
on surface, plain dendrimers showed a positive zeta potential of 12.7 mV. After 
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conjugation with NHS-PEG-Mal, the zeta potential was decreased to 6.8 mV and, 
after grafting of TZ to the dendrimer surface, to -2.3 mV.  
Table 5.1: Zeta potential of plain dendrimers, dendrimer-PEG-NHS ester and 
dendrimer-Trastuzumab conjugate (Dend-TZ) 
Step No. Conjugate Zeta Potential (mV) 
1 Dendrimers 12.3 ± 0.9 
2 Dendrimer PEG-NHS ester  6.8 ± 1.5 
3 Dend-TZ conjugate -2.3 ± 0.6 
 
5.3.2. DTX loading  
For the determination of drug loading, dendrimer formulations were 
appropriately diluted (50 times) with distilled water and then analyzed using a HPLC 
system. In plain dendrimers, DTX was loaded to a concentration of 241.7±3.82 
µg/mL. In TZ-Dend conjugates, the DTX loading concentration was decreased 
significantly to 159.5±5.4 µg/mL. The decrease in DTX loading in the TZ-Dend 
conjugates may be due to the presence of TZ on the dendrimer surface which may 
restrict DTX molecules from reaching the interior cavities. DTX loaded dendrimers 
that were conjugated to TZ exhibited a DTX concentration of 216.4±2.79 µg/mL.  In 
this case, the decrease in DTX loading concentration may be attributed to loss or 
release of drug during the conjugation process. 
5.3.3. In vitro drug release studies 
 Release of DTX from Taxotere, Dend-DTX and TZ-Dend-DTX dendrimers 
was monitored in PBS. Results are shown in Figure 5.4. DTX was released faster 
from Taxotere than dendrimer-mediated formulations. About 94% of DTX was 
released from Taxotere dendrimers within 10 h. Dend-DTX and TZ-Dend-DTX 
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displayed controlled release of drug up to 48 h. Dend-DTX released 71.84% of drug 
after 24 h and 93.5% of drug after 48 h, respectively. DTX release from TZ-Dend-
DTX was 58.6% and 73.9% after 24 and 48 h, respectively.  
 
Figure 5.4: In vitro drug release profiles of Taxotere®, Dend-DTX and TZ-Dend-DTX up 
to 48 h  
The slower release of DTX from TZ-Dend-DTX than Dend-DTX can be 
explained by the presence of TZ on the surface of the dendrimers. This could make 
a long release path for the drug or alternatively create a coat around the dendrimers.  
5.3.4. Hemolytic toxicity 
Biocompatibility of the drug delivery carriers were assessed by hemolytic 
toxicity studies. Plain dendrimers showed concentration-dependent hemolysis 
(Figure 5.5). TZ-conjugated dendrimers caused lower hemolysis than plain 
dendrimers. At 10 mg/mL dendrimers concentration, plain dendrimers caused 5.3% 
hemolysis compared to 1.5% by TZ-Dend conjugates. These results suggest TZ-
Dend conjugates are more biocompatible than plain dendrimers. The decrease in 
toxicity of TZ-Dend conjugates compared to plain dendrimers can be explained by 
the presence of opposite charges on their surfaces (Table 1). Plain dendrimers 
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exhibited a high positive charge of 12.7 mV, whereas TZ-Dend conjugates were 
anionic in nature, with a zeta potential value of -2.3 mV. PAMAM dendrimers have 
been reported to cause hemolysis because of their cationic nature. They rapidly 
interact with anionic red blood cells (RBC) membranes, causing hemolysis 
(Domanski et al., 2004). This positive charge was neutralized by the TZ moiety on 
TZ-Dend conjugates, making them anionic and decreasing interaction between 
dendrimers and RBC membranes. 
 
Figure 5.5: Hemolytic toxicity of plain dendrimers and TZ conjugated dendrimers 
5.3.5. In vitro cytotoxicity 
 To investigate the anticancer actions of the DTX formulations two breast 
cancer lines (MDA-MB-453 and MDA-MB-231) were selected. The cell lines were 
chosen on the basis of their immuno-profiles.  MDA-MB-453 cells are oestrogen 
receptor negative (ER-), progesterone receptor negative (PR-) and HER2 positive 
(HER2+); whilst MDA-MB-231 cells are triple negative (ER-, PR- and HER2-). 
Moreover, sensitivity of both cell lines to chemotherapy is comparable (Holliday and 
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Speirs, 2011; Liu et al., 2013). Therefore, a comparative evaluation of cytotoxicity 
against these cell lines could provide a better understanding of the contribution of TZ 
in drug targeting to HER2+ breast cancers. 
 Cytotoxicity measures of DTX, Dend-DTX and TZ-Dend-DTX against MDA-
MB-453 and MDA-MB-231 cells are shown in Figure 5.6a and b, respectively. At 125 
ng/mL drug concentration, viability of MDA-MB-453 cells was 69, 57.6 and 36.2% for 
DTX, Dend-DTX and TZ-Dend-DTX, respectively. The results clearly indicated that 
DTX loaded dendrimers were more cytotoxic than plain DTX. Comparing the 
targeted and non-targeted dendrimers, cells treated with TZ-Dend-DTX showed 
enhanced cell death than with Dend-DTX. This may be attributed to the interaction 
between TZ and HER2 on MDA-MB-453 cells leading to internalization of TZ-Dend-
DTX through receptor-mediated endocytosis. However, against MDA-MB-231, TZ-
Dend-DTX did not cause significantly increased cytotoxicity over Dend-DTX. The 
Viability of MDA-MB-231 cells after 48 h of treatment was 61.9, 59.3 and 60.9% for 
DTX, Dend-DTX and TZ-Dend-DTX, respectively (Figure 5.6b).  
 
(a) 
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(b) 
Figure 5.6: % Cell viability of a) HER+ MDA-MB-453 human breast cancer cells and b) 
HER- human breast cancer cells MDA-MB-231 after 48 h incubation with varying 
concentrations of empty dendrimers (control), DTX, Dend-DTX and TZ-Dend-DTX  
 
It was also noted that the different formulations caused dose-dependent 
decrease in the cell viability to both cell lines tested. Against MDA-MB-453 cells after 
48 h treatment, the IC50 values for Dend-DTX and TZ-Dend-DTX were 201 ng/mL 
and 56.18 ng/mL, respectively. Therefore, TZ-Dend-DTX conjugate was 3.57 times 
more cytotoxic than unconjugated dendrimers. However, against HER2 negative 
MDA-MB-231 cells, the TZ-Dend-DTX conjugate did not show any increase in 
cytotoxicity compared to Dend-DTX. The IC50 value for Dend-DTX and TZ-Dend-TZ 
against MDA-MB-231 cells was 163.4 ng/mL and 149.5 ng/mL, respectively. These 
results demonstrate that TZ can specifically target and deliver DTX to HER2 positive 
tumor cells. After treatment with different DTX formulations, the changes in cell 
morphology of MDA-MB-453 cells are shown in Figure 5.7. Normal or untreated cells 
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formed loosely cohesive grape-like or stellate like structures and grew in a colony. 
Treated cells showed less colony formation and decrease in cell numbers.  
 
Figure 5.7: Cell morphology of HER+ human breast cancer cells MDA-MB-453 after 
incubation with varying concentration of DTX, Dend-DTX and TZ-Dend-DTX for 24 h. 
 
5.3.6. Cellular uptake of fluorescent dendrimer formulations 
 Cellular uptake studies are important tools to track internalization of 
fluorescent nanoparticles. Uptake of free FITC, Dend-FITC and TZ-Dend-FITC is 
shown in Figure 5.8. The fluorescent microscope images show that plain FITC was 
not taken up by the cells even after 4 h incubation, whereas fluorescence was 
detected in cells incubated with Dend-FITC and TZ-Dend-FITC after 1 h. 
Fluorescence intensity was significantly higher with TZ-Dend-FITC than Dend-FITC. 
The results were confirmed by quantitative analysis (Table 5.2). After 1 h of 
treatment, percentage uptake of free FITC, Dend-FITC and TZ-Dend-FITC was 
1.6%, 11.4% and 23.5%, respectively. Dendrimer formulations also showed time-
dependent uptake. After 4 h of incubation, uptake was increased to 34.2% and 
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57.9% for Dend-FITC and TZ-Dend-FITC, respectively. The increased uptake of TZ-
Dend-FITC when compared to Dend-FITC, clearly demonstrates the contribution of 
TZ to the internalization of dendrimers.  
 
Figure 5.8: Fluorescent microscopic images of MDA-MB-453 human breast cancer 
cells incubated with free FITC, Dend-FITC and TZ-Dend-FITC for 1 and 4 h. 
 
Table 5.2: Quantitative cellular uptake of free FITC, Dend-FITC and TZ-Dend-FITC by 
human MDA-MB-453 breast cancer cells after 1 and 4 h of incubation 
Formulation % Cell uptake after 1 h % Cell uptake after 4 h 
Free FITC  2.59 ± 0. 73 6.01 ± 0.48 
Dend-FITC 11.28 ± 1.4 34.2 ± 1.95 
TZ-Dend-FITC 23.49 ± 1.85 57.92 ± 2.71 
 
5.3.7. AO/EB staining 
 AO stains both live and dead cells whereas EB stains only dead cells or the 
cells that have lost membrane integrity. Therefore, live cells appear as intense green 
colour while apoptotic and necrotic cells appear as orange colour. Figure 5.9 shows 
the fluorescent images of untreated MDA-MB-453 cells, cells treated with DTX, 
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Dend-DTX and TZ-Dend-DTX followed by AO/EB staining. Untreated cells showed 
evenly spread green color. Comparing the targeted and non-targeted dendrimers, 
cells treated with TZ-Dend-DTX showed enhanced apoptosis than with Dend-DTX. 
 
Figure 5.9: Fluorescent microscopic images of MDA-MB-453 human breast cancer 
cells incubated with free DTX, Dend-DTX and TZ-Dend-DTX for 24 h followed by 
staining with acridine orange and ethidium bromide  
5.3.8. Annexin-V FITC/ PI assay 
Quantitation of apoptosis induced by different DTX formulations were studied 
by Annexin-V FITC/ PI assay (Figure 5.10). A high percentage of live cells (94.8%) 
was observed in untreated cells. The percentage of live cells was decreased to 83% 
with Taxotere, 64.6% with Dend-DTX and 54.3% with TZ-Dend-DTX treatment. The 
data suggests TZ-Dend-DTX induced more apoptosis than unconjugated and 
Taxotere conjugated dendrimers. The total percentage of apoptotic cells was 42.5%, 
32.6% and 16.4% with TZ-Dend-DTX, Dend-DTX and Taxotere, respectively.  Higher 
levels of apoptosis with TZ-Dend-DTX compared to Dend-DTX treated cells can be 
attributed to more uptake and higher accumulation of DTX; thus leading to inhibition 
of cellular proliferation.  
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Figure 5.10: Quantification of apoptosis induced by free DTX, Dend-DTX and TZ-Dend-
DTX using flow cytometer 
5.3.9. Pharmacokinetic studies 
Plasma-concentration profiles of DTX after intravenous injection of Taxotere, 
TZ-Dend-DTX and Dend-DTX are shown in shown in Figure 5.11 and correspond to 
the pharmacokinetic parameters presented in Table 5.3. Results suggest plasma 
pharmacokinetics of dendrimer formulations (TZ-Dend-DTX and Dend-DTX) were 
completely different from those of Taxotere. The area-under-the-curve (AUC0-∞) of 
TZ-Dend-DTX (271.6 µg.h/mL) and Dend-DTX (204.2 µg.h/mL) was approximately 
4.7 and 3.5 times higher, respectively, than that of Taxotere (57.2 µg.h/mL). This 
could be explained by decreased clearance of DTX that is released from dendrimer-
based formulations. The observed clearance values for Taxotere, Dend-DTX and 
TZ-Dend-DTX were 268.8, 48.9 (5.5 times less) and 36.8 mL/h (7.3 times less), 
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respectively. Mean residence time (MRT) increased approximately 3.4× and 2.5× for 
TZ-Dend-DTX and Dend-DTX, respectively.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: Pharmacokinetic profiles Taxotere, docetaxel loaded dendrimers (Dend-
DTX) and Trastuzumab conjugated Dend-DTX (TZ-Dend-DTX) administered 
intravenously to Balb/c mice at a dose of 10 mg/Kg body weight. 
 
Compared to unconjugated dendrimers, (Dend-DTX) and TZ-Dend-DTX 
induced significantly higher AUC0-∞ (271.6 versus 204.2, p<0.005), lower clearance 
(48.9 versus 36.8, p<0.05) and longer MRT values (6.85 versus 4.99; p<0.05). The 
differences between the two dendrimer formulations may be attributed to the 
presence of PEG-linkers and TZ on the surface of TZ-Dend-DTX. Polyethylene 
glycol (PEG) is a non-ionic hydrophilic polymer with an average molecular weight 
between 20 to 50 kDa. PEG is a well-documented molecule that could alter the 
pharmacokinetics of different nanocarrier systems (Zhu et al., 2010; Kim et al., 2009; 
Li et al., 2012; Zamboni et al., 2005). Being an antifouling molecule, PEG increases 
the circulation time of nanoparticles in the blood stream by delaying their capture by 
the reticulo-endothelial system. Additionally, TZ is a high molecular weight, clinically 
approved mAb (~ 145 KD), known for its high specificity for HER2 receptors (Raju et 
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al., 2013). It may therefore lengthen TZ-Dend-DTX circulation and slow release of 
DTX from conjugated dendrimers. 
Table 5.3: Pharmacokinetic parameters for the three DTX formulations-Taxotere, DTX 
loaded dendrimers (Dend-DTX) and trastuzumab conjugated Dend-DTX (TZ-Dend-
DTX) 
PK Parameter Taxotere Dend-DTX TZ-Dend-DTX 
Cmax (µg/mL) 42.7 ± 1.82 69.01 ± 4.38** 61.72 ± 3.92**,ns 
T1/2 (h) 1.35 ± 0.21 1.99 ± 0.3* 3.24 ± 0.17*,# 
Cl (mL/h) 268.81 ± 11.2 48.97 ± 5.65** 36.82 ± 4.06**,# 
AUC0-∞ 37.2 ± 2.94 204.16 ± 8.03*** 271.58 ± 7.95***, ## 
MRT (h) 1.98 ± 0.08 4.99 ± 0.19** 6.85 ± 0.11***,## 
 
Cmax: peak plasma concentration; t1/2: terminal half-life; MRT: Mean residence time; Cl: 
Clearance; AUC: Area under the curve; MRT: Mean residence time 
 
5.3.10. Stability studies 
 After 2 months of storage at 4 °C (specify), there was no sign of precipitation 
or significant change in consistency, zeta potential and drug content (Table 5.4). 
Table 5.4: Physicochemical stability of TZ-Dend-DTX conjugate after 60 days of 
storage at refrigeration conditions (4 °C) 
 
 
 
 
 
Parameter Day 0 Day  60 
Precipitation No No 
Change in consistency No + 
ZP (mV)  -2.3 ± 0.72 -3.89 ± 0.51 
% DTX content 100 99.12 
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5.4. Conclusion 
In summary, multifunctional TZ-conjugated dendrimers were synthesized 
using a heterocross-linker MAL-PEG-NHS and characterized by DLS, NMR and 
PAGE analysis. Targeted dendrimers selectively and specifically targeted DTX to 
HER2-positive breast cancer cells. Grafting TZ onto the surface of dendrimers could 
inhibit the growth of HER2-positive cancer cells, as demonstrated by our anti-
proliferation and apoptosis studies. Furthermore, conjugation of TZ onto the surface 
of dendrimers decreased the hemolytic toxicity of unconjugated cationic PAMAM 
dendrimers and enhanced the circulation half-life of the conjugate. These findings 
could help to develop a better therapeutic profile for DTX and deliver better health 
outcomes for people with HER2-positive cancer.  
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succinoyl-TPGS nanomicelles for targeted 
delivery of docetaxel to integrin receptor 
over-expressing angiogenic tumours 
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6.1. Background 
Targeting angiogenesis is a strategy to better control tumour growth and 
metastasis (Zhaofei et al., 2008). Angiogenesis involves the formation of new blood 
vessels from pre-existing vessels and thus promotes tumor growth and metastasis. 
Angiogenesis is stimulated by hypoxia that causes up-regulation of proangiogenic 
proteins such as vascular endothelial growth factor, fibroblast growth factor, Ron, 
platelet derived growth factor, tumour necrosis factor-α and integrins (Thobe et al., 
2010; Danhier et al., 2012; Carmeliet and Jain, 2000).  
Among these, integrins are cell adhesion receptors which are over expressed 
on endothelial cells and tumour cells but poorly expressed in resting endothelial cells 
and normal tissues. Integrins expression in tumour cells promotes tumour 
progression and metastasis by increasing tumour cell migration, invasion, 
proliferation and survival. Thus, targeting a drug to integrin receptors can increase 
specificity and reduce the systemic toxicities of anticancer drugs (Danhier et al., 
2012; Desgrosellier and Cheresh). 
Among all integrins, αvβ3 is one of the most commonly involved integrins in 
the regulation of angiogenesis. It is over expressed in various cancers including 
breast, prostate, pancreatic and brain cancer. The RGD (Arg-Gly-Asp) based 
peptides, in general, have shown significant affinity towards integrin receptors. There 
is an increasing emphasis on employing cyclic RGD peptides for the development of 
targeted drug delivery systems because they are more stable, potent and specific 
than linear RGD peptides, which are otherwise highly susceptible to chemical 
degradation (Arosio et al., 2012). cRGDfK peptide has high specificity in particular 
towards αvβ3 integrin receptors making it a desirable targeting ligand for drug 
delivery applications (Danhier et al., 2012). 
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Docetaxel (DTX) is the semi-synthetic derivative of 10-deacetylbaccatin-III 
and widely used either alone or in combination with other drugs to treat breast, 
ovarian, prostate, non-small cell lung cancer, gastric and neck cancer (Zhao P, 
Astruc, 2012; Zhang and Zhang, 2013). The clinical application of DTX is limited 
owing to not only its poor aqueous solubility and low oral bioavailability (Cho et al., 
2008), but also due to its intolerable side effects such as acute hypersensitivity 
reactions, fluid retention, neurotoxicity, and febrile neutropenia (Zhang and Zhang, 
2013; Baker et al., 2009).  
The use of nanocarrier-based drug delivery systems for anticancer drugs 
combines the advantages of passive and active targeting by enhancing permeability 
and retention, the EPR effect, avoidance of the reticulo-endothelial system, 
prolonged blood circulation time, controlled release of drug and providing an 
opportunity for surface modification for active drug targeting (Sultana et al., 2013; 
Farrell et al., 2011; Kulhari et al., 2015; Feng and Mumper, 2013). 
D-α-tocopheryl polyethylene glycol succinate (TPGS or Vit E TPGS) is a water 
soluble derivative of natural D-α-tocopherol (Vit E). It is synthesized by the 
esterification of Vit E succinate with polyethylene glycol. TPGS is amphiphilic in 
nature with a hydrophilic-lipophilic balance (HLB) value of 13.2 that allows micelle 
formation above 0.02% w/w concentration. A HLB value indicates the relationship of 
the hydrophobic and hydrophilic groups of the surfactant. High HLB value means 
that the surfactant contains more hydrophilic groups and is soluble in water whereas 
a low HLB value represents lipophilicity of the surfactant. Compounds having HLB 
value in a range of 13-15 are categorized as detergents (Hait and Moulik, 2001). At a 
particular concentration, called as critical micellar concentration (CMC), these 
compounds self-aggregates in a defined orientation and form micelles. In an 
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aqueous system, micelles are arranged with an interior hydrophobic core and outer 
hydrophilic surface. Below CMC, surfactants enhance the aqueous solubility of 
poorly water soluble drugs by providing regions for hydrophobic drug interactions in 
solution. Above the CMC, drug is encapsulated in the hydrophobic core of the 
micelles resulting in to enhanced solubility (Narang et al., 2007). With a polar 
hydrophilic head (polyethylene glycol 1000) and a lipophilic tail (phytyl chain of d-α-
tocopherol), TPGS has the HLB value about 13.2 and has been widely used as a 
solubiliser, emulsifier, and to enhance permeability and bioavailability. Several drug 
delivery systems have been developed using TPGS after it was approved by the 
FDA as pharmaceutically safe adjuvant (Sun and Feng, 2009; Raju et al., 2013; 
Muthu et al., 2012; Guo et al., 2013; Zhang et al., 2012; Mi et al., 2012; Pandey et 
al., 2013, Cao et al., 2008). Such TPGS-based engineered nanocarrier systems have 
been shown to transport and deliver anticancer drugs more efficiently than drug 
alone. 
Notably, although TPGS nanomicelles and cRGDfK peptides have been 
independently employed for drug-delivery applications (Kutty et al., 2013; Zhu et al., 
2014; Zhao et al., 2014; Wang et al., 2012; Graf et al., 2012), cyclic peptide 
(cRGDfK)-conjugated succinoyl TPGS nanomicelles have not been hitherto explored 
for their potential to target delivery of anticancer drugs to prostate cancer. The aim of 
this study was to successfully develop cRGDfK-conjugated succinoyl-TPGS 
nanomicelles for the targeted delivery of DTX in prostate cancer treatment.  
6.2. Experimentation 
6.2.1. Materials 
TPGS, succinic anhydride (SA) and coumarin were purchased from Sigma 
Aldrich, (St. Louis, MO, USA). DTX was kindly provided by TherDose Pharma Pvt. 
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Ltd. (Hyderabad, India). Cyclic RGDfK was purchased from Peptide International 
(Kentucky, USA). Nylon membrane filters of pore size 0.22 µm were procured from 
Pall India Pvt. Ltd. (Mumbai, India). Human prostate cancer cell line (DU145) was 
obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA).  
DMEM, Dulbecco's phosphate buffered saline (DPBS), fetal bovine serum (FBS) 
trypsin–EDTA, antibiotic anti-mycotic solution, phosphate buffered saline (Ca2+, Mg2+ 
free), MTT and dimethyl sulfoxide (DMSO) were purchased from Sigma Aldrich, (St. 
Louis, MO, USA). Human umbilical vein endothelial cells (HUVECs) and EBM-2 
media were purchased from Lonza (USA). Cell culture plastic wares were purchased 
from Tarson Ltd (Mumbai, India). All other chemicals were of analytical grade and 
used as received unless otherwise specified. 
6.2.2. Synthesis and Characterization of Succinoyal-TPGS (TPSA) 
TPGS was functionalized with a free carboxylic group by reaction with 
succinic anhydride. TPGS (200 mg), SA (13.2 mg) and 4-(Dimethylamino)pyridine 
(43.1 mg) were mixed in 20 mL of dichloromethane and stirred for 24 h at room 
temperature under strict anhydrous conditions. The reaction mixture was washed 
thrice with saturated NaCl aqueous solution. The organic layer was separated and 
dried with Na2SO4. The solvent was evaporated by rotary evaporation and 
lyophilized to remove traces of water. The activated TPGS was confirmed by proton 
nuclear magnetic resonance (1HNMR), FTIR and mass analysis. For 1HNMR 
analysis, samples were dissolved in CDCl3 and scanned using Avance500 NMR. 
The presence of free carboxylic groups in TPSA was confirmed by FTIR analysis. 
The lyophilized TPSA was mixed with KBr, palletized and scanned for transmittance 
using a FTIR spectrophotometer (Perkin Elmer, Spectrum one) in the wave number 
range 4000 to 450 cm-1.  
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6.2.3. Determination of Critical Micellar Concentration (CMC) 
The CMC value of TPSA was determined by dynamic light scattering (DLS) 
using a Malvern Zetasizer Nano ZS (Malvern instrument Ltd., Malvern, UK). Different 
sample concentrations were prepared and particle diameter and intensity measured. 
Particle size and intensity were plotted against log concentration of sample. The 
concentration at which sharp changes in intensity or size appeared was considered 
the CMC. 
6.2.4. Preparation and characterization of DTX loaded TPSA nanomicelles 
(DNM) 
TPSA (50 mg) and DTX (2.5 mg) were dissolved in methanol (1 mL) and 
added to 5 mL of MilliQ water. The solution was kept stirring overnight in an open, 
round bottom flask to evaporate methanol. The excess or precipitated DTX was 
removed by filtration through a 0.22 µm filter and the filtrate used for further studies. 
For the preparation of FITC loaded fluorescent nanomicelles (FNM), FITC was 
dissolved in 0.2 mL acetone and mixed with TPSA solution without DTX. 
The particle diameter and zeta potential of DNM were determined by DLS 
using a Zetasizer Nano-ZS. The samples were analyzed at 25 ºC with a 
backscattering angle of 173º. Thermal characteristics of pure DTX, TPSA and DNM 
were evaluated using DSC-Q100 (TA Instruments, USA). The samples were 
scanned from 25 ºC to 200 ºC at a speed of 10 ºC/min, under nitrogen environment. 
X-ray diffraction patterns of DTX, TPSA and DNM were obtained using an X-ray 
diffractometer (D8 Advance, Bruker, Germany) equipped with a Cu-Kα X-ray 
radiation source. The instrument was set at 40 KV and 30 mA and the diffraction 
angle (2θ) was measured at 2º to 60º. DTX content was determined by validated 
HPLC method. Encapsulation efficiency (EE) was calculated as follows:  
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% EE = (amount of drug present in nanomicelles / initial amount of drug 
added to the formulation) × 100 
6.2.5. Bioconjugation of cRGDfK on the surface of DNM 
Lyophilized DNM/FNM was dispersed in 0.5 mL phosphate buffer saline pH 
7.4 (PBS) and incubated with 0.2 mL each of 0.1M EDC and 0.1M NHS for 30 min at 
room temperature with gentle stirring. The cRGDfK was dissolved in 0.3 mL PBS, 
added to the reaction mixture and stirred for another 2 h at room temperature. The 
cRGDfK-conjugated DNM (PDNM) and cRGDfK-conjugated FNM (PFNM) were 
purified by dialysis against a saturated solution of DTX or FITC.  
cRGDfK conjugation onto the DNM surface was characterized by FTIR 
analysis. The FTIR spectra of PDNM, DNM and cRGDfK were obtained using a FTIR 
spectrophotometer (Perkin Elmer, Spectrum One, USA) in the wave number range of 
4000 to 450 cm-1. 
6.2.6. In vitro drug release studies 
In vitro release of DTX from peptide conjugated nanomicelles was studied in 
plasma, PBS, pH 7.4 and SAB, pH 5.0. A volume of PDNM equivalent to 1 mg DTX 
was placed in dialysis tubing and tubing incubated in 75 mL of release media. The 
release medium temperature was maintained at 37 ± 0.5 °C and stirred magnetically 
at 100 rpm. At predetermined time intervals, a 1 mL sample of release media was 
withdrawn and replaced with the same volume of fresh medium to maintain sink 
conditions and a constant volume of external release medium. The sample was 
filtered through a 0.22 µm nylon filter and analyzed for DTX content using HPLC.  
6.2.7. Cell culture 
DU145 prostate cancer cells were grown as an adherent layer in RPMI 
medium supplemented with 10% fetal bovine serum, 100 µg/mL penicillin, 200 
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µg/mL streptomycin and 2 mM L-glutamine. The culture was maintained at 37 °C in a 
humidified atmosphere with 5% CO2. Dilutions were made with sterile PBS to the 
required concentration. Formulations were filtered with 0.22 µm sterile filter before 
adding to wells containing cells. HUVECs were cultured in complete EBM-2 media 
containing 5% FBS and maintained at 37 °C humidified incubator with 5% CO2.  
6.2.8. Cell proliferation assay  
The MTT assay was used to determine the anti-cytoproliferative activity of 
different docetaxel formulations. About 1×104 cells (counted by Trypan blue 
exclusion dye method) per well were seeded in culture media in a 96 well plate and 
allowed to attach for 24 h. The cultured cells were then incubated with varying 
concentrations (7.8-500 ng/mL) of DTX, DNM and PDNM. After 24, 48 and 72 h 
incubation, the media was replaced with 90 µL of fresh serum free media and 10 µl 
of MTT reagent (5 mg/mL) and plates incubated at 37 ºC for 4 h, there after the 
above media was replaced with 200 µL of DMSO and incubated at 37 ºC for 10 min. 
The absorbance at 570 nm was measured on a spectrophotometer (Spectra max, 
Molecular Devices). The half maximum inhibitory concentration (IC50) values were 
determined. Cytotoxicity tests were repeated three times and data are expressed as 
mean and standard deviation of three replicates.  
6.2.9. Cellular uptake of unconjugated and peptide conjugated fluorescent 
nanomicelles  
Coumarin, a fluorescent compound, was loaded in nanomicelles to facilitate 
cell-uptake studies. Coumarin-loaded unconjugated and cRGDfK peptide conjugated 
nanomicelles are annotated as FNM and PFNM, respectively. About 5×104 cells 
were seeded in 24-wells plate and allowed to attach for 24 h. Cells were then 
exposed to 50 µl of Coumarin, FNM, and PFNM formulations and incubated for 
intervals of 1, 3, 6, 12 and 24 h. The culture media was removed, cells washed twice 
Chapter 6                                                                         Integrins targeted cRGDfK-TPSA-DTX nanomicelles  
 Peptide and monoclonal antibody mediated targeting of anticancer drugs  149 
 
with cold PBS, and fluorescence photographs taken with a digital camera (Nikon, 
Inc. Japan) at 200X magnification. 
6.2.10. Assessment of cell morphology 
Cells (1×106 cells/well) were grown in 24 well plates and treated with DTX, 
DNM and PDNM at concentration of 60 ng/mL (IC50 of PDNM) for 48 h. 
Morphological changes were observed with an inverted phase contrast microscope 
(Model: Nikon, Japan) and photographs taken with a digital camera (Nikon, Inc. 
Japan) at 200X magnification. Acridine orange/ethidium bromide (AO/EB) staining 
procedure was followed to differentiate live, apoptotic and necrotic cells. Briefly, 
treated or untreated cells were stained with AO (10 µg/mL) and EB (10 µg/mL) and 
analyzed with a fluorescence microscope with excitation (488 nm) and emission (550 
nm) and 200X magnification.  
6.2.11. Apoptosis studies 
Cells were seeded in 6 well plates at a density of 3×106 cells per well and 
incubated overnight at 37 °C in a humidified atmosphere and 5% CO2. Next day, 
DTX, DNM or PDNM (equivalent to 60 ng/mL of DTX) was added and cells 
incubated for another 48 h. Then cells were analyzed by a Muse™ Cell Analyzer 
(Merck-Millipore, Germany) according to the manufacturer instructions using 
MuseTMAnnexin-V and Dead Cell reagent (Merck-Millipore, Germany). Apoptosis and 
necrosis were analyzed with quadrant statistics on propidium iodide-negative cells, 
fluorescein positive cells and propidium iodide (PI)-positive cells, respectively. 
6.2.12. Anti-angiogenic activity 
Anti-angiogenic activity of DTX, DNM and PDNM was studied by two assays, 
namely cell viability assay and scratch wound directional migration assay using 
HUVEC cells. Cell viability assay was carried out in the presence of VEGF.  
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6.2.12.1. Endothelial cell proliferation assay 
HUVEC cells (1 × 104 cells/well) were seeded into 96-wells cell culture plate 
for 24 h.  Next day, the cells were starved with EBM-2 media containing 0.2% FBS 
for 8 h. Cells were then incubated with different materials at various concentrations 
for 24 h. After discarding the old media, fresh MTT solution (0.5 mg/mL) was added 
to each well and the plate was kept at 37 °C for 4 h. Media in each well was then 
replaced with DMSO-methanol mixture (1:1; v/v) to solubilise the purple formazan 
dye. Absorbance of the purple solution was measured using a multimode reader 
(Biotek Synergy) at 570 nm. 
6.2.12.2. Scratch wound directional migration assay 
HUVEC cells (4 ×104 cells/mL) were seeded in 24-wells plate for 24 h. The 
monolayers were then scratched with a sterile micro-tip. Cells were thoroughly 
washed with DPBS and incubated with different materials for up to 24 h. Phase 
images of cells were captured using a bright field microscope at different time points 
(0 h, 8 h and 24 h). The % of wound closure was calculated by measuring the wound 
area using Image J analysis software.  
6.2.13. Stability Studies  
The PDNM was stored at 2-8 °C and change in particle size, zeta potential 
and drug content were measured for up to 2 months. 
6.2.14. Statistical analysis  
The studies were performed in triplicate and results expressed as mean along 
with standard deviation (SD). Statistical significance was analysed using student t-
test for two groups and one way ANOVA for multiple groups. P values of < 0.05 were 
considered significant.  
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6.3. Results and discussion 
6.3.1. Synthesis and characterization of Succinoyl-TPGS (TPSA) 
Carboxylic group functionalized succinoyl-TPGS (TPSA) was prepared by a 
ring opening reaction with succinic anhydride (Scheme 1). The activated TPGS 
showed two important characteristic 1HNMR signals- one at 2.4 ppm assigned to 
succinoyl methylene (-CH2) protons and a second at 3.6 ppm assigned to the –CH2− 
protons of PEG moiety in TPGS (Figure 6.1) (Cao and Feng, 2008). The FTIR 
spectra of SA showed two sharp peaks at 1863 and 1784 cm-1 that are characteristic 
of cyclic anhydride group. However, in FTIR spectra of TPSA, we observed a new 
peak at 1735 cm-1 (characteristic –COOH group peak) instead of these peaks. The 
absence of cyclic anhydride group peaks and appearance of a characteristic –COOH 
group peak at 1735 cm-1 confirmed successful ring opening of SA and then 
functionalization of TPGS (Figure 6.2).  
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Scheme 6.1: Chemical synthesis of succinoyl TPGS (TPSA) by a ring opening reaction 
between Vit-E TPGS and succinic anhydride 
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Figure 6.1: 1H NMR spectra of stearic acid (SA), TPGS and stearic acid modified TPGS 
(TPSA) 
 
 
 
Figure 6.2: FTIR spectra of stearic acid (SA), D-α-tocopheryl polyethylene glycol 
succinate (TPGS) and SA functionalized TPGS (TPGS-SA) 
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6.3.2. Preparation and characterization of different nanomicelles  
For surfactant molecules, the CMC value is an important parameter for 
determination of surface activity. TPSA is an amphiphile where its tocopherol part 
serves as a lipophilic tail, while polyethylene glycol serves as a polar head. The CMC 
value of TPSA was determined using the DLS technique and found to be 0.008%. A 
significant (p<0.05) decrease in CMC value of TPSA compared to TPGS (0.02%) 
could be attributed to surface modification of the stearate moiety to more a 
hydrophilic acid derivative. The lower CMC value indicated the high stability of 
TPSA. Determination of the CMC value for TPSA allowed simple synthesis of 
nanomicelles. 
DTX-loaded TPSA nanomicelles (DNM) were prepared by the solvent loading 
and evaporation (SLE) method. In this method, DTX and TPSA were dissolved in 
methanol and added to the aqueous phase. However, to allow nanomicelle 
formation, the concentration of TPSA was kept higher than its CMC value (0.008%). 
As the methanol evaporated, excess DTX precipitated and after complete methanol 
evaporation (as determined by the total volume of the formulation) removed by 
filtration. Blank nanomicelles (BNM) were prepared without DTX. Coumarin-loaded 
fluorescent nanomicelles (FNM) were also prepared for cellular uptake studies. 
Coumarin was dissolved in acetone, mixed with TPSA methanol solution and then 
added to the water. The drug entrapment efficiencies of DNM and PDNM were found 
to be 79.55±2.98 and 73.42±1.54%, respectively. 
The prepared nanomicelles were characterized by particle size, 
polydispersity, surface potential, DSC, XRD and FTIR analysis. Observed particle 
diameters and zeta potentials of different formulations are shown in Table 6.1. All the 
formulations exhibited very small sizes, ranging from 22.41 to 30.26 nm and with 
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narrow distribution (PDI< 0.25). Peptide conjugated formulations showed reduction in 
negative zeta potential values from those of unconjugated formulations, indicating 
the presence of cationic peptide on the surface. The zeta potential values for PDNM 
and PFNM were -10.3±1.5 and -13.3±2.2 mV, respectively, while these were 
19.7±2.6 mV for DNM and -14.3±2.2 mV for FNM. 
Table 6.1: Physicochemical characterization of various nanomicelles formulations 
(Mean ± SD, n=3) 
Formulation Particle 
Diameter 
(nm) 
Polydispersity 
Index 
Zeta 
potential 
(mV) 
Entrapment 
efficiency 
(%) 
Peptide 
conjugation 
efficiency 
(%) 
BNM 23.80±0.56 0.21±0.016 -25.5±1.2  - - 
DNM 27.92±0.85 0.14±0.019 -19.7±2.6 79.55±2.98 - 
PDNM 30.26±0.48 0.18±0.022 -10.3±1.5 73.42±1.54 84.21±2.59 
FNM 22.41±0.73 0.22±0.038 -22.6±1.4 89.56±3.65 - 
PFNM 26.95±1.06 0.23±0.027 -14.3±2.2 87.63±2.90 82.98±1.76 
BNM: Blank nanomicelles; DNM: Docetaxel loaded nanomicelles; PDNM: cRGDfK peptide 
conjugated and docetaxel loaded nanomicelles; FNM: Coumarin loaded nanomicelles; 
PFNM: cRGDfK peptide conjugated and Coumarin loaded nanomicelles. 
Nanomicelles showed high encapsulation efficiency (Table 6.1). The EE of 
57.76% was considerably higher than that reported by Muthu et al, 2012. Increased 
EE of DNM can be attributed to the altered method of micelle preparation and to the 
functional group modification of TPGS. cRGDfK conjugation to nanomicelle surfaces 
was determined by the Bradford assay. The conjugation efficiencies were 
84.21±2.59% and 82.98±1.76% for PDNM and PFNM, respectively. Bioconjugation 
of cRGDfK to the surface of DNM was confirmed by FTIR analysis (Figure 6.3). FTIR 
spectra of free DTX showed absorption bands of O-H  at 3480 cm-1, C=O stretching 
of ester group at 1741 cm-1 and a band corresponding to C-O band at 1109 cm-1. 
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The C=O stretching of the carboxylic acid group of TPSA appeared at 1736 cm-1. 
This carbonyl band disappeared from the spectra of PDNM and a new peak 
appeared at 1644 cm-1, corresponding to C=O stretching of the amide bond formed 
between the -COOH group of DNM and the -NH2 group of cRGDfK.  
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Figure 6.3a-b: a) Chemical structure of Cyclo(Arg-Gly-Asp-D-Phe-Lys) (cRGDfK) 
b) FTIR spectra of docetaxel (DTX), DTX loaded nanomicelles (DNM) and cRGDfK 
peptide conjugated DNM (PDNM) 
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The thermal behaviour of pure DTX, TPSA and DNM was investigated by 
DSC analysis (Figure 6.4). DSC scanning of pure DTX showed sharp endothermic 
transition at 176 °C corresponding to its melting point. TPSA demonstrated the 
characteristic endothermic peak of TPGS at 38 °C. Therefore, surface group 
modification did not change the melting point of TPGS. The thermogram of DNM 
showed only the peak of TPSA at 36.5 °C. Absence of a DTX peak in the DSC 
spectra of DNM indicates phase transition of pure DTX from crystalline to 
amorphous, disordered crystalline or solid states. Such phase transformation of DTX 
has been observed in other nanocarrier systems (Kulhari et al., 2014; Roy et al., 
2014). 
 
 
 
Figure 6.4: DSC spectra of docetaxel (DTX), TPSA and DTX loaded TPSA nanomicelles 
(DNM) 
Figure 6.5 displays powder XRD patterns of DTX, TPSA and DNM. Native 
DTX spectra showed sharp peaks at 2θ angles at 5, 8.7, 9.8, 10.3, 11.5, 13.9 and at 
16° showing the crystalline nature of DTX. These characteristic peaks of DTX were 
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absent in the DNM XRD pattern which instead showed peaks only at 19° and 23° 
corresponding to TPSA. Sharp and characteristic peaks of DTX were not observed in 
DNM spectra which suggest that during encapsulation DTX was transformed to the 
amorphous form. 
 
Figure 6.5: Powder XRD spectra of docetaxel (DTX), TPSA and DTX loaded TPSA 
nanomicelles 
6.3.3. In vitro drug release studies  
For the determination of the effect of pH and media on the release of DTX 
from nanomicelles, formulations were exposed to three different media—PBS pH 
7.4, SAB pH 5 and plasma. Here, PBS represents the neutral to slightly alkaline pH 
of blood while SAB represents the acidic pH of cancer cells. The release of DTX 
from PDNM was faster in SAB than plasma and PBS (Figure 6.6). In SAB, 99.48% of 
encapsulated DTX was released within 48 h.  However, about 70.53% and 76.9% of 
drug was released in PBS and plasma respectively, after 72 h. Drug release was 
faster at acidic pH (SAB pH 5). The slower drug release in plasma and faster release 
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in SAB would help to would enhance the therapeutic efficacy of the formulation. 
There was statistically no difference in the drug release rates in PBS and plasma.  
 
Figure 6.6: In-vitro drug release profiles of cRGDfK conjugated (PDNM) in plasma, 
phosphate buffer saline pH 7.4 (PBS) and sodium acetate buffer pH 4.5 (SAB) (Mean ± 
SD, n=3) 
6.3.4. In vitro cytotoxicity 
The potential for DNM and PDNM to inhibit cancer cell growth was tested in 
DU145 human prostate cancer cells and compared with that of DTX. As shown in 
Table 6.2, DNM and PDNM inhibited cell growth in a concentration and time-
dependent manner. From the half-maximal inhibitory concentration (IC50) values, it 
was found that DTX encapsulated in nanoformulations was more cytotoxic than plain 
DTX. Pure drug and nanomicelles displayed time-dependent anticancer activities 
against cancer cells and cytotoxicity was found to increase with exposure time. After 
24 h incubation, IC50 values were >500 ng/mL for DTX, 325.9 ng/mL for DNM and 
216.7 ng/mL for PDNM. The observed IC50 values of DTX, DNM and PDNM were 
481.3, 179.6 and 56.3 ng/mL, respectively after 48 h of treatment. A further increase 
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in exposure time continued to decrease the amount of the drug required for the 50% 
growth inhibition of DU145 cells. After 72 h incubation, the IC50 values were 
decreased to 378.5 ng/mL for DTX, 70.7 ng/mL for DNM and 16.4 ng/mL for PDNM. 
Phase contrast images of DU145 human prostate cancer cells after 72 h exposure to 
different DTX formulations are shown in Figure 6.7. 
Thus, at each time point (24, 48 and 72 h), nanomicelle formulations showed 
higher toxicity than pure DTX. The enhanced cytotoxicity of these formulations can 
be attributed to receptor mediated uptake of nanomicelles by the cells. In 
comparison to DNM, PDNM was 4.3 times more effective. Increased therapeutic 
efficacy of PDNM may be explained by increased intracellular delivery of DTX and 
active targeting through integrin receptors. The results were verified with 
comparative cellular uptake studies.  
Table 6.2: IC50 (half-maximal inhibitory concentration) values for DTX, DTX loaded 
TPSA nanomicelles (DNM) and cRGDfK peptide conjugated DNM (PDNM) against 
DU145 human prostate cancer cells after treatment of 24, 48 and 72 h. The data 
represent the mean ± SD values for the three experiments performed in triplicate. 
Time (h)  IC50 value (ng/ml)  
DTX DNM PDMN 
24 >500 325.9±12.5 216.7±11.8 
48 481.3±16.3 179.6±14.9 56.3±4.3 
72 378.5±12.9 70.7±2.5 16.4±1.1 
 
6.3.5. Cellular uptake studies 
Coumarin-loaded TPSA nanomicelles (FNM) and cRGDfK-conjugated FMN 
(PFNM) were separately formulated for cellular uptake studies. PFNM displayed 
higher cellular uptake than FNM and plain coumarin. Figure 6.8 shows the 
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fluorescent images of DU145 cells treated with coumarin, FNM and PFNM at 
different time intervals.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Phase contrast images of DU145 human prostate cancer cells after 72 h 
exposure of free docetaxel (DTX), docetaxel loaded nanomicelles (DNM) and cRGDfK 
conjugated DNM (PDNM) (Mean ± SD, n=3) 
Nanomicelle uptake in cells was time-dependent, with maximum uptake 
observed after 12 h. The insets in Figure 6.8 show localization of nanomicelles in 
cells. Nanoparticles bind to the cell surface are then internalized to the cytoplasm 
and finally localized near the nucleus. Difference in cellular uptake of various 
formulations can be explained by their uptake mechanisms. Cellular uptake of free 
coumarin is through passive diffusion. Cellular uptake of PFNM is via integrin 
receptor-mediated endocytosis, while FNM enters the cell via nonspecific 
endocytosis.  
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Figure 6.8: Cellular uptake of coumarin, coumarin loaded TPSA nanomicelles (FNM) 
and cRGDfK conjugated FNM (PFNM). Fluorescence microscope images of DU145 
cells incubated for different time intervals. 
6.3.6. Effect of nanomicelles on morphological changes 
Obvious morphological changes were observed, with chromatin condensation, 
fragmentation and formation of apoptotic bodies in a dose-dependent manner. 
However, control cells exhibited a normal healthy shape with intact nuclei and no 
abnormalities. The results of phase contrast microscopy (Figure 6.9) were consistent 
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with those of the fluorescence microscope images using AO/EB. AO is only taken up 
by live cells while EB enters dead cells. Cells in apoptotic phase are stained by both 
AO and EB. Therefore, the AO/EB dual staining method differentiates condensed 
chromatin of dead apoptotic cells from the intact nuclei.  Figure 9 shows the 
significant increase in apoptotic cells (orange fluorescence after treatment with 
nanomicelles. Green, intact nuclei were observed in control or untreated cells. 
 
 
 
 
 
 
 
 
 
Figure 6.9: Fluorescence microscope images of DU145 human prostate cancer cells 
after 24 h incubation with acridine orange and ethidium bromide for the assessment 
of apoptotic morphology. Orange-red colour indicates the apoptosis while green 
colour indicates lack of apoptosis. 
6.3.7. Apoptosis studies 
Docetaxel induces apoptotic programmed cell death by interfering with 
microtubule dynamics during the cell division process. It binds to microtubules, 
stabilizes them and prevents their depolymerisation (Ting et al., 2007). The apoptotic 
stage can be determined by annexin-V FITC analysis. Cells are incubated with 
annexin-V FITC and propidium iodide (PI). Living or intact cells are stained 
negatively with both annexin-V FITC and PI, early apoptotic cells are stained only 
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with annexin-V FITC, cells at late apoptotic stage are stained with both annexin-V 
FITC and PI while necrotic cells are stain only with PI.  
As shown in Figure 6.10, untreated, control DU145 cells had 87.17% of  intact 
nuclei, 1.41% of cells were in early apoptosis, 4.84% were in the late apoptotic stage 
and 6.58% were necrotic. Pure DTX treatment did not induce a significant increase 
in apoptosis. However, significant apoptosis was observed when nanomicelles were 
used. With DNM, about 72.3% of cells were viable whereas 14.2% cells were in early 
apoptosis and 9.9% of cells in late apoptotic stages. Most apoptosis was observed 
with PDNM. In PDNM treated cells, only 41.13% of cells were viable and 57.12% 
were in apoptotic stages (39.87% in early apoptosis and 17.25% in late apoptosis).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10: Quantification of docetaxel-induced apoptosis in DU145 human prostate 
cancer cells.  Cells were incubated with DTX, DNM and PDNM for 48 h. Untreated cells 
served as controls. 
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6.3.8. Anti-angiogenic activities 
Tumor growth and metastasis depend on angiogenesis thus it is an important 
factor in cancer progression (Rundhaug, 2005, Nethi et al., 2014). PDNM showed 
potential anti-angiogenic activities against HUVEC cells and in the presence of 
angiogenic factor VEGF. Endothelial cells are activated by VEGF which produces 
matrix metalloproteinases. These matrix metalloproteins aid in the development of a 
network of new blood vessels by multi-mechanism processes (Rundhaug, 2005). 
Endothelial cell proliferation assays were performed in HUVECs and results 
are presented in Figure 6.11. After 24 h, cell viability was 86.6%, 61.4%, and 52% for 
DTX, DNM and PDNM, respectively. Cells incubated with VEGF exhibited 113% 
viability indicating angiogeneic activity of VEGF. Cells treated with PDNM in the 
presence of VEGF showed 61.2% cell viability. The results suggest anti-angiogenic 
activity for PDNM. 
 
Figure 6.11. Endothelial cell proliferation assay: % cell viability of HUVECs treated 
with VEGF, DTX, DNM and PDNM after 24 h. (Mean ± SD, n=3) 
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In order to further elucidate the anti-angiogenic properties of PDNM, scratch 
wound directional migration assay was performed in HUVECs. Figure 6.12 shows 
that the untreated control HUVECs and cells treated with the positive control VEGF, 
migrate in a time dependent manner. The % of wound closure observed after 8 h 
was 25.3%, 44%, 14.8%, 4.44%, 2.3%, and 16.5% for control, VEGF, DTX, DNM, 
PDNM and VEGF with PDNM; respectively. A similar pattern was observed after 24 
h incubation where the % wound closure was 54.4%, 95.5%, 28.1%, 13.2%, 7.47%, 
and 25.2% for control, VEGF, DTX, DNM, PDNM and VEGF with PDNM; 
respectively. 
PDNM showed significant inhibition of endothelial cell proliferation in a dose 
dependent manner compared to untreated control HUVECs and cells treated with 
DTX or DNM (Figure 6.11). The results suggest anti-angiogenic properties for 
PDNM. It has been found that the potent angiogenic growth factor VEGF induces 
endothelial cell proliferation compared to untreated control cells (Barui et al., 2012). 
Interestingly, PDNM also significantly inhibits VEGF induced endothelial cell 
proliferation, supporting the anti-angiogenic potential of this drug delivery system.  
Endothelial cell migration is also a key step of angiogenesis process (Nethi et 
al., 2014). In wound healing assays, cells incubated with VEGF showed rapid cell 
migration, with the wound area completely filled after 24 h (Figure 12a). However, 
cells treated with DTX, DNM or PDNM, did not migrate similarly. The wound area 
remained almost unaltered, especially for PDNM. Additionally, PDNM inhibits VEGF 
induced endothelial cell migration.  
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a) 
 
b) 
Figure 6.12 (a-b): Scratch wound directional migration assay in HUVECs. (a) Untreated 
cells and cells treated with VEGF (100 ng/mL) migrated towards the wound area while 
cells treated with DTX, DNM and PDNM did not. PDNM also inhibited VEGF induced 
endothelial cell migration suggesting anti-angiogenic activity. (b) Quantification of 
wound healing activity using Image J Analysis software. 
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6.3.9. Stability Studies  
PDNM showed high physical and chemical stabilities. After 2 months, 
nanomicelle size was 31.7 ± 0.59 nm, zeta potential -13. 2 ± 1.16 mV and DTX 
content was 93.52 ± 2.08%.  
6.4. Conclusion 
In summary, the present study reveals the enhanced cytotoxic potential of 
DTX against DU145 human prostate cancer cells when it is formulated in cRGDfK 
peptide conjugated succinoyl TPGS nanomicelles. The increased cytotoxicity of the 
nanomicelle system was further analysed by cellular uptake and apoptosis studies. 
Peptide-conjugated nanomicelles displayed controlled release of drug and good 
physicochemical stability in the colloidal state. Moreover, PDNM was able to inhibit 
endothelial cell proliferation and migration induced by angiogenic factors. Hence, the 
targeted nanomicelle system could be developed as a drug carrier for the site-
specific delivery of DTX and other anticancer drugs to integrin receptor over-
expressing angiogenic tumour vasculature. 
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7.1. Introduction 
Design and development of new drug delivery systems to achieve controllable 
targeted delivery of clinically approved anticancer drugs is an area of active 
investigation (Brannon-Peppas and Blanchette, 2012; Kanapathipillai et al;., 2014). It 
is well recognised that most of the clinically approved anticancer drugs face a major 
issue around the lack of biological target specificity (Kwon et al., 2012; Cheng et al., 
2012). This leads to uncontrolled bio-distribution of anticancer drugs to non-specific 
tissues, resulting in severe unwanted side effects. To ensure safety and efficacy, 
these anticancer drugs are needed to be delivered to their target site selectively and 
at an optimal rate. In contrast to conventional drug delivery systems, a carefully 
designed targeted drug delivery system has the potential to deliver a therapeutic 
agent to the tissue of interest at higher dosages, while reducing the relative drug 
concentration in non-target tissues. Such delivery systems not only overcome the 
problems of non-specificity of anticancer drugs but also improve their therapeutic 
indices (Cunliffe et al., 2005; Cho et al., 2008; Zhang et al., 2008; Akhtar et al., 
2014). 
An example of such US-FDA approved chemotherapy is gemcitabine (GEM), 
which is used for the treatment of various cancers including breast, non-small cell 
lung, pancreatic and platinum-resistant ovarian cancer (Duenas-Gonzalez et al., 
2011; Martín-Banderas et al., 2013). Being a pseudo-nucleotide, the efficacy of GEM 
relies on its incorporation into cellular DNA. This blocks DNA chain elongation, 
leading to cell arrest in the G1 phase and cytostatic effects (Huang and Plunkett, 
1995; Lorusso et al., 2006). Although GEM offers an efficient chemotherapy option, 
its short plasma half-life (<20 min), enzymatic degradation in body fluids and non-
specificity are major limitations in current clinical settings (Hodge et al., 2011; Tao et 
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al., 2012). The rapid clearance of GEM requires it to be administered at high doses, 
which leads to severe haematological and gastrointestinal side effects (Chu and 
Devita, 2007; Paolinoet al., 2010; Derakhshandeh and Fathi, 2012). Nano-
engineered systems have shown considerable advances for a range of biomedical 
applications including imaging, diagnosis and delivery of therapeutic agents 
(Torchilin, 2012). As a drug carrier system, nanoparticles can deliver drugs at 
predetermined rates, thereby controlling clearance and maintaining drug 
concentration within the therapeutic index. In addition, nanoparticle surfaces can be 
modified with a ligand for specific targeting. Among various nanoparticle systems, 
polymeric nanoparticles exhibit some of the best characteristics for the delivery of 
hydrophilic drugs. For instance, they allow high payload, controllability over drug 
release, good physicochemical stability, biodegradability and opportunity for facile 
surface modification (Jia et al., 2013). Considering the importance of biocompatible 
polymers in drug delivery, it is not surprising that different types of nano-particulate 
polymers are regularly investigated as drug delivery platforms (Dend et al., 2012; Ye 
et al., 2014). These investigations are motivated by the rationale that the design 
principles of these nano-based drug delivery systems influence the biological fate of 
these materials, which remains predominantly unique for different drug candidates. 
In the current study, a new targeted drug delivery platform was investigated 
for ovarian cancer by developing GEM-loaded poly(D,L-lactic-co-glycolic) acid [GEM-
PLGA] nanoparticles, and functionalising them with cyclic RGDfK (cRGDfK), a five 
amino acid peptide [GEM-PLGA@cRGDfK], to achieve targetability. cRGDfK was 
chosen as a targeting ligand due to known high stability of cyclic peptides as well as 
high specificity of cRGDfK to the αvβ3 integrin receptors (Danhier et al., 2012). These 
integrin receptors are over-expressed in malignant ovarian cells and their levels are 
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strongly associated with tumour progression (Landen et al., 2008; Lossner et al., 
2008). The reduced haemolytic toxicity accompanied with enhanced uptake and 
cytotoxicity of the proposed drug delivery system towards integrin-overexpressing 
SKOV-3 human ovarian cells suggests that up-regulation of integrin receptors may 
provide a unique opportunity to deliver anticancer drugs selectively to ovarian 
tumours.  
7.2. Experimentation 
7.2.1. Materials  
Gemcitabine (GEM) was obtained as a gift from TherDose Pharma Pvt Ltd 
(Hyderabad, India). cRGDfK peptide was purchased from Peptide International 
(Kentucky, USA). Poly(D,L-lactic-co-glycolic) acid [PLGA, 30-60 kDa, 
lactide:glycolide - 50:50], polyvinyl alcohol [PVA, 89-98 kDA], sodium cholate, 
Pluronic F68 [8.5 kDa], RPMI-1640, trypsin–EDTA, antibiotic-antimycotic solution, 3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide 
(DMSO), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) were purchased from Sigma Aldrich (St. Louis, MO, 
USA). Tween® 80 was purchased from sd Fine Chemicals (Mumbai, India). Foetal 
bovine serum (FBS) was purchased from Gibco, USA. Mycoplasma-free SKOV-3 
human ovarian cancer cells were kindly gifted by Prof. Rodney Hicks and Dr. 
Carleen Cullinane at Peter MacCallum Cancer Centre, Australia.  
7.2.2. Synthesis of drug-loaded nanoparticles (GEM-PLGA) 
GEM-loaded PLGA nanoparticles (GEM-PLGA) were synthesised by using a 
double emulsion solvent evaporation method. GEM (1 mg) was dissolved in 0.5 mL 
aqueous Pluronic F68 surfactant solution (1% w/v) and added to 2 mL of PLGA 
solution (5 mg/mL in ethyl acetate), followed by sonication for 1 min using a probe 
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sonicator. The resulting primary w/o emulsion was redispersed in 10 mL of Pluronic 
F68 surfactant solution (0.25% w/v), sonicated for 2 min and stirred for 3 h on a 
magnetic stirrer. This resulted in a w/o/w double emulsion that was centrifuged at 
15,000 rpm for 30 min. The supernatant was collected and analysed for the 
quantification of free drug, whereas the pellet containing GEM-PLGA nanoparticles 
was washed three times with deionised MilliQ water and lyophilised. Preparation of 
drug-free PLGA nanoparticles was optimised to study the effects of organic solvent 
(dichloromethane, ethyl acetate, choloroform and mixture of solvents) and surfactant 
type (PVA, Tween® 80, pluronic F68, sodium cholate) on particle size and surface 
charge. GEM-PLGA formulations were also optimised for drug encapsulation 
efficiency and drug loading.  
7.2.3. Estimation of entrapment efficiency and drug loading 
GEM content in different samples was determined using a HPLC system 
(Agilent), wherein the analyses were carried out on a Chromolith Performance RP-
18e column (100 mm × 4.6 mm, Merck). In HPLC, The optimal mobile phase was 
found to a mixture of acetonitrile and water (30:70, v/v), which was delivered at a 
flow rate of 1 mL per min. Sample injection volume was 20 μL and HPLC peaks were 
monitored at 269 nm using an UV detector. Linear calibration curves were obtained 
over 0.1–10 μg per mL concentration range (correlation coefficient, R2 = 0.998). 
Entrapment efficiency (EE) and drug loading (DL) were calculated as follows:  
EE (%) = WI −WF
WI
×100  …….. (1) 
DL (%) = WE 
WN
×100   …….. (2) 
wherein, WI, WF, WE, and WN correspond to the weights of initial amount of drug 
employed for nanoparticle synthesis, free drug in supernatant, drug encapsulated in 
nanoparticles, and drug-loaded nanoparticles, respectively.  
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For estimation of GEM drug content in lyophilised nanoparticles, 5 mg of 
nanoparticles were dissolved in 5 mL of acetone, followed by addition of 10 mL of 
water, subsequent evaporation of acetone to precipitate polymer, filtration of polymer 
through a 0.22 µm filter to obtain drug in the aqueous solution, and GEM estimation 
by HPLC.  
7.2.4. Conjugation of cRGDfK peptide to drug-loaded nanoparticles 
cRGDfK peptide-conjugated nanoparticles (GEM-PLGA@cRGDfK) were 
prepared by a carbodiimide reaction, in which GEM-PLGA nanoparticles (25 mg) 
were dispersed in phosphate buffer saline (PBS, pH 7.4, 5 mL) and incubated with 
EDC (20 mg) and N-hydroxysuccinimide (NHS, 12 mg) for 45 min at room 
temperature. To this solution, cRGDfK peptide (0.5 mg, 1 mL) was added and stirred 
for 6 h at room temperature. GEM-PLGA@cRGDfK nanoconjugates were obtained 
by centrifugation at 12,000 rpm for 30 min. The supernatant was collected to 
determine the amount of unconjugated peptide by measuring the arginine content, 
as per the previously reported protocol (Annett Schmitt et al., 2005). 
7.2.5. Physico-chemical characterisation of nanoconjugates 
Particle size distribution and surface charge of nanoparticles were analysed 
by Malvern Zetasizer Nano-ZS by appropriately diluting the samples with deionised 
water. The nanoparticle morphology was examined by TEM using a JEOL 1010 
instrument operated at an accelerating voltage of 100 kV. For TEM, samples were 
prepared by drop casting the sample on a carbon-coated copper TEM grid, followed 
by air drying. FTIR spectra were obtained on a Perkin Elmer 1000 FTIR 
spectrometer at a resolution of 4 cm−1 by acquiring 8 scans and averaging them. 
DSC measurements of nanoparticles were carried out on DSC-Q100 (TA 
Instruments, USA) between 225-325 °C at a scan speed of 10 °C per min, under 
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nitrogen environment. XRD analysis of powder samples was performed using an X-
ray diffractometer (D8 Advance, Bruker, Germany) using CuKα irradiation at 40 KV 
and 20 mA.  
AFM measurements on nanoconjugates were obtained using a JPK 
Nanowizard 3 AFM, mounted on an inverted epifluorescence microscopy (Nikon 
TE2000). AFM images were made in AC (intermittent contact) mode using Bruker 
NCHV cantilevers that have a nominal resonant frequency and spring constant of 
340 kHz and 40 N/m respectively. AFM images were acquired with a force set point 
of <1 nN and the same area were imaged repeatedly to ensure that no sample 
damage had occurred. 
Small-angle neutron scattering (SANS) measurements were made on the 
Quokka instrument at the Bragg Institute, ANSTO, Lucas Heights, Australia. 
Samples were prepared in 2 mm thick quartz cells using D2O as solvent, and 
scattering spectra were obtained at 25 °C. An incident neutron wavelength of 5 Å 
(with a typical Gaussian spread of 10%) was used, and scattering was measured at 
a two-dimensional array detector at three sample-to-detector distances: 2 m, 14 m 
and 20 m (in the latter of which a neutron optics system was used to detect 
scattering at lower q), giving an effective q range of 0.001–0.4 Å–1.  Data were 
modelled using a standard form factor for homogeneous ellipsoidal particles (Freigin 
and Svergu, 1987; Guinier and Fournet, 1995), assuming a simple hard-sphere 
structure factor. 
7.2.6. In vitro drug release 
In vitro drug release from drug-loaded nanoconjugates was studied by dialysis 
method at 37±0.5 ºC, in which an aqueous solution (2 mL) containing GEM-PLGA 
nanoparticles (equivalent to 2 mg of GEM) was placed in a 12 kDa dialysis bag. The 
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dialysis bag was suspended in 100 mL of PBS and the buffer was stirred at 100 rpm 
using a magnetic stirrer. Aliquots of 3 mL PBS were withdrawn at various time 
intervals over 72 h, which was replenished with equivalent volumes of fresh PBS 
buffer to maintain the volume and sink conditions. The obtained aliquots were filtered 
through a 0.22 µm filter, diluted appropriately and analysed by HPLC for released 
drug content. The experiments were repeated three times and average values 
calculated.  
7.2.7. Hemolytic toxicity studies 
Haemolytic toxicity studies on nanoparticles were performed as per our 
previously reported protocol (Pooja et at., 2014). Briefly, 5 mL of red blood cell 
(RBCs) suspension (2% v/v) in normal saline was incubated with 50-1000 µg/mL 
equivalent of drug in the form of either pristine GEM or GEM-PLGA@cRGDfK 
conjugate at 37 ºC for 1 h. Cells were centrifuged at 1000 rpm for 5 min and 
absorbance of supernatant was measured at 540 nm using a UV/VIS 
spectrophotometer. Cells incubated with distilled water and normal saline were 
considered to show 100% (standard) and 0% (control) hemolysis, respectively. 
% Hemolysis was determined as follows:  
% Hemolysis = {(AT – AC) / (AS– AC)} × 100 
Whereas; AT is absorbance of test sample, AS: absorbance of standard; and 
AC: absorbance of control 
7.2.8. Cell culture 
Mycoplasma-free SKOV-3 human ovarian cancer cells were grown in RPMI-
1640 medium supplemented with FBS (10%), glutamine (2 mM), penicillin (100 U per 
mL) and streptomycin (0.1 mg/mL). Cells were cultured under standard conditions at 
37 °C in a humidified atmosphere (85% relative humidity) containing 5% CO2. 
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7.2.9. Anti-proliferation assay 
Cytotoxicity of free GEM as well as nanoconjugates was determined by MTT 
assay as described previously (Kulhari et al., 2014) Briefly, SKOV-3 cells (5 × 103) 
were seeded in 96-well culture plates and allowed to adhere for 24 h. The cells were 
then exposed to various concentrations (0.01-10 μg/mL) of free drug or 
nanoconjugates containing equivalent amounts of drug for 48 h in triplicates. 
Following treatment, culture media was replaced with serum-free media containing 
0.5 mg/mL MTT and allowed to incubate for 4 h. This was followed by removal of 
MTT agent, addition of 200 μL of DMSO to each well and shaking the plates on a 
rocking shaker for 10 min at room temperature. The absorbance from the plates was 
then measured at 570 nm using a micro-plate reader (Perkin Elmer, USA). Untreated 
cells were also incubated under identical conditions and served as the controls. IC50 
values were determined by probit analysis software package of MS-excel. 
7.2.10. Cellular uptake studies 
To study cellular uptake of nanoconjugates, fluorescent Rhodamine-B (RhB)-
encapsulated polymeric nanoconjugates without any targeting ligand (RhB-PLGA) 
and with cRGDfK peptide as a targeting ligand (RhB-PLGA-cRGDfK) were prepared 
in a manner similar to that of GEM-PLGA and GEM-PLGA-cRGDfK, respectively. For 
uptake studies, SKOV-3 cells were seeded into 12-well plates up to 80% confluency, 
followed by incubation with 100 µL of these particles (20 µg/mL of RhB) for 2 h.  
Cells were then washed three times with chilled PBS and cellular uptake was 
assessed using fluorescent microscopy (Nikon, Inc. Japan). 
7.2.11. Measurement of mitochondrial membrane potential (MMP) 
SKOV-3 cells (2 × 105) were seeded in 24-well plates for 24 h, followed by 
treatment with GEM, GEM-PLGA and GEM-PLGA@cRGDfK at concentrations 
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equivalent to the IC50 value of GEM-PLGA@cRGDfK (0.1 μg/mL) for 24 h in 0.4 mL 
of RPMI-1640 medium. Cells were then washed twice with PBS and incubated with 
0.4 mL of Rhodamine-123 (2 µg/mL) for 30 min in the dark under ambient conditions, 
followed by washing with PBS. Cells were observed using a Nikon fluorescence 
microscope. The changes in the MMP (Δψ) in response to different nanoconjugates 
were quantitatively estimated after adjusting cell counts for equal numbers and 
measuring Rhodamine-123 fluorescence at the excitation and emission wavelengths 
of 480 and 530 nm, respectively, using a Hitachi F-3010 spectrofluorometer. 
7.2.12. Measurement of reactive oxygen species (ROS) 
This was achieved using a protocol similar to that detailed above for the 
measurement of MMP. However, in this case, the Rhodamine-123 treatment step 
was replaced with an ROS-active reagent 2,7-dichlorofluorescin diacetate (DCFDA - 
10 µg/mL). Cells were observed using a fluorescence microscope. For quantitative 
estimation, cell counts were adjusted for all formulations and fluorescence intensity 
of 2,7-dichlorofluorescin (DCF), an oxidised fluorescent product, was measured at 
excitation and emission wavelengths of 495 and 520 nm, respectively, using a 
Hitachi F-3010 spectrofluorometer. 
7.2.13. Measurement of nuclear fragmentation by Hoechst 33242 staining 
To assess the apoptotic nuclear morphology, SKOV-3 cells were grown and 
treated with various formulations, as elaborated above for the measurement of MMP 
and ROS. This was followed by fixing the cells using 4% paraformaldehyde in PBS 
for 15 min, washing with PBS, staining with Hoechst 33342 (5 μg/mL) in 0.4 mL PBS 
for 30 min, and washing the stained cells twice with PBS. Nuclear condensation was 
monitored using a fluorescent microscope through a UV excitation filter. 
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7.3. Results and Discussion 
7.3.1. Synthesis and characterisation of drug-loaded nanoparticles 
Gemcitabine (GEM), being a hydrophilic anticancer drug with serious side 
effects, it is not ideal for intravenous injection directly in the aqueous blood stream. 
Scheme 7.1 illustrates the double emulsification strategy for the encapsulation and 
targeting of GEM to the αvβ3 integrin receptors overexpressing SKOV-3 human 
ovarian cells. Initially, GEM is dissolved in aqueous Pluronic F68, an amphiphilic 
copolymer, followed by exposure to PLGA, a hydrophobic copolymer dissolved in 
ethyl acetate. In Pluronic F68, the alternating blocks of hydrophilic polyethylene 
oxide (PEO) and hydrophobic polypropylene oxide (PPO), arranged in the A-B-A tri-
block structure, provides this copolymer with amphiphilic characteristics that allow 
Pluronic F68 to behave as a surfactant above its critical micellar concentration (CMC 
– 0.04 mM at 20-25 °C). Step 1, in the scheme, shows the spontaneous self-
assembly of hydrophilic GEM drug molecules, amphiphilic Pluoronic F68 chains, and 
hydrophobic PLGA chains to form water-in-oil (w/o) micellar structures in ethyl 
acetate. Step 2 shows that when this primary w/o emulsion is re-exposed to 
amphiphilic Pluronic F68 chains in water, secondary micellar structures comprised of 
w/o/w double emulsions are formed. Further, Steps 3 and 4 show the 
functionalisation of cRGDfK (Arginine-Glycine-Aspartate-Phenylalanine-Lysine), an 
integrin-targeting cationic cyclic peptide to the GEM-loaded secondary micelles. In 
Step 3, when carboxylic groups of PLGA are activated using carbodiimide chemistry, 
this allows the primary amine of lysine residue in the cRGDfK peptide to act as a 
preferred conjugation site with PLGA, while the adjacent phenylalanine residue 
facilitates this conjugation through hydrophobic interactions with the Pluronic F68 
chains.  
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Scheme 7.1: Schematic diagram showing the preparation of cRGDfK conjugated and 
gemcitabine loaded PLGA nanoparticles by double emulsification method 
 
The successful synthesis of integrin receptor targetable GEM-loaded 
nanoconjugates is evident from their physicochemical characteristics presented in 
Figure 1. DLS revealed that the hydrodynamic diameter of nanoconjugates prepared 
with or without GEM encapsulated in their cavity were 82.8 ± 3.1 nm and 89.7 ± 2.9 
nm, respectively, with a PDI less than 0.2, indicating a narrow size distribution of 
these particles (Figure 1a). SANS measurements indicated that the particles were 
non-spherical in shape when dispersed in solvent, with the best fit being achieved 
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using an oblate spheroidal (ellipsoidal) model (Figure 1b). The PLGA particles 
(without GEM) indicated a semi-major radius of 23 nm and a semi-minor radius of 52 
nm, suggesting a squat spheroid of aspect ratio approximately 2:1. Similar to the 
DLS measurements, a modest particle size increase when going from the drug-free 
PLGA to the drug-loaded GEM-PLGA particles was observed, where the semi-major 
and semi-minor axes increased to 24 nm and 58 nm respectively. Clearly the SANS 
data correlate well with the DLS measurements of particles when in dispersion, and 
corroborate their highly hydrated nature. TEM and AFM images of GEM-PLGA 
particles in Figures 1c and d, respectively, indicate that the particles shrink 
considerably when dried onto a surface, suggesting a high level of hydration when in 
solvated form. However, their collapsed size (50-75 nm in lateral dimension and ~4 
nm in height), particularly the height may be an underestimate, as the particles are 
very soft and could be easily deformed by the AFM cantilever. The GEM-PLGA 
particles showed an impressive encapsulation efficiency of 93.16 ± 0.8%, while the 
drug loading was calculated to be 7.92 ± 0.17% of the total weight of these 
nanocarriers.  
Zeta potential measurements revealed that drug-loading had insignificant 
effect on their highly negatively charged surface, with ζ-values corresponding to -
25.9 ± 1.7 mV and -23.56 ± 1.93 mV for PLGA and GEM-PLGA particles, 
respectively. After conjugation of cRGDfK peptide, GEM-PLGA@cRGDfK 
nanoconjugates exhibited a slight increase in average DLS hydrodynamic diameter 
to 94.02 ± 2.3 nm along with concomitant decrease in the zeta potential value -13.7 
± 0.76 mV. This decrease in the negative zeta potential value results from the 
passivation of the negatively charged –COO- groups of PLGA after covalent 
conjugation with cationic cRGDfK peptide (Scheme 1), and therefore supports the 
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successful functionalization of GEM-PLGA nanoparticles with the integrin receptor 
targetable cationic peptide.  
FTIR spectroscopy was employed to validate the successful drug loading and 
conjugation of targeting peptide on the nanoparticle surface (Figure 1e). FTIR 
spectrum of PLGA showed the characteristic carboxylic group (C=O stretching) 
vibration at 1751 cm-1, whereas in the FTIR spectra of pristine GEM, signature bands 
appeared at 1676 cm-1 and 1061 cm-1, corresponding to ureido and hydroxyl groups, 
respectively. FTIR spectrum of GEM-PLGA particles revealed characteristic peaks of 
PLGA alongside GEM, suggesting successful drug encapsulation. Further, the 
appearance of slightly shifted amide signatures (1646 and 1542 cm-1) in GEM-
PLGA@cRGDfK supports successful covalent conjugation of cRGDfK peptide on the 
nanoparticle surface, which otherwise appeared at 1641 and 1530 cm-1 in the 
pristine cRGDfK peptide.  
DSC studies revealed that the physical state of GEM changes from crystalline 
to amorphous or a solid solution phase during drug loading (Figure 1f). While the 
DSC thermogram of pristine GEM shows an endothermic peak corresponding to its 
melting temperature at 291 °C, this peak is found absent in the thermogram for 
GEM-PLGA nanoparticles.  
XRD analysis also confirmed this change in the physical state of the drug 
within nanoparticles (Figure 1g). Highly crystalline nature of pristine GEM is evident 
from sharp peaks in its XRD pattern, whereas the non-crystalline amorphous nature 
of GEM in GEM-PLGA nanoparticles leads to loss of these features. 
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Figure 7.1: Characterization of nanoparticles by a) DLS b) TEM c) SANS d) AFM) e) 
FTIR f) DSC and g) XRD analysis 
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7.3.2. In vitro drug release 
The cumulative release profile of GEM from pristine aqueous drug solution 
and from nanoparticles was evaluated in vitro (Figure 7.2). More than 90% of GEM 
was released from the pristine drug solution within 8 h. In contrast, drug release from 
GEM-PLGA and GEM-PLGA@cRGDfK particles showed a biphasic profile 
characterised by initial fast release, followed by a slower release phase. 
Approximately 40% of encapsulated drug was released in the first 8 h, with 
remaining drug released up to 96 h. The initial burst release may be attributed to the 
release of drug adsorbed on the surface of nanoparticles or present in the periphery 
of the polymeric matrix. The second phase could be due to drug diffusion through the 
matrix, or due to polymer degradation, or a combination both. Insignificant difference 
in the drug release profiles of GEM-PLGA and GEM-PLGA@cRGDfK particles 
indicate that the targeting peptide does not affect the release profiles of these drug-
delivery carriers.  
 
Figure 7.2: In vitro drug release profile of Gemcitabine (GEM), GEM loaded PLGA 
nanoparticles (GEM-PLGA) and cRGDfK conjugated GPN (GEM-PLGA@cRGDfK) in 
phosphate buffer saline pH 7.4 (PBS) 
0 12 24 36 48 60 72 84 96
0
20
40
60
80
100
Cu
m
ul
at
iv
e 
GE
M
 re
le
as
e 
(%
)
Time (h)
 GEM
 GEM-PLGA
 GEM-PLGA@cRGDfK
 
 
Chapter 7                                                                 Integrin-targeted cRGDfK-PGA-GEM for ovarian cancer 
 Peptide and monoclonal antibody mediated targeting of anticancer drugs  187 
 
7.3.3. In vitro blood compatibility and tumour cytotoxicity 
The in vivo efficacy of drug delivery systems relies on improved blood 
compatibility and higher specific toxicity against tumour cells. To assess these 
parameters, in vitro hemolytic toxicity assays were performed on RBCs and anti-
proliferation assays were performed against SKOV-3 human ovarian cancer cells 
(Figure 7.3). Blood compatibility studies showed that while pristine GEM as well as 
peptide-grafted GEM-PLGA@cRGDfK nanoparticles caused concentration-
dependent hemolysis, the amount of haemoglobin released from the rupture of 
RBCs was significantly less (p<0.005) in case of GEM-loaded nanoparticles in 
comparison to the pristine drug (Figure 7.3). For instance, at the highest 
concentration tested (1 mg/ml), pristine drug caused 5.2% hemolysis compared to 
1.7% by GEM-PLGA@cRGDfK nanoparticles. This significant increase in blood 
compatibility may be attributed to efficient drug encapsulation within a nanoparticle 
that reduces direct contact of GEM with RBCs. 
 
Figure 7.3: Hemolytic toxicity assay of gemcitabine (GEM), GEM loaded PLGA 
nanoparticles (GEM-PLGA) and cRGDfK conjugated GPN (GEM-PLGA@cRGDfK) 
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Figure 7.4: % Cell viability of SKOV-3 human ovarian cancer cells incubated with 
Gemcitabine (GEM), GEM loaded PLGA nanoparticles (GEM-PLGA) and cRGDfK 
conjugated GPN (GEM-PLGA@cRGDfK) 
 
The relative anti-cancer efficacy of pristine GEM, GEM-PLGA and GEM-
PLGA@cRGDfK is evident from Figure 7.4, which shows that all these formulations 
inhibited cell proliferation in a dose-dependent manner. At the lowest tested 
concentration (0.01 µg/mL), cell viability was 92.1%, 70.8% and 56.9% for GEM, 
GEM-PLGA and GEM-PLGA@cRGDfK, respectively. After 48 h incubation, the IC50 
of GEM-PLGA@cRGDfK (0.034 ± 0.004 µg/mL) was 16.4 fold and 3.8 fold lesser 
than pristine GEM (0.572 ± 0.013 µg/mL; p < 0.001) and GEM-PLGA (0.148 ± 
0.01 µg/mL; p < 0.05), respectively. These results clearly indicate that cRGDfK-
conjugated nanoparticles exhibit significantly higher cytotoxicity than free drug or 
targeting peptide-free nanoparticles against SKOV-3 human ovarian cancer cells. 
This improved anticancer efficacy of GEM-PLGA@cRGDfK particles is due to the 
ability of cRGDfK peptide to bind to αvβ3 integrin receptors. This allows enhanced 
uptake of drug-loaded particles through integrin receptor-mediated endocytosis while 
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avoiding drug efflux pumps, leading to sustained intracellular drug concentration 
resulting in greater cytotoxic effects (Liu et al., 2008; Danhier et al., 2012). In 
contrast, regular efflux of free drug from the cytoplasm via P-glycoprotein pumps 
leads to the lower cytotoxicity of pristine GEM (Alexander et al., 2005). This is 
supported by the observation that as the drug concentration is increased, the three 
formulations start showing similar cytotoxicity effects due to a sustained intracellular 
drug concentration. For instance, at the highest tested drug concentration (10 
µg/mL), cell viability was 32.5%, 28% and 26.9% for GEM, GEM-PLGA and GEM-
PLGA@cRGDfK, respectively. Therefore, our findings suggest that while GEM-
based chemotherapy offers high potential against SKOV cancer cells, conventional 
GEM formulation (pristine drug solution) is not effective as it requires high dosage 
treatment that leads to systematic toxicity, as evident from the blood compatibility 
studies. Conversely, the ability of targeted nanoparticles to allow high intracellular 
drug concentrations even following a low dosage administration offers an efficient 
drug delivery platform for gemcitabine. 
7.3.4. Influence of intracellular drug uptake on mitochondrial membrane 
potential (MMP), reactive oxygen species (ROS), and apoptosis 
Cellular uptake studies were performed to validate whether integrin receptor 
targeting ability of cRGDfK peptide is indeed responsible for higher intracellular drug 
concentrations achieved by cRGDfK-conjugated particles over that of unconjugated 
PLGA particles. Since gemcitabine does not have fluorescence properties, a set of 
two new fluorescent particles, viz. RhB loaded PLGA (RPN) and cRGDfK conjugated 
RPN (RRPN) were prepared in a manner similar to that of drug-loaded particles; 
however in this case GEM was replaced with RhB, a red fluorescent dye. On 
exposure of these particles to SKOV-3 cells for 2 h, it becomes clear that conjugation 
of cRGDfK peptide on the particle surface significantly improves their intracellular 
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uptake, most likely due to the overexpression of αvβ3 receptors in these ovarian 
cancer cells (Figure 7.5). These results also validate the effectiveness of our 
cRGDfK peptide grafting strategy onto the nanoparticle surface, as the ability of αvβ3 
integrin receptors to specifically recognize cRGDfK peptide and promote its 
internalisation is well-established (Danhier et al., 2012). Further, the Hoechst nuclear 
staining of particle-treated cells suggests that particles remain in the cytoplasm post-
internalisation. Control experiments revealed that SKOV-3 cells treated with these 
drug-free particles retained more than 95% cell viability, indicating high 
biocompatibility of polymers and surfactants employed to prepare the proposed 
nanocarrier system. 
 
Figure 7.5: Comparative cellular uptake of Rhodamine-b loaded PLGA nanoparticles 
(RPN) and cRGDfK conjugated RPN (RRPN) after 2 h of incubation 
 
The higher effective intracellular drug concentration achieved by cRGDfK 
peptide functionalised nanocarriers may influence important intracellular processes 
such as MMP and ROS generation, both of which jointly participate in promoting 
cancer cell death via apoptosis (Pelicano et al., 2004; Kuznetsov et al., 2011). 
Mitochondria are the major cellular organelles that involved in regulation of cell death 
and a decrease in MMP provides an early indication of the initiation of cellular 
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apoptosis (Baracca et al., 2003). Figure 7.6 shows the effect of various formulations 
of gemcitabine on MMP of SKOV-3 cells, as evaluated using Rh-123, a 
mitochondria-specific fluorescent dye. When SKOV-3 cells are exposed to 0.1 µg/mL 
equivalent of gemcitabine in the form of pristine GEM, GEM-PLGA and GEM-
PLGA@cRGDfK nanoparticles, respectively, a sequential decrease in the cellular 
uptake of Rh-123 dye is observed (Figure 7.6). This reduction in dye uptake 
corresponds to 71.49%, 68.35% and 53.65% fluorescence intensity, respectively, for 
these three formulations with respect to 100% fluorescence in untreated cells. This 
shows that among different formulations, peptide-conjugated particles cause the 
highest reduction in the MMP of SKOV-3 cells, most likely due to the highest 
effective drug concentration per cell achieved by high cellular uptake. 
 
 
 
 
 
 
 
 
      a)         b) 
Figure 7.6 a-b: Change in mitochondrial membrane potential (MMP) determined 
qualitatively a) and quantitatively b) using rhodamine-123 
 
Induction of ROS is another mechanism by which it elicits antitumor activity 
(Donadelli et al., 2007). ROS activity in cells can be monitored by DCFDA, which is a 
cell-permeable, fluorogenic dye that gets deacetylated by cellular esterases to a non-
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fluorescent compound in healthy cells. However, ROS produced in the stressed cell 
environment can oxidise, this non-fluorescent compound into fluorescent 2’,7’-
dichlorofluorescein (DCF) (Eruslanov and Kusmartsev, 2010). Therefore, an 
increase in DCF fluorescence indicates increased levels of intracellular ROS. While 
untreated cells showed minimal ROS generation; among three formulations, GEM-
PLGA@cRGDfK particles generated the highest levels of ROS, followed by GEM-
PLGA particles and pristine GEM drug, as evident from the levels of fluorescence in 
the respective image (Figure 7.7a). Quantitative assay shows that in comparison to 
control cells, the DCF fluorescence intensity was enhanced by 3.31, 2.54 and 1.91 
times, in cells treated with GEM-PLGA@cRGDfK, GEM-PLGA and free GEM, 
respectively (Figure 7.7b). The highest level of ROS generation in those ovarian 
cancer cells that were treated with targeting peptide-conjugated nanoparticles further 
supports the importance of high intracellular uptake of drug in improving its 
chemotherapeutic potential. 
 
      a)             b) 
Figure 7.7a-b: a) Qualitative and b) quantitative estimation of reactive oxygen species 
(ROS) generation by various gemcitabine formulations 
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After treatment with an anticancer drug, apoptosis is the most common mode 
of cell death (Doonan et al., 2008). Apoptosis can be assessed by changes in 
biochemical and morphological features such as cell shrinkage, chromatin 
condensation, DNA fragmentation, and breakdown of the cell into apoptotic bodies 
(Doonan et al., 2008). Nuclear or DNA fragmentation, a late event in apoptosis, was 
assessed in SKOV-3 cells with a nucleus-specific Hoechst 33342 dye (Figure 7.8). 
The nuclei of untreated SKOV-3 cells were spherical and integral with homogenous 
fluorescence, whereas the nuclei of cells treated with different GEM formulations 
became increasing condensed and severely fragmented on exposure to pristine 
GEM (9.8%), GEM-PLGA nanoparticles (23.7%) and GEM-PLGA@cRGDfK 
nanoparticles (42.3%). Apoptosis studies therefore further validate the importance of 
cRGDfK peptide in achieving high anticancer activity of gemcitabine formulations 
against integrin-overexpressing ovarian cancer cells. 
 
a)       b) 
Figure 7.8a-b: a) Qualitative and b) quantitative determination of apoptosis using 
Hoechst 33342 staining 
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7.4. Conclusion 
To summarise, new targetable drug delivery system was developed to 
enhance the efficacy of an FDA-approved water-soluble chemotherapeutic drug 
(Gemcitabine hydrochloride) against ovarian cancers. The proposed nanoparticle 
formulations demonstrate narrow size distribution, high encapsulation efficiency, 
sustained release of drug and high biocompatibility. Our nanocarrier utilises the 
outstanding ability of a cationic cyclic pentapeptide (cRGDfK) to specifically target 
the αvβ3 integrin receptors overexpressed in ovarian cancer cells (SKOV-3). This 
targeting ability promotes the receptor-mediated internalisation of nanocarriers in 
SKOV-3 cells while remaining relatively safer towards non-target cells, such as that 
observed via low hemolytic toxicity against RBCs. The efficient uptake of 
nanocarriers by SKOV-3 cells leads to a high effective intracellular concentration of 
drug, even at low dosages treatments. This efficient drug uptake, in turn enhances 
the antiproliferative activity of gemcitabine hydrochloride by influencing important 
intracellular processes such as reduction in MMP, increase in intracellular ROS and 
cellular apoptosis. Considering the increasingly recognised association of integrin 
receptors with ovarian tumour progression, our findings provide a good basis for 
future preclinical and clinical studies, along with future development of smart 
targeted drug delivery systems for newly approved hydrophilic anticancer drugs-
based chemotherapeutics. 
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8.1. Background 
Glioblastoma (GBM) is the most common type of brain tumor, accounting for 
29% of primary brain cancers (Tirapelli et al., 2010). Among all types of cancer, GBM 
is the most difficult to treat as it localizes in brain that has limited capacity to repair 
itself. In addition GBM tumors show inherent resistance to conventional therapy and 
have poor blood supply; thus drug delivery is inhibited (Mrugala, 2013). Tumor 
infiltration into brain tissue makes it very difficult to treat GBM with conventional 
surgical removal. Because of this diffusive invasion, recurrence from residual tumors 
is also very common (Nikki et al., 2012). Therefore, multiple therapies are needed to 
treat GBM. Currently, the best approach for the management of GBM is initial 
surgery followed by radiation and adjuvant chemotherapy (Reardon and Wen, 2006; 
Chang et al., 2006; Kanu et al., 2009). Chemotherapy plays an important role in the 
treatment of GBM especially in recurrent GB, however, the blood brain barrier, drug 
resistance and systemic toxicity of anticancer drugs decrease the therapeutic 
efficacy of available agents (Harr et al., 2012).  
In recent years, ligand-mediated, targeted drug delivery has shown promise in 
effective delivery of drugs to brain tumors (Huile Gao et al., 2013; Chen and Liu, 
2012).  In ligand-mediated drug delivery, nanoparticle surfaces are modified with a 
ligand that selectively binds to specific receptors on cancer cells. Receptors for 
molecules such as glucose (Dhanikula et al., 2008), folate (Beduneau et al., 2007), 
human epidermal growth factor (Kuo et al., 2011), lectins (Du et al., 2009; He at el., 
2011), lactoferrin (Pang et al., 2010;), transferrin (Tianet al., 2010; Pang et al., 2011) 
and integrin have been studied  as a potential targets for chemotherapy to treat brain 
cancer (Gabathuler, 2010; Ulbrich et al., 2009; Demeule et al., 2008; Quin et al., 
2011; Hu et al., 2009; Morris and Sharma, 2011; Bies et al., 2004; Wu et al., 2006). 
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Peptides, such as TAT-peptide, that can penetrate cells have also been used 
to target brain tumor (Qin et al., 2011; Han et al., 2010). However, these cell 
penetrating peptides may also enhance the penetration of nanocarriers into normal 
cells resulting in toxicity. αvβ3 integrins are over-expressed on endothelial and tumor 
cells in both primary and recurrent GBM. RGD-based peptides have high affinity 
towards αvβ3integrins and cyclic RGD peptides have been used successfully for in 
vivo imaging, magnetic resonance imaging and drug delivery to GBM (Jiang et al., 
2011; Zhan et al., 2010; Xie et al., 2008). Kim et al., (2011) used RGD-conjugated 
peptide and radioactive iodine-labelled gold nanoparticles for imaging of tumor sites. 
Jin et al., (2013) synthesised cRGDyK conjugated paramagnetic nanoprobes for the 
imaging of αvβ3 overexpressing U87MG tumor xenografts.  
In this study, cRGDfK conjugated poly(glutamic) acid nanoparticles were 
synthesized for the selective delivery of camptothecin (CPT) to GBM. CPT is a 
natural quinone alkaloid that has high efficacy against malignant gliomas (Lee et al., 
2010; Cirpanli et al., 2011; Martins et al., 2013). CPT binds to the topoisomerase I-
DNA complex during cell division, stabilizing the complex and therefore prevents the 
replication processes (Li et al., 2006). Moreover, CPT acts only in the S-phase of cell 
cycle. As cancer cells have longer S-phase compared to normal healthy cells, s-
phase selectivity makes CPT a suitable drug candidate in the development of a 
targeted drug delivery system for GBM (Pizzolato and Saltz, 2003).  
8.2. Experimentation 
8.2.1. Materials 
cRGDfK was purchased from Peptide International (Kentucky, USA). CPT, 
Poly (glutamic) acid (PGA), phenyl alanine (PA), EDC, NHS, DMEM, trypsin–EDTA, 
penicillin, streptomycin, MTT, dimethyl sulfoxide (DMSO) and propidium iodide (PI) 
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were purchased from Sigma Aldrich (Australia). FBS was purchased from Gibco, 
USA. DCFDA and Hoechst 33342 were purchased from Life Technologies Australia 
Pty Ltd. (Australia). 
8.2.2. Synthesis and characterization of phenylalanine ester (PAE) 
 Thionyl chloride (0.87 mL, 12.1 mM) was added to a solution of phenylalanine 
(1 g, 6.05 mM) in methanol. The reaction was continued for 30 min in an ice-bath 
and then stirred for 24 h at room temperature. After completion of the reaction (as 
monitored by thin layer chromatography), an excess of thionyl chloride was removed 
under reduced pressure using a rota-evaporator. PAE was obtained as a white solid 
powder and characterized by1H NMR and FTIR analysis. 
8.2.3. Synthesis and characterization of PGA-PA conjugate 
PGA-PA conjugate was synthesized as described previously (Matsusaki et al., 
2004). Briefly, 200 mg of PGA was dissolved in 30 mL of sodium bicarbonate 
solution (50 mM) and placed in an ice-bath on a magnetic stirrer. Then, EDC (300 
mg) was added and stirred for 1 h. Thereafter, PAE (310 mg) was added to the 
reaction mixture and stirred overnight.  PGA-PA conjugate was purified by dialysis 
against distilled water for three days, freeze-dried and stored. The conjugate was 
characterized by 1HNMR and FTIR analysis.  
8.2.4. Preparation and characterization of CPT loaded PGA-PA nanoparticles 
(CPN) 
 For the preparation of CPT loaded PGA-PA nanoparticles (CPN), CPT and 
PGA-PA were dissolved in DMSO and mixed with surfactant solution (1.5% w/v 
Tween 80). The dispersion was dialyzed against distilled water for 24 h and then 
centrifuged for 30 min at 15,000 rpm. The nanoparticle pellet was redispersed in 
distilled water and again centrifuged to remove free or non-encapsulated drug. Drug 
loaded nanoparticles were freeze-dried and stored at 4 °C. The amount of drug in 
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the supernatant was determined using an Ultra performance liquid chromatography 
(UPLC) system (Waters Acquity UPLC, AUS). A reversed-phase column (Acquity 
C18, 1.7 μm, 2.5 × 50 mm) was used at 30 °C. The mobile phase was composed of 
methanol and water (45:55). The flow rate was set at 0.45 mL/min and the detection 
wavelength was 256 nm.  
Particle size and zeta potential were determined by photon correlation 
spectroscopy using a Zetasizer Nano-ZS. The surface morphology of nanoparticles 
was studied by TEM. DSC analysis of native CPT and CPN were carried out on a 
DSC-Q100 (TA Instruments, USA). The samples were scanned from 220 to 300 °C 
at a speed of 10 °C/min, under nitrogen environment. XRD patterns of CPT and CPN 
were obtained in the range of 5–45º using an X-ray diffractometer, equipped with a 
graphite crystal monochromator (CuKa). The instrument was set at a voltage of 40 
KV and a current of 40 mA.  
8.2.5. Bioconjugation of cRGDfK to CPN 
 Nanoparticles (50 mg) were dispersed in 5 mL of PBS and incubated with 
EDC (35 mg) and NHS (21 mg). After 30 min, cRGDfK was added and stirred for 4 h 
at room temperature. cRGDfK conjugated nanoparticles were obtained by 
centrifugation and washed three times with PBS. The supernatant was used to 
determine the amount of unconjugated cRGDfK. 
8.2.6. Cell culture 
U87MG Human glioblastoma cells were obtained from Peter MacCallum 
Cancer Institute, Australia. Cells were grown in DMEM media supplemented with 
10% FBS, 2 mM glutamine, penicillin (100 U/mL), and streptomycin (0.1 mg/mL). 
Cells were cultivated under standard conditions at 37 °C in a humidified atmosphere 
(85% relative humidity) containing 5% CO2. 
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8.2.7. In vitro cytotoxicity assay 
The cytotoxicity of the pure CPT and drug-loaded nanoparticles was 
evaluated by the MTT assay. U87MG cells (5×103) were seeded in 96-well plates 
and incubated for 24 h. Cells were then treated with CPT, CPN or RCPN (1-400 
ng/mL) for 24 and 48 h at 37 °C. Untreated cells served as controls. After incubation, 
100 μL of DMEM medium containing MTT reagent (0.5 mg/mL) was added to each 
well. The plate was then incubated at 37 °C for 4 h. The violet-colour formazan 
crystals were dissolved in 150 μL of DMSO. Absorbance was measured at 570 nm 
using a microplate reader and the percentage viability of cells was calculated as the 
ratio of absorbance of sample to control wells.  
8.2.8. Cellular uptake of nanoparticles in cells 
Comparative uptake of unconjugated (RPN) and cRGDfK conjugated 
nanoparticles (RRPN) was studied using rhodamine-b loaded nanoparticles. Cells 
were incubated with RPN and RRPN for 2 h at 37 °C. Cells were washed twice with 
PBS and stained with 5 µg/mL of Hoechst 33342 to stain nuclei. After 30 min 
incubation, cells were washed with PBS and observed by fluorescence microscopy. 
8.2.9. Estimation of apoptosis  
Apoptosis in cells treated with CPT, CPN and RCPN was estimated by an 
Annexin V PE Cys5.5 and PI assays. Concentration of all three reagents was 50 
ng/mL. Cells were seeded in 6-well plates at 1 × 106 cells/well and incubated for 24 h 
to allow adherence to the plate surface. Cells were treated with 50 ng/mL of CPT, 
CPN or RCPN for 24 h. The cells were then collected, washed with PBS, stained 
according to the manufacturer’s instructions and analyzed using a flow cytometer 
(BD FACSCanto™ II).  
8.2.10. Nuclear staining with Hoechst 33242 
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Nuclear morphology of CPT, CPN or RCPN treated cells was studied by 
Hoechst 33342 staining. Hoechst 33342 is a DNA specific fluorescent dye used to 
study nuclear morphology. U87MG cells (1×105) were seeded in 24-well microplates 
and incubated overnight. Cells were then incubated with free drug or nanoparticles 
(CPT concentration 20 ng/mL). After washing with PBS, cells were stained with 
Hoechst 33342 (5 μg/mL) at 37 °C for 30 min in the dark. Cells were washed again 
with PBS and observed under afluorescence microscope. % Apoptosis was 
determined as follows: 
% Apoptosis = (Number of apoptotic cells/ Total number of cells) × 100 
8.2.11. Measurement of reactive oxygen species (ROS) 
U87MG cells were seeded at a density of 1×105 cells per well in 24-well plates 
and incubated for 24 h at 37 °C. Cells were then treated with CPT formulations 
equivalent to 20 ng/mL of CPT for 24 h, washed twice with PBS and fixed with 4% 
paraformaldehyde for 10 min. After washing two times with PBS, cells were 
incubated with DCFDA (10 µM) for 30 min in the dark. Cells were finally washed with 
PBS and observed using a fluorescence microscope (Nikon, Japan).  
For quantitative estimation of ROS, cells were harvested using 0.25% trypsin-
EDTA and washed with PBS. Cell counts were adjusted for all formulations. Cells 
were incubated with DCFDA (10 µM) for 30 min in the dark and fluorescence 
intensity was measured at excitation and emission wavelengths of 495 and 520 nm, 
respectively, using a Hitachi F-3010 spectrofluorometer. 
8.2.12. Wound healing scratch assay 
The effect of CPT formulations on wound healing or the migration of cells was 
analyzed by the scratch-wound healing assay, with slight modification as reported by 
Ma et al., 2014. U87MG cells were cultured to form an approximate80% confluent 
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monolayer. The monolayers were scratched with a sterile 200-μL pipette tip to form a 
“wound”. Cells were washed twice with PBS to remove cellular debris. Cells were 
then incubated with CPT, CPN or RCPN in serum-free media for 24 h. Images were 
captured at 0 and 24 h to monitor the migration of cells into the wound area using a 
photomicroscope (Nikon, Japan). The % of wound closure was determined by 
measuring the wound area using Image J analysis software. 
8.2.13. Statistical analysis 
All studies were performed in triplicate and results are expressed as Mean ± 
SD (standard deviation). Statistical significance was determined using the student t-
test for two groups and one-way ANOVA for multiple groups. Statistical significance 
was assumed at p < 0.05. 
8.3. Results and discussion 
8.3.1. Synthesis and characterization of PGA-PA conjugates 
PGA is a water soluble, biodegradable, naturally occurring poly(amino acid) 
composed of glutamic acid molecules linked through the amide bonds between α-
amino and γ-carboxylic acid groups (Kim et al., 2009; Moncha and Mararitis, 2008). 
Because of aqueous solubility, native PGA is not suitable as drug delivery carrier. 
Therefore, it was conjugated with hydrophobic PA to produce an amphiphilic 
copolymer which spontaneously forms nanoparticles in aqueous solution. The 
structure of PGA-PA nanoparticles is a shell type with a hydrophobic PA core and an 
outer hydrophilic cortex of PGA (Scheme 1).   
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Scheme 8.1: a) Chemical synthesis of phenyl alanine ester (PAE) from phenyl alanine 
(PA) and then conjugation of PAE to poly (glutamic) acid (PGA) to form PGA-PA 
conjugate b) Schematic diagram showing cRGDfK conjugated and Camptothecin 
loaded self-assembled PGA-PA nanoparticles  
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For the synthesis of poly (glutamic acid)-phenyl alanine conjugate (PGA-PA) 
firstly, phenyl alanine (PA) was converted to phenylalanine ester (PAE). Esterified 
PA was conjugated to PGA through a carbodiimide reaction and conjugation 
efficiency was determined by NMR analysis (Figure 1a). The peaks corresponding to 
the methylene protons (δ 2.1) of PGA and the aromatic protons of the benzene ring 
(δ 7.3) of PA were compared. The conjugation efficiency was 52.9%. The PGA-PA 
conjugate was also confirmed by FTIR analysis (Figure 1b). The FTIR spectrum of 
PA showed two characteristic N-H stretching vibration bands at 3078 cm-1 and 3030 
cm-1. Bands corresponding to asymmetric and symmetric stretching vibrations of the 
carboxylic group (COO-) were observed at 1557 cm-1 and 1409 cm-1, respectively. 
The stretching vibration band of benzene appeared at 745 cm-1. After esterification of 
the carboxylic group of PA, a sharp band was observed at 1736 cm-1indicative of 
C=O stretching of the ester bond. The FTIR spectrum of PGA showed bands at 3263 
cm-1 (NH stretching), 1644 cm-1 (amide I) and 1551 cm-1 (amide II).  
 
 
 
 
 
 
 
 
 
                                                                                
 
a) 
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b) 
Figure 8.1a-b. a).1H NMR spectra of phenylalanine ester (PAE), poly(glutamic acid) 
(PGA) and poly(glutamic acid)-phenylalanine conjugate (PGA-PA) b). FTIR spectra of 
phenyl alanine (PA), phenylalanine ester (PAE), poly(glutamic acid) (PGA) and 
poly(glutamic acid)-phenylalanine conjugate (PGA-PA) 
PGA was conjugated to PA through amide coupling between the amine group 
of PA and carboxylic group of PGA. The FTIR spectrum of the PGA-PA conjugate 
showed a shift in the PGA peaks (3263 to 3278, 1644 to 1648 and 1551 to 1544 cm-
1). A new peak at 746 cm-1 corresponding to the benzene ring of PA confirmed 
successful conjugation of PA to PGA. 
8.3.2. Characterization of nanoparticles 
BPN and CPN were prepared by the dialysis method. Physicochemical 
parameters of different nanoparticles are presented in Table 1. BPN showed particle 
size of 66 nm with very low polydispersity 0.08 and high negative zeta potential -30.9 
mV. After CPT loading, the particle size of nanoparticles was increased slightly to 
81.6 nm without a significant change in polydispersity (0.09) and zeta potential (-29.7 
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mV). cRGDfK grafted nanoparticles were of 89.7 nm in size and -16.7 mV zeta 
potential (Table 1). A decrease in negative zeta potential of RCPN confirmed the 
conjugation of cRGDfK on the surface of CPN. The size of the nanoparticles after 
drug loading and cRGDfK conjugation was less than 100 nm; an ideal size for a 
nanocarrier system to across the blood-brain barrier (Chen and Liu, 2012). 
Table 8.1: Physicochemical characterization of empty poly(glutamic acid) 
nanoparticles (BPN), campatothecin-loaded PGA nanoparticles (CPN) and cRGDfK 
conjugated CPN (RCPN) 
Formulation Particle size (nm) PDI ZP (mV) %EE 
BPN 66.07 ± 2.41 0.08 ± 0.03 -30.9 ± 2.36 - 
CPN 81.68 ± 1.79 0.09 ± 0.02 -29.7 ± 1.14 68.41 ± 3.95 
RCPN 89.76 ± 2.58 0.10 ± 0.02 -16.4 ± 1.86 65.22 ± 1.47 
 
Morphology of nanoparticles was studied using TEM analysis (Figure 2). The 
size of the nanoparticles after drug loading and cRGDfK conjugation was less than 
100 nm; an ideal size for a nanocarrier system to cross the blood-brain barrier (Chen 
and Liu, 2012). RCPN were also characterized by FTIR analysis (Figure 3). % 
encapsulation efficiency for CPN and RCPN was 68.4% and 65.2%, respectively.  
 
Figure 8.2. Transmission electron microscopic image of PGA-PA nanoparticles. 
The scale represent diameter in nanometer.  
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Figure 8.3: FTIR spectra of CPT, CPN, cRGDfK peptide and cRGDfK conjugated 
CPN. 
Drug loaded nanoparticles were also characterized for differential scanning 
calorimetry (DSC) and x-ray diffraction (XRD) analysis. DSC spectra of CPT and 
CPN are presented in Figure 4a. The DSC spectra of CPT showed a sharp 
endothermic peak at 268 °C corresponding to its melting point. However, the 
absence of a CPT peak in may be due to its amorphous or disordered crystalline 
sate or to solid solution in polymeric matrix of nanoparticles.  
Figure 4b demonstrates the XRD patterns of pure CPT, PGA-PA conjugate, a 
physical mixture of CPT and PGA-PA, and CPN. The XRD pattern of raw CPT 
showed characteristic high-intensity diffraction peaks at diffraction angles of 2θ 6.2°, 
8.5°, 11.5°,12.1°, 13.6°, 17.8° and 25° suggesting the crystalline nature of the drug 
(Guijin et al., 2013). Due to its amorphous nature, the XRD patterns of PGA-PA did 
not show any sharp peaks. We observed all the characteristic peaks of CPT in the 
XRD pattern of the physical mixture of CPT and PGA-PA, demonstrating a lack of 
chemical interaction between CPT and PGA-PA. However, owing to transformation 
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of CPT from a crystalline to an amorphous phase during nanoparticle preparation, 
the peaks representing CPT were absent in the CPN XRD pattern. 
                      
  
 
 a)   
    b) 
Figure 8.4a-b. a) Differential scanning calorimetry spectra of camptothecin (CPT), 
Poly(glutamic acid)-phenylalanine conjugate (PGA-PAE) and CPT loaded PGA-PAE 
nanoparticles (CPN). b) X-ray diffraction pattern of CPT, PGA-PA, physical mixture of 
CPT and PGA-PA (PM) and CPN. 
8.3.3. In vitro cytotoxicity 
In order to investigate the anti-proliferation activity of native CPT and CPT 
loaded formulations (CPN and RCPN), cell viability of U87MG human glioblastoma 
cells was determined using the MTT assay. Anticancer activities of pure drug as well 
as drug-loaded nanoparticles depend on both the dose of drug and time of 
incubation. Therefore, U87MG cells were incubated with free CPT, CPN or RCPN, 
equivalent to 1-400 ng/mL of CPT, for 24 and 48 h. The cell viability of U87MG cells 
after 24 h and 48 h are shown in Figure 5a and 5b, respectively. All three 
formulations showed caused a significant decrease in cell viability. IC50 values for 
the three formulations are presented in Table 2. After 24 h, targeted nanoparticles 
(RCPN, IC50 30.46 ng/mL) were more effective than non-targeted nanoparticles 
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(CPN, IC50 168.29 ng/mL) and native CPT (IC50 552.21 ng/mL). A similar pattern 
was observed after 48 h incubation where the IC50 value of RCPN (11.34 ng/mL) 
was 2.3 and 5.4 times lower than CPN (27.05) and CPT (61.78 ng/mL), respectively. 
The results suggest RCPN not only inhibits cell growth at higher efficiency than 
native CPT but also lowers the minimum effective dose required for cytotoxicity. 
 
Table 8.2: IC50 value of pure campatothecin (CPT), CPT loaded PGA nanoparticles 
(CPN) and cRGDfK conjugated CPN (RCPN) against U87MG human glioblastoma after 
24 and 48 h incubation. 
 
Formulation IC50 (ng/mL) 
After 24 h After 48 h 
CPT 552.21 ± 7.38 54.51 ± 2.06 
CPN 168.29 ± 4.92 22.57 ± 0.98 
RCPN 30.46 ± 1.59 11.34 ± 1.25 
  
 
 
 
 
 
 
 
Figure 8.5a-b. % Cell viability of U87MG human glioblastoma cells treated with 
Camptothecin (CPT), CPT loaded PGA-PAE nanoparticles (CPN) and cRGDfK 
conjugated loaded CPN (RCPN) for a) 24 h and b) 48 h. 
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8.3.4. Uptake of nanoparticles by U87MG cells 
Internalization of nanoparticles was studied using Rho-b loaded nanoparticles. 
Nuclei were visualized by Hoechst 33342 staining. Figure 6 shows fluorescence 
microscopic images of U87MG cells after 2 h of incubation with nanoparticles. 
cRGDfK conjugated and Rho-b loaded PGA nanoparticles (RRPN) showed higher 
intracellular accumulation of Rho-b than unconjugated nanoparticles (RPN). The 
increased uptake of targeted nanoparticles could be attributed to the presence of 
cRGDfK on the surface of nanoparticles. Peptide containing RGD moieties have 
been reported to be taken uptake by U87MG cells more efficiently than unconjugated 
nanoparticles (Chen et al., 2009; Rangger et al., 2013). Therefore, the enhanced 
cytotoxicity of RCPN formulation than CPN can be correlated to the higher uptake of 
RRPN.  
 
 
 
 
Figure 8.6: Cellular uptake of Rhodamine-b loaded PGA nanoparticles (RPN) and 
cRGDfK conjugated RPN (cRGDfK) by U87MG human glioblastoma cells. 
 
8.3.5. Analysis of apoptosis  
GBM cells exhibit less apoptosis than normal cells (Kesari, 2013). Apoptosis 
induced by targeted CPT nanoparticles was also analysed by flow cytometer 
analysis. As shown in Figure 7a, the percentage of live U87MG cells was decreased 
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with the three CPT formulations. The percentage of live cells in control, CPT, CPN 
and RCPN was 98.4%, 71.6%, 62.4% and 52.5%, respectively. The ability of the 
different CPT formulations to induce cell death followed the order: RCPN>CPN>CPT 
(Figure 4a). Cells treated with RCPN were more apoptotic compared to those treated 
with native drug and CPN. The percentage of apoptotic cells after treatment with 
RCPN (46.9%), was much higher than with CPN (35.6%) and CPT (26.9%) 
treatment. Thus, RCPN induced more apoptosis than CPN or non-encapsulated 
CPT; most likely due to enhanced intracellular delivery of drug. 
Apoptosis was also studied qualitatively and quantitatively using Hoechst 
staining. Cells treated with CPT, CPN or RCPN showed fragmented nuclei whilst 
control or untreated cells demonstrated intact nuclei (Figure 7b, c). The findings are 
consistent with those from Annexin Cys5.5 PI assays. 
 
 
a) 
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b)           c) 
 
Figure 8.7a-c: Apoptosis studies: a) Quantitative analysis of apoptosis induced by 
camptothecin (CPT), CPT loaded PGA-PA nanoparticles (CPN) and cRGDfK 
conjugated loaded CPN (RCPN) in U87MG human glioblastoma cell. (b) Fluorescent 
microscopic images of nucleus of U87MG cells stained with Hoechst 33342 stained 
after treatment with CPT, CPN and RCPN and (c) % apoptosis determined by Hoechst 
33342 staining after treatment 24 h of treatment with CPT, CPN and RCPN. 
 
8.3.6. Intracellular ROS generation 
Anticancer drugs, including CPT, generate ROS (Hollomon et al., 2013; 
Pizzolato and Saltz, 2003; Mizutani et al., 2002, 2005). Intracellular generation of 
ROS can be measured using the DCFDA dye. Fluorescent intensity of DCFDA is 
directly related to intracellular ROS levels. In present study, fluorescence intensity 
was measured both qualitatively and quantitatively (Figure 8a, b). Control, or 
untreated cells, showed less green fluorescence than drug treated cells. Among the 
three CPT formulations, RCPN showed 2.51 and 1.48 times higher fluorescence 
intensity than CPT and CPN, respectively. This may be explained by the enhanced 
intracellular delivery of CPT by targeted nanoparticles.  
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                   a)                   b) 
Figure 8.8a-b: a) Qualitative and b) Quantitative determination of reactive oxygen 
species (ROS) generation in U87MG human glioblastoma cell after treatment with 
camptothecin (CPT), CPT loaded PGA-PA nanoparticles (CPN) and cRGDfK 
conjugated loaded CPN (RCPN). 
8.3.7. Wound-healing assay 
Gliomas exhibit significant angiogenesis that is induced by vascular 
endothelial growth factor (VEGF). VEGF is responsible for the formation of new 
blood vessels required for tumor growth and cell migration (Kesari et al., 2011; 
Hoeben et al., 2004).  To study the effect of targeted delivery of RCPN on the cell 
migration of U87MG, wound-healing or scratch assays were performed. Cells were 
observed by light microscopy. Figure 9 shows the migration distance observed after 
0 and 24 h of wound creation. % closure of wound area observed after 24 h of 
treatment was 98.1%, 63.8%, 47.4% and 5.7% for control, CPT, CPN and RCPN, 
respectively.  
Control or untreated U87MG cells exhibit self-healing and migration. RCPN 
significantly diminishes cell migration, while CPN and CPT show slight inhibitory 
activity. The greater inhibition of cell migration by RCPN can be attributed to higher 
anti-angiogenic activity via αvβ3integrin receptors that are up regulated on vascular 
endothelial cells in tumors (Hoeben et al., 2004).   
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Figure 8.9: Wound healing scratch assay: Figure shows the wound area in U87MG 
cells after 0 and 24 h of treatment with different formulations. Campatothecin 
formulations showed inhibition of wound healing by decreasing the migration of the 
cells. However, inhibition of cell migration was more in cRGDfK peptide conjugated 
nanoparticles (RCPN) than plain CPT and unconjugated nanoparticles (CPN). Control 
or untreated cells showed almost complete healing of wound after 24 h. 
 
8.3.8. Stability of nanoparticles 
Lyophilized RCPN were stable up to 2 months. RCPN did not show a 
significant change in the physicochemical parameters such particle size, surface 
charge and drug content. 
8.4. Conclusion 
In summary, self-assembled poly(amino acid) based nanoparticles were 
successfully prepared for the targeted delivery of CPT to glioma cells. The 
nanoparticles contain a hydrophobic phenylalanine core and a hydrophilic surface 
corona of poly(glutamic acid). Antitumor effects of RCPN are shown by anti-
proliferation activity, cell morphology and induction of apoptosis. Targeted 
nanoparticles show higher cellular uptake, induced apoptosis through ROS 
generation and better control over cell migration than non-targeted nanoparticles.  
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Cancer is one of the most deadly diseases world-wide. After the discovery of 
nitrogen mustard as first anticancer drug in 1940’s, various anticancer drugs have 
been synthesized or isolated from natural sources (DeVita and Chu, 2008). These 
anticancer drugs have significant potential against various types of cancer. Taxanes, 
podophyllotoxins, platinum derivatives and anthracyclines are most commonly used 
anticancer drugs (Smith and Clark, 2011). However, all of these suffer from several 
drawbacks such as non-specificity, poor physicochemical properties, poor 
bioavailability and increasing drug resistance over the course of treatment (Krishna 
and Mayer, 2000; Ross et al., 2204; Cho et al., 2008). To enhance the aqueous 
solubility of water insoluble anticancer drugs, pharmaceutical companies use 
solubilizers such as tween 80 and cremophore EL that cause severe anaphylactic 
hypersensitivity reactions, neutropenia, hepatotoxicity and fluid retention (Pooja et 
al., 2014). 
This thesis was planned to develop peptide and monoclonal antibody 
mediated targeted nanoparticles for delivery of current anticancer drugs. 
Nanoparticles have the ability to deliver the anticancer drugs through enhanced 
permeability and retention (EPR) effect due to defective vasculature in tumor tissues 
(Peer et al., 2007). However, when EPR approach is applied, the specificity of the 
nanoparticles towards cancer cells is only about 30% (Kobayashi et al., 2014). 
Therefore, there is a strong need for innovative strategies such as ligand-mediated 
targeted drug delivery systems to deliver anticancer drugs more specifically to 
cancer cells. Among various targeting ligands, peptides and monoclonal antibodies 
have high binding affinity towards the specific receptors over-expressed on tumor 
cells.  
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Therefore, the work presented in thesis originally aimed to focus on the 
development of targeted nanoparticles using two peptides, Bombesin (BBN) and 
cRGDfK, and a monoclonal antibody Trastuzumab (TZ) for the delivery of docetaxel, 
a hydrophobic anticancer drug (Chapters 2-6). Among different targeting ligands, 
the promising results of cRGDfK-conjugation allowed further studies on delivery of 
two additional clinically approved anticancer drugs. In those studies, gemcitabine 
hydrochloride, a hydrophilic drug was utilised for the chemotherapy of ovarian tumor 
(Chapter 7); and Camptothecin, a hydrophobic drug, for the treatment of 
glioblastoma (Chapter 8). 
Bombesin conjugated PLGA nanoparticles as drug delivery carrier for 
docetaxel 
PLGA is a clinically-approved biodegradable polymer and has been 
extensively explored as a component of drug delivery carriers. As demonstrated in 
Chapter 2, the preparation of PLGA nanoparticles was optimized using three 
surfactants, viz., Tween 80, sodium cholate and PVA. Nanoparticles prepared with 
sodium cholate showed the smallest particle size with low polydispersity index and 
high negative zeta potential. These nanoparticles were conjugated with BBN through 
carbodiimide chemistry to provide them with a breast targeting ability. During stability 
studies of these nanoparticles, it was observed that BBN conjugated nanoparticles, 
even though showed reduced zeta potential, were more stable than unconjugated 
nanoparticles. Detailed investigations revealed that the increase in stability of 
conjugated nanoparticles was attributed to change in the surface properties and 
stabilization mechanism of nanoparticles, as conjugated nanoparticles were less 
hydrophobic than unconjugated nanoparticles. Further, the conjugated nanoparticles 
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were found to be stabilized by steric stabilization in contrary to electrostatically 
stabilized unconjugated nanoparticles.  
Nanoparticles optimized from chapter 2 were used for the encapsulation of 
docetaxel (Chapter 3). Docetaxel is a highly potent anticancer agent and being used 
for the treat of various types of cancer. Encapsulation of docetaxel in nanoparticles 
was optimized for drug loading and entrapment efficiency. In-vitro cytotoxicity studies 
in GRP receptors over-expressing MDA-MB-231 human breast cancer cells revealed 
that BBN peptide conjugated nanoparticles had significantly higher cytotoxicity than 
unconjugated nanoparticles and pure docetaxel. As GRP receptors are also 
overexpressed on prostate cancer, the above formulations were also tested against 
DU145 and PC3 human prostate cancer cells (Chapter 4). It was observed that 
BBN-conjugated docetaxel loaded nanoparticles exhibited higher cytotoxicity and 
inhibition of cell migration and colony formation than non-targeted nanoparticles and 
docetaxel alone. Moreover, BBN-conjugated nanoparticles showed faster cellular 
uptake than unconjugated nanoparticles. During pharmacokinetic and tissue-
distribution studies in male Balb/c mice, BBN-conjugated nanoparticles displayed 
improved pharmacokinetics of docetaxel by increasing mean residence time and 
decreasing clearance. This suggests that the prepared formulations have significant 
potential to treat GRP overexpressing breast and prostate cancers. 
Trastuzumab conjugated dendrimers for targeted delivery of docetaxel to 
HER2 receptor overexpressing breast cancer 
Another type of receptors that are overexpressed in breast cancer cells 
includes human epidermal growth factor 2 receptors (HER2). About 20-30% of 
breast cancer cells overexpress HER2 receptors. Trastuzumab, a monoclonal 
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antibody, has high affinity towards HER2 receptors. Using a hetero crosslinker MAL-
PEG-NHS, transtumuzab was conjugated to PAMAM dendrimers for the selective 
delivery of docetaxel to HER2 positive breast cancer cells (Chapter 5). TZ 
conjugated dendrimer formulations showed higher cellular uptake and toxicity than 
unconjugated dendrimers against MDA-MB-453, the HER2 positive breast cancer 
cells. However, no significant difference between toxicities of both the formulations 
against MDA-MB-231, the HER2 negative breast cancer cells. This confirmed that 
the transtuzumab antibody present on the surface of conjugated dendrimers was 
responsible for its high efficacy. During docetaxel-induced apoptosis studies, cells 
treated with transtuzumab conjugated formulation were more apoptotic than 
unconjugated dendrimers. This effect could be attributed to enhanced intracellular 
delivery of docetaxel by conjugated dendrimers.  
Pure PAMAM dendrimers, particularly those with amine surface groups are 
known to cause hemolysis of red blood cells. Hemolysis assays showed that 
conjugation of trastuzumab to dendrimers significantly reduce their hemolysis 
toxicity. Plain PAMAM dendrimers with amine surface groups are cationic in nature 
and therefore interact with anionic RBC membranes to cause hemolysis. After 
conjugation with trastuzumab, the surface of PAMAM dendrimers became negatively 
charged which reduced their interaction with RBC membrane. In-vivo studies 
revealed higher plasma docetaxel concentration and half-life, decreased clearance 
and longer mean residence time in trastuzumab-conjugated dendrimers than 
Taxotere®, a marketed formulation of docetaxel. Therefore, the prepared 
trastuzumab-mediated dendrimers formulation has the potential as an improved drug 
delivery platform for the treatment of HER2 positive breast cancer.    
Chapter 9  Summary and Future Prospective 
 Peptide and monoclonal antibody mediated targeting of anticancer drugs 226 
 
Cyclic-RGDfK peptide conjugated succinoyl-TPGS nanomicelles for targeted 
delivery of docetaxel to integrin receptor over-expressing angiogenic tumours 
In a series of development of targeted drug delivery systems, Chapter 6 
investigated the role of cyclic-RGDfK peptide conjugated succinoyl-TPGS 
nanomicelles for the targeting of docetaxel to integrin receptor over-expressing 
angiogenic tumours. cRGDfK is a cyclic pentapeptide and has affinity to integrin 
receptors, particularly αvβ3 that are overexpressed in various cancers including 
breast, prostate, ovarian, pancreatic and brain cancer (Danhier et al., 2012). TPGS 
is a water soluble derivative of natural Vitamin E. As a drug delivery carrier, TPGS 
has several advantages like enhancement of aqueous solubility of water-insoluble 
compounds, simple method of preparation, small micellar size, and opportunity for 
surface modification (Pooja et al., 2014). The surface of TPGS was modified with 
succinic anhydride to achieve free carboxylic group bearing TPGS. Docetaxel was 
encapsulated by solvent casting method and nanomicelles were conjugated to 
cRGDfK to prepare integrin targeted nanomicelles. The prepared nanomicelles were 
found to be more effective than plain drug against DU145 human prostate cancer 
cells. Anti-angiogenic assays revealed strong ability of peptide conjugated 
nanomicelles to inhibit VEGF-induced proliferation and migration of endothelial cells 
(HUVEC). 
Improving intracellular delivery of hydrophilic gemcitabine hydrochloride 
(GEM) using cRGDfK peptide functionalized PLGA nanoparticles 
With the promising results of cRGDfK conjugated and docetaxel loaded TPSA 
nanomicelles, cRGDfK conjugated PLGA nanoparticles were developed for the 
delivery of gemcitabine hydrochloride for the treatment of ovarian cancer. Being a 
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hydrophilic drug, GEM cannot be encapsulated in hydrophilic TPGS, and therefore 
PLGA-based drug carriers were developed in this study (Chapter 7). GEM loaded 
PLGA nanoparticles (GPN) were prepared by a double emulsification method and 
cRGDfK peptide attached to the nanoparticle surface via a carbodiimide reaction. 
Anticancer efficacy of different GEM formulations was evaluated against integrin 
receptor over-expressing, SKOV-3 human ovarian cancer cells. cRGDfK conjugated 
GPN (RGPN) improved the intracellular accumulation of GEM in SKOV-3 cells, 
leading to an increased anti-proliferative activity and induction of apoptosis. 
Mitochondrial membrane potential, intracellular reactive oxygen species (ROS) 
levels and apoptosis-mediated nuclear fragmentation were also evaluated. Overall, 
this study revealed that this targeted drug delivery system may also have substantial 
promise for effective delivery and targeting of hydrophilic chemotherapeutics. 
cRGDfK conjugated PGA nanoparticles for the targeted delivery of 
camptothecin to integrin over expressing brain tumors 
It has always been challenging to treat brain diseases due to presence of 
blood brain barrier. As αvβ3 integrin receptors are also overexpressed on brain tumor 
cells, particularly glioblastoma (Danhier et al., 2012), in this last sub-project of this 
thesis (Chapter 8), cRGDfK-based targeted drug delivery system was prepared for 
the targeting and specific delivery of camptothecin to brain cancer cells. 
Poly(glutamic acid)-phenyl alanine conjugate was employed for the preparation of 
nanoparticles. Peptide conjugated nanoparticles (RCPN) with a particle size of less 
than 100 nm and 65% drug encapsulation efficiency exhibited a dose and time 
dependent cytotoxicity to U87MG human glioblastoma cells. U87MG cells show high 
angiogenesis and are one of the best model cancer cells for the anti-angiogenesis 
studies. RCPN showed induced apoptosis, increase in ROS generation and greater 
Chapter 9  Summary and Future Prospective 
 Peptide and monoclonal antibody mediated targeting of anticancer drugs 228 
 
inhibition of cell migration of U87MG than native camptothecin and unconjugated 
nanoparticles. In summary, cRGDfK-mediated and amphiphilic copolymer based 
nanomedicine could offer a promising approach for the delivery of anticancer drugs 
against glioblastoma and cGRDfK peptide could be a versatile targeting ligand 
against different cancers including ovarian, prostate and brain cancer. 
Future Prospective 
Overall, the work presented in this thesis provides an understanding towards 
development of new nanocarrier systems by employing a number of drug 
encapsulation and bioconjugation strategies. The results of these studies could be a 
strong basis for future preclinical studies in tumor-bearing mice and clinical studies. 
For examples:  
 During tissue-distribution studies, it was observed that bombesin grafted PLGA 
nanoparticles were preferentially accumulated in lungs in comparison to other 
body tissues. Therefore, the use of bombesin conjugated nanocarriers for 
delivery of anticancer drugs to lung cancer could be a research interest. 
 Additionally, trastuzumab has also been approved by FDA for the treatment of 
the gastric cancers. Therefore, the efficacy of docetaxel loaded dendrimer-
trastuzumab conjugate could be tested for efficacy against HER-2 over 
expressing gastric cancer.  
 The future work could be focused on real-time biodistribution studies using a 
near-infrared active dye loaded nanoparticles and efficacy studies of drug loaded 
nanoparticles in tumor bearing mice. 
 In recent years, combination therapy (delivering multiple therapeutic agents with 
a single nanocarrier) has been motivated to overcome some of the problems 
associated with chemo-resistance. By administering two drugs simultaneously, 
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the resistance acquired by cells to one of the drugs could be immediately 
eliminated by another. Therefore, higher therapeutic efficacy could be achieved 
by simultaneous delivery of multiple drugs targeting the same cellular pathway. 
The prepared various types of nanocarrier systems in this thesis could be 
explored as delivery vehicle for combination cancer chemotherapy. 
 Last but not the least; it is commonly observed that a particular chemotherapy is 
effective only for a subset of population. For instance, trastuzumab is found to be 
effective only against 20% of breast cancer patients that overexpress HER2 
receptors (Senkusa et al., 2014). Since, cancer cells typically overexpress more 
than one type of receptors simultaneously; a unique approach may involve co-
grafting of two or more targeting ligands on a single nanocarrier system. This 
approach many not only further improve the specificity of targeted drug delivery 
systems, this may also potentially offer an interesting avenue to successfully 
implement targeted chemotherapy against a larger set of population. 
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